chronic
obstruct
pulmonari
diseas
copd
signific
caus
death
australia
access
palli
care
limit
addit
previou
studi
indic
patient
chronic
lung
diseas
like
first
encount
palli
care
critic
care
set
cabrini
hospit
develop
share
model
earli
referr
access
palli
care
patient
advanc
copd
integr
across
respiratori
continu
care
program
palli
homecar
team
enabl
patient
live
activ
possibl
focu
qualiti
life
reduc
time
hospit
optim
util
continu
care
servic
support
prefer
place
care
optim
function
comfort
physic
psychosoci
emot
spiritu
minim
physic
psychosoci
symptom
provid
adequ
knowledg
open
commun
patient
carer
help
time
inform
support
carer
throughout
person
ill
support
patient
carer
death
inevit
bereav
period
patient
famili
report
posit
patient
experi
improv
prefer
place
death
patient
feel
abandon
hand
anoth
servic
famili
end
life
experi
improv
due
patient
famili
well
known
palli
homecar
staff
respiratori
nurs
direct
admiss
inpati
palli
care
servic
prevent
visit
emerg
prevent
hospit
admiss
final
year
life
improv
qualiti
life
reduct
emerg
call
ambul
servic
due
breathless
anxieti
share
model
earli
referr
access
palli
care
markedli
improv
qualiti
servic
patient
advanc
lung
diseas
train
requir
support
palli
homecar
nurs
deliv
care
patient
diseas
equal
chronic
diseas
nurs
support
deliv
palli
care
approach
withdraw
non
invas
ventil
niv
end
life
extrem
challeng
vari
patient
experi
littl
evid
describ
medic
titrat
prior
weaningpost
niv
cessat
increas
risk
undignifi
death
st
georg
hospit
palli
care
servic
sghp
receiv
referr
assist
niv
withdraw
patient
fail
respond
treatment
malign
diseas
recogn
need
develop
consist
way
wean
patient
niv
titrat
medic
depend
level
depend
niv
sghpc
receiv
respiratori
failur
patient
referr
receiv
niv
specif
refer
end
life
care
treatment
deem
futil
chang
direct
care
niv
wean
ceas
identifi
level
niv
depend
end
life
eol
requir
differ
dose
medicationsadjust
ventil
wean
process
ensur
symptom
free
death
led
provis
specif
educ
respiratori
medic
nurs
staff
unit
use
niv
effect
withdraw
niv
requir
integr
team
approach
provid
best
practic
care
provis
regular
educ
support
staff
improv
staff
confid
compet
care
patient
wean
process
niv
patient
die
regular
opioid
benzodiazepin
time
death
number
day
referr
death
rang
die
referr
day
need
research
guidelin
palli
care
niv
withdraw
respiratori
failur
consist
collabor
approach
respiratorypalli
care
servic
optim
eol
manag
encourag
grant
support
nil
histor
common
practic
administ
oxygen
regardless
need
without
suffici
monitor
adjust
consist
demonstr
audit
carri
waitemata
district
health
board
waitemata
dhb
hospit
new
thorac
societi
australia
new
zealand
tsanz
recent
releas
guidelin
acut
use
oxygen
adult
promot
prescrib
oxygen
therapi
target
level
prescrib
rang
oxygen
exampl
appropri
patient
patient
retain
carbon
dioxid
chronic
obstruct
pulmonari
diseas
copd
oxygen
titrat
swim
flag
innov
multidisciplinari
collabor
improv
prescrib
safe
administr
oxygen
waitemata
dhb
campaign
plan
showcas
mix
utilis
technolog
via
electron
prescrib
social
media
educ
session
sport
catchi
phrase
fix
aim
high
aim
improv
awar
oxygen
improv
prescrib
administr
baselin
patient
oxygen
prescrib
remain
patient
receiv
oxygen
without
prescript
six
month
later
show
increas
oxygen
prescrib
staff
also
report
increas
understand
import
safeti
concept
regard
oxygen
deliveri
devic
improv
patient
safeti
rais
awar
oxygen
devic
prescrib
includ
specifi
target
satur
rang
team
continu
monitor
oxygen
devic
prescrib
continu
spread
import
safeti
messag
grant
support
nil
boyl
wong
j
prescrib
oxygen
therapi
audit
oxygen
prescrib
practic
medic
ward
north
shore
hospit
auckland
new
zealand
nz
med
j
holbourn
wong
j
oxygen
prescrib
practic
waikato
hospit
meet
guidelin
recommend
int
med
j
beasley
r
chien
j
dougla
j
eastlak
l
farah
c
king
g
moor
r
pilcher
j
richard
smith
walter
h
thorac
societi
australia
new
zealand
oxygen
guidelin
acut
oxygen
use
adult
swim
flag
respirolog
patient
hospitalis
acut
exacerb
copd
aecopd
australia
nation
intern
guidelin
optimis
inpati
manag
copd
exist
howev
complianc
remain
unclear
westmead
hospit
implement
copd
integr
care
team
ict
review
optimis
inpati
outpati
manag
copd
review
manag
aecopd
inpati
admit
tertiari
teach
hospit
develop
checklist
monitor
care
inpati
aecopd
adher
copd
nation
intern
guidelin
perform
retrospect
chart
review
checklist
adher
aecopd
admiss
westmead
hospit
ict
review
patient
usual
within
day
hospitalis
high
depend
record
complianc
checklist
provid
advic
inpati
team
regard
optimis
copd
manag
review
inpati
aecopd
male
mean
age
year
identifi
good
adher
oxygen
prescript
medic
chart
earli
antibiot
rationalis
spirometri
measur
complianc
howev
found
inhal
prescript
error
review
includ
incorrect
miss
prescript
duplic
inhal
class
patient
still
nebulis
therapi
ict
review
patient
current
smoker
half
offer
smoke
cessat
measur
respiratori
vaccin
patient
offer
pulmonari
rehabilit
ict
identifi
area
improv
inpati
manag
aecopd
includ
inhal
therapi
prescript
smoke
cessat
measur
referr
pulmonari
rehabilit
assess
immunis
role
ict
educ
ongo
monitor
optimis
inpati
aecopd
manag
research
need
understand
impact
improv
complianc
aecopd
guidelin
ambulatori
outcom
patient
copd
among
indigen
australian
asthma
common
chronic
respiratori
problem
asthma
relat
health
outcom
also
poorer
among
indigen
australian
address
innov
intervent
need
develop
mobil
phone
applic
app
exist
asthma
flipchart
local
indigen
languag
use
mixtur
static
interact
format
studi
aim
evalu
whether
app
improv
health
knowledg
understand
asthma
among
indigen
carer
children
asthma
evalu
app
includ
quantit
qualit
method
addit
usabl
test
schedul
quantit
compon
involv
studi
knowledg
base
previou
flipchart
studi
eighti
indigen
carer
children
asthma
enrol
carer
undergo
questionnair
follow
asthma
educ
use
app
questionnair
administ
immedi
session
subset
carer
repeat
questionnair
two
week
later
determin
knowledg
retent
qualit
compon
indigen
health
profession
without
asthma
particip
interview
ascertain
perspect
function
usabl
app
recruit
studi
commenc
late
octob
month
improv
asthma
relat
health
outcom
import
requir
focus
multidisciplinari
approach
particularli
group
indigen
australian
educ
form
mobil
app
innov
method
commun
health
messag
cultur
linguist
divers
group
move
toward
reduc
languag
context
barrier
particularli
face
indigen
peopl
rural
remot
set
asthma
app
potenti
improv
commun
knowledg
increas
access
usabl
health
educ
deliv
health
centr
declar
interest
nil
grant
support
asthma
australia
chronic
obstruct
pulmonari
diseas
copd
signific
impact
healthcar
system
patient
although
literatur
worldwid
support
efficaci
studi
tradit
entrench
econom
model
support
primari
outcom
decreas
healthcar
utilis
limit
literatur
rural
set
explor
copd
len
patient
experi
studi
aim
explor
concept
eye
patient
copd
live
rural
western
new
south
wale
nsw
understand
measur
heideggerian
phenomenolog
inquiri
form
framework
research
allow
explor
patient
live
experi
depth
interview
conduct
total
eight
particip
four
male
four
femal
report
diagnosi
copd
live
region
rural
western
nsw
met
inclus
criteria
interview
transcrib
verbatim
data
theme
analys
themat
satur
achiev
find
unveil
four
emerg
theme
adapt
pace
preserv
ownership
explor
identifi
social
emot
physic
domain
within
theme
adapt
pace
preserv
explor
phenomena
patient
len
identifi
true
mean
measur
success
explor
patient
live
experi
copd
provid
meaning
explan
patient
percept
open
concept
subject
patient
measur
indic
grant
support
research
support
nsw
ministri
health
rural
research
capac
build
program
western
nsw
lhd
conflict
interest
copd
nurs
present
lung
foundat
australia
fund
menarini
year
smoke
kill
estim
australian
cost
australia
billion
health
econom
cost
smoke
harm
nearli
everi
organ
bodi
caus
diseas
reduc
qualiti
life
life
expect
inpati
care
episod
repres
opportun
identifi
smoker
current
health
need
interven
consist
improv
health
care
outcom
nsw
health
polici
requir
consist
identif
smoker
minimum
brief
intervent
manag
nicotin
depend
health
care
system
transit
paper
electron
record
possibl
document
qualiti
may
suffer
area
purpos
audit
determin
qualiti
practic
import
area
whether
document
compromis
transit
electron
medic
record
emr
record
respiratori
medicin
inpati
januari
may
emr
analys
document
smoke
statu
admiss
hospit
offer
brief
advic
pharmacotherapi
referr
specialist
support
servic
current
smoker
paper
emr
record
analys
paper
record
identifi
smoke
statu
fell
significantli
p
test
emr
record
smoker
identifi
paper
record
smoker
emr
offer
smoke
cessat
intervent
smoke
statu
could
consist
identifi
record
provis
andor
document
smoke
cessat
intervent
poor
transit
emr
may
risk
poorer
health
servic
provis
document
audit
shown
need
improv
document
health
profession
smoke
intervent
per
nsw
govern
guidelin
achiev
conflict
interest
conflict
interest
grant
support
nil
asthma
allergi
rhinoviru
rv
speci
c
infect
associ
increas
sever
acut
wheez
asthma
compar
rv
speci
rvc
utilis
differ
host
cellular
receptor
rva
b
mechan
pathway
activ
rvc
contribut
sever
diseas
unknown
previous
identifi
gene
express
differ
nasal
cell
sampl
children
acut
asthma
wheez
infect
rvc
versu
rva
gene
includ
wherea
identifi
respons
hypothesis
protein
level
gene
would
differ
nasal
fluid
children
respiratori
exacerb
infect
rvc
versu
rva
nasal
fluid
sampl
collect
children
rva
rvc
present
tertiari
children
hospit
emerg
depart
acut
respiratori
ill
protein
measur
part
multiplex
elisa
thermofish
wherea
protein
measur
use
singl
elisa
kit
cusabio
urea
measur
use
quantit
chromat
assay
bioassay
system
use
standardis
elisa
measur
present
pg
protein
per
urea
level
significantli
differ
rva
median
rang
rvc
case
median
rang
level
also
significantli
differ
rva
median
rang
rvc
case
median
rang
level
differ
rva
median
rang
rvc
case
median
rang
gene
express
nasal
cell
sampl
collect
rvc
vs
acut
wheez
andor
asthma
differ
translat
alter
nasal
fluid
protein
level
grant
support
nation
health
medic
research
council
children
hospit
research
fund
univers
western
australia
asthma
foundat
western
australia
astrazeneca
declar
interest
none
thicken
airway
smooth
muscl
asm
layer
present
children
asthma
implic
development
origin
littl
known
structur
chang
occur
airway
asm
layer
late
gestat
adulthood
aim
studi
assess
matur
chang
airway
wall
structur
examin
mechan
asm
growth
term
hyperplasia
hypertrophi
extracellular
matrix
ecm
sheep
euthan
late
gestat
birth
post
wean
month
sexual
matur
year
lung
fix
instil
formaldehyd
sampl
obtain
trachea
main
bronchu
segment
bronchu
bronchu
peripher
airway
area
asm
layer
inner
outer
wall
perimet
basement
membran
pbm
measur
planimetri
number
size
asm
cell
assess
stereolog
fraction
muscl
ecm
within
asm
layer
determin
point
count
predomin
period
airway
matur
birth
month
age
airway
size
pbm
airway
wall
area
includ
asm
increas
trachea
p
segment
bronchu
p
bronchu
p
wall
area
normalis
pbm
effect
age
indic
airway
structur
grew
proport
airway
size
chang
less
pronounc
peripher
airway
mechan
asm
growth
due
increas
cell
number
result
cell
hypertrophi
chang
proport
ecm
substanti
airway
growth
occur
wean
includ
expans
asm
layer
result
cell
hyperplasia
upregul
asm
prolifer
infanc
could
facilit
thicken
asm
layer
develop
asthma
childhood
grant
support
nhmrc
declar
interest
statement
none
asthma
manag
pregnanc
associ
reduct
bronchiol
episod
first
year
life
matt
et
al
thorax
aim
analysi
investig
associ
infant
lung
function
week
age
bronchiol
first
month
life
cohort
babi
born
women
asthma
pregnanc
tidal
breath
loop
tbfvl
measur
perform
quiet
unsed
sleep
infant
born
mother
particip
ongo
rct
asthma
manag
versu
usual
care
breath
life
trial
research
remain
blind
regard
pregnanc
intervent
babi
recruit
date
attend
clinic
assess
remain
quiet
sleep
test
tbfvl
attempt
femal
age
week
sd
test
technic
accept
time
abstract
submiss
month
old
infant
one
episod
bronchiol
first
month
life
mean
time
peak
tidal
expiratori
flowtim
expiratori
flow
tpteft
sd
week
age
infant
episod
bronchiol
mean
tpteft
sd
without
bronchiol
mean
tpteft
sd
differ
respiratori
rate
rr
group
episod
mean
rr
breath
per
minut
episod
mean
rr
breath
per
minut
bronchiol
mean
rr
breath
per
minut
lung
function
may
associ
risk
develop
bronchiol
could
provid
link
mechan
effect
manag
bronchiol
preval
grant
support
nhmrc
john
hunter
hospit
prc
growupwel
hmri
hcrf
earli
life
respiratori
infect
associ
develop
sever
asthma
detect
respiratori
virus
bacteria
occur
frequent
children
acut
wheez
howev
mechanist
interact
neonat
respiratori
infect
establish
allerg
neutrophil
lung
inflamm
remain
poorli
understood
sever
asthma
aim
investig
role
neonat
exposur
infecti
pathogen
develop
asthmat
pathogenesi
airway
remodel
intranas
inocul
streptococcu
pneumonia
cfu
salin
influenza
viru
pfu
salin
perform
neonat
mice
femal
balbc
age
day
day
respect
age
day
hous
dust
mite
hdm
salin
administ
intranas
daili
week
therapeut
studi
separ
cohort
mice
treat
describ
last
week
hdm
regim
receptor
isotyp
antibodi
inject
intraperiton
everi
second
day
hdm
challeng
mice
neonat
significantli
increas
pneumococc
lung
infect
neutrophil
inflamm
mucu
product
neutrophil
lung
inflamm
associ
increas
stimul
factor
block
significantli
reduc
neutrophl
inflamm
bronchoalveolar
bal
myeloperoxidas
activ
lung
tissu
without
increas
pneumococc
lung
load
addit
elev
marker
netosi
includ
neutrophil
elastas
dna
reduc
treat
mice
therapi
also
potent
reduc
inflamm
includ
bal
eosinophil
lung
transcript
cell
mucu
product
disrupt
significantli
reduc
neutrophil
mobilis
netosi
without
worsen
pneumococc
lung
infect
furthermor
reduc
inflamm
allerg
airway
diseas
monoclon
antibodi
may
repres
novel
therapeut
target
mix
granulocyt
sever
asthma
grant
support
work
support
nation
health
medic
research
council
australia
grant
number
australian
research
council
grant
number
human
rhinovirus
rv
respiratori
syncyti
viru
rsv
common
respiratori
virus
children
acut
wheez
ill
virus
use
human
receptor
enter
host
cell
rsv
use
nucleolin
ncl
rv
use
intercellular
adhes
molecul
low
densiti
lipoprotein
receptor
ldlr
cadherin
relat
famili
member
aim
assess
whether
variant
viral
receptor
gene
associ
asthma
sever
cohort
children
present
tertiari
children
hospit
emerg
depart
acut
asthma
sampl
nasal
sampl
rv
detect
dna
extract
peripher
blood
analysi
viral
receptor
gene
sequenc
use
ion
ampliseq
primer
thermo
fisher
scientif
data
collect
includ
number
hour
present
discharg
number
respiratori
hospit
present
admiss
birth
number
salbutamol
dose
administ
first
hour
statist
analysi
complet
use
spss
version
analys
adjust
age
gender
mean
age
children
male
detect
rv
children
genotyp
gc
cc
ncl
cc
fold
less
like
rhinoviru
detect
recruit
children
genotyp
confid
interv
ci
ci
respect
children
tt
genotyp
fold
hospit
visit
recruit
ci
took
fold
longer
discharg
hospit
ci
compar
children
cc
genotyp
children
gg
genotyp
fold
fewer
treatment
dose
hour
ci
children
aa
genotyp
gene
variant
viral
receptor
gene
may
play
role
viral
infect
treatment
respons
thu
recurr
respiratori
ill
requir
present
hospit
grant
support
nhmrc
financi
market
foundat
children
univers
postgradu
award
uwa
scholarship
conflict
interest
nomin
nil
abstract
withdrawn
paediatr
avail
robust
commerci
multipl
breath
nitrogen
washout
mbnw
equip
offer
improv
feasibl
widespread
preschool
lung
function
test
cystic
fibrosi
cf
clinic
clinic
util
emerg
commerci
equip
prognost
valu
perform
preschool
mbw
defin
age
year
remain
unclear
previous
shown
associ
higher
preschool
lung
clearanc
index
lci
valu
greater
medic
use
incid
bacteri
isol
within
clinic
studi
aim
explor
associ
preschool
lci
valu
later
spirometri
well
establish
clinic
tool
older
cf
subject
current
spirometri
valu
collat
origin
preschool
children
mbw
perform
mean
sd
age
rang
yr
median
rang
lci
spirometri
result
express
gli
refer
equat
abnorm
preschool
lci
defin
base
recent
publish
preschool
healthi
control
data
use
ident
equip
test
uln
lci
technic
accept
spirometri
data
avail
one
move
state
one
autism
mean
sd
rang
age
year
year
origin
mbw
test
time
point
data
present
mean
sd
abnorm
lci
valu
preschool
year
associ
later
spirometri
deficit
suggest
prognost
util
mbw
test
younger
preschool
age
rang
predict
later
spirometri
valu
stanojev
et
al
ajrccm
grant
support
cf
fundrais
chw
conflict
interest
conflict
interest
declar
despit
bronchiti
common
find
flexibl
bronchoscopi
fb
mani
paediatr
centr
valid
object
system
exist
previous
record
fb
determin
correl
among
differ
macroscop
find
airway
neutrophilia
examin
repeat
find
develop
experiment
model
object
bronchiti
score
bscoreexp
review
consecut
previou
record
databas
exclud
fb
bal
data
unavail
incomplet
fb
record
fb
children
endotrach
tube
tracheostomi
foreign
bodi
fb
record
assess
scorer
independ
blind
clinic
histori
compon
amount
secret
score
previou
valid
score
colour
secret
use
bronkotest
mucos
oedema
ridg
erythema
pallor
base
criteria
pictori
chart
variou
model
bscoreexp
plot
neutrophil
use
receiv
oper
characterist
roc
curv
report
preliminari
find
first
children
valid
fb
secret
amount
colour
significantli
correl
bal
neutrophil
macroscop
find
correl
fb
examin
repeat
kappa
valu
secret
ci
colour
ci
excel
k
rang
use
bal
neutrophilia
defin
inflamm
highest
aroc
ci
obtain
give
three
time
weightag
secret
amount
colour
ad
compon
except
pallor
repeat
bronchiti
score
system
deriv
howev
prospect
studi
need
perform
larger
number
evalu
differ
model
obtain
aroc
grant
support
kpe
fund
apsr
scholarship
abc
nhmrc
practition
fellowship
declar
interest
statement
none
pbb
common
caus
paediatr
chronic
cough
defin
chronic
wet
cough
without
specif
sign
symptom
altern
caus
respond
appropri
antibiot
therapi
first
outcom
data
children
pbb
aim
describ
clinic
outcom
children
pbb
children
median
age
rang
recruit
follow
monthli
contact
research
staff
possibl
annual
physician
clinic
review
flexibl
bronchoscopi
bronchoalveolar
lavag
basic
immun
test
perform
baselin
chest
ct
perform
clinic
featur
suggest
bronchiectasi
bronchiectasi
diagnos
paediatr
radiolog
criteria
clinic
featur
present
spirometri
undertaken
final
possibl
present
data
initi
children
n
cohort
data
children
pbb
median
age
rang
boy
ct
undertaken
children
period
bronchiectasi
diagnos
within
frequenc
recurr
pbb
decreas
durat
studi
children
pbb
tracheomalacia
andor
bronchomalacia
bronchoscopi
whilst
visibl
evid
bronchiti
point
mean
predict
sd
pbb
control
group
pbb
associ
subsequ
diagnosi
bronchiectasi
proport
children
recognis
within
month
initi
pbb
diagnosi
recurr
pbb
decreas
time
recurr
episod
review
bronchiectasi
spirometri
valu
remain
normal
rang
children
diagnos
pbb
grant
support
work
support
nation
health
medic
research
council
pg
sp
sh
ac
support
nhmrc
fellowship
kb
support
lung
foundat
australia
fellowship
spinomuscular
atrophi
sma
uncommon
progress
neuromuscular
disord
nmd
signific
respiratori
morbid
eventu
respiratori
failur
current
clear
guidelin
ventil
niv
instig
condit
newer
treatment
option
like
chang
current
clinic
practic
improv
respiratori
assess
method
need
object
cohort
analys
pattern
sleep
breath
measur
polysomnographi
psg
determin
earli
clinic
lung
function
predictor
nocturn
hypoventil
retrospect
review
clinic
record
psg
data
children
sma
iiiii
live
queensland
spirometri
forc
oscillatori
techniqu
fot
lung
clearanc
index
lci
respiratori
muscl
strength
test
prospect
perform
measur
prospect
arm
studi
ongo
complet
data
collect
expect
novemb
children
sma
ii
median
age
month
includ
median
fvc
predict
z
score
snip
lci
median
iqr
rem
relat
index
rahi
high
children
sma
ii
requir
nocturn
niv
initi
median
age
month
acut
respiratori
ill
children
older
vs
month
significantli
wors
score
vs
p
rahi
vs
lci
vs
snip
vs
predictor
niv
need
analys
use
logist
regress
model
prospect
arm
complet
children
sma
ii
need
nocturn
ventilatori
support
begin
earli
childhood
fvc
may
predictor
fot
snip
lci
derang
may
help
predict
earli
respiratori
insuffici
particularli
earli
year
grant
support
none
declar
interest
conflict
interest
chorioamnion
associ
preterm
birth
develop
airway
diseas
later
life
chorioamnion
promot
lung
inflamm
effect
airway
smooth
muscl
asm
function
unknown
postnat
steroid
given
preterm
infant
sever
lung
diseas
may
benefici
effect
airway
develop
studi
examin
separ
combin
effect
chorioamnion
postnat
steroid
asm
contract
preterm
ovin
model
chorioamnion
induc
ia
inject
lipopolysaccharid
lp
ewe
gestat
postnat
lamb
receiv
intraven
dexamethason
lpsdex
salin
lpssal
commenc
within
h
birth
postnat
control
receiv
ia
salin
gestat
daili
intraven
dexamethason
saldex
salin
salsal
postnat
lamb
deliv
via
caesarean
section
gestat
receiv
respiratori
support
requir
euthanis
ie
postconcept
age
fifth
group
fetal
control
lamb
euthanis
immedi
gestat
matur
control
bronchial
ring
studi
organ
bath
chamber
isometr
forc
product
acetylcholin
measur
curv
construct
determin
maxim
respons
slope
sensit
asm
thick
determin
histolog
masson
trichrom
maxim
respons
slope
sensit
similar
matur
postnat
placebo
control
indic
asm
contract
unaffect
preterm
deliveri
maxim
respons
increas
ia
lp
administr
p
significantli
affect
postnat
dexamethason
slope
reduc
postnat
dexamethason
p
lamb
asm
thick
lower
anim
treat
postnat
dexamethason
irrespect
prior
exposur
lp
p
asm
contract
enhanc
offspr
born
pregnanc
suppress
postnat
dexamethason
reduc
asm
thick
postnat
dexamethason
may
reduc
incid
futur
airway
diseas
chorioamnion
grant
support
nhmrc
tpchrf
mhrif
larg
prevent
csld
includ
bronchiectasi
remain
highli
preval
amongst
disadvantag
indigen
popul
high
incom
countri
adult
studi
csld
shown
persist
airway
infect
inflamm
longer
durat
chronic
product
cough
result
poorer
clinic
outcom
howev
prospect
studi
children
csld
last
help
guid
clinic
care
manag
evalu
clinic
outcom
indigen
children
csld
particip
previou
studi
multicentr
bronchiectasi
studi
bo
mani
children
possibl
bo
australia
alaska
new
zealand
research
staff
administ
standardis
questionnair
undertook
medic
note
review
clinic
examin
spirometri
medic
histori
extract
origin
dataset
current
medic
record
base
clinic
assess
physician
classifi
children
overal
categori
well
better
stabl
wors
children
current
median
age
iqr
male
review
birth
current
age
children
median
iqr
acut
lower
respiratori
infect
iqr
respiratori
hospitalis
respiratori
infect
decreas
age
examin
wheez
present
wet
cough
digit
club
children
children
summari
clinic
statu
well
better
stabl
wors
airway
obstruct
spirometri
present
restrict
pattern
normal
spirometri
valu
within
popul
norm
children
csld
clinic
care
stabl
improv
adolesc
howev
mani
still
experi
respiratori
symptom
demonstr
impair
lung
function
clinic
recommend
adolesc
optimis
clinic
manag
declar
interest
nil
grant
support
nhmrc
cre
lung
health
gb
ac
support
nhmrc
fellowship
asthma
allergi
salbutamol
oppos
airway
hyperrespons
asthma
efficaci
limit
desensitis
free
fatti
acid
receptor
express
mous
human
lung
mizuta
et
al
ajp
lung
agonist
caus
relax
mous
airway
greater
efficaci
salbutamol
bourk
et
al
ajrcmb
compar
bronchodil
salbutamol
agonist
agonist
condit
desensitis
test
potenti
desensitis
assess
ffar
express
mous
airway
model
chronic
allerg
airway
diseas
human
airway
subject
without
asthma
precis
cut
lung
slice
prepar
male
balbc
mice
airway
relax
salbutamol
compar
overnight
incub
salbutamol
vehicl
immunohistochemistri
ffar
perform
lung
section
salin
control
c
ovalbumin
ova
mice
airway
biopsi
na
asthmat
subject
salbutamol
ffar
agonist
relax
airway
methacholin
relax
salbutamol
overnight
incub
salbutamol
reduc
subsequ
relax
salbutamol
p
cf
control
respect
incub
affect
relax
resepect
express
similar
c
ova
mous
airway
posit
pixel
c
ova
receptor
evid
airway
smooth
muscl
epithelium
na
human
airway
relax
ffar
agonist
maintain
condit
desensitis
resist
homolog
desensitis
express
asthma
context
suggest
receptor
may
target
altern
adjunct
bronchodil
therapi
sever
asthma
sa
chronic
obstruct
pulmonari
diseas
copd
bronchiectasi
obstruct
airway
diseas
oad
share
clinic
characterist
like
impair
patient
physic
activ
pa
level
howev
pa
extens
studi
oad
outsid
copd
aim
describ
preval
pa
impair
differ
oad
compar
control
test
whether
oad
group
pa
associ
share
clinic
characterist
diseas
studi
adult
oad
control
conduct
particip
underw
multidimension
assess
involv
measur
bodi
mass
index
bmi
lung
function
exercis
capac
walk
distanc
health
statu
sgrq
system
inflamm
hscrp
pa
stepsday
measur
use
actigraph
oad
group
includ
particip
femal
median
iqr
age
year
mean
predict
control
group
includ
particip
femal
age
year
compar
control
oad
accumul
less
stepsday
median
differ
copd
sa
bronchiectasi
result
compar
copd
sa
bronchiectasi
accumul
stepsday
median
differ
respect
statist
signific
differ
found
sa
bronchiectasi
group
separ
adjust
regress
model
predict
sgrq
associ
physic
activ
particip
oad
full
multivari
model
predict
bmi
remain
significantli
associ
explain
adjust
varianc
pa
peopl
oad
p
peopl
oad
engag
lower
level
pa
compar
control
degre
activ
impair
differ
diseas
despit
level
activ
associ
share
clinic
characterist
intervent
improv
pa
multifactori
target
oad
popul
irrespect
diagnosi
grant
support
nhmrc
john
hunter
hospit
charit
trust
hmri
conflict
interest
vmm
support
nhmrc
trip
fellowship
particip
educ
symposia
fund
glaxosmithklin
astrazeneca
menarini
novarti
particip
advisori
board
glaxosmithklin
astrazeneca
menarini
pgg
hold
nhmrc
practition
fellowship
particip
educ
symposia
fund
astrazeneca
boehring
ingelheim
glaxosmithklin
novarti
particip
studi
fund
glaxosmithklin
astrazeneca
pag
support
dementia
research
develop
fellowship
particip
educ
symposium
fund
boehring
ingelheim
epitheli
appear
import
role
polar
type
immun
respons
allergen
though
whether
also
modifi
respons
respiratori
virus
asthma
clear
examin
effect
cellular
immun
asthma
focus
role
two
chain
receptor
interleukin
receptor
like
also
known
receptor
accessori
protein
peripher
blood
mononuclear
cell
isol
peopl
mildmoder
allerg
asthma
healthi
donor
expos
activ
rhinoviru
rv
serotyp
mrna
protein
express
assess
qpcr
flow
cytometri
andor
elisa
asthma
rv
induc
greater
type
cytokin
product
wherea
control
subject
enhanc
type
cytokin
product
rv
alon
rv
induc
upregul
mrna
surfac
protein
express
asthma
respect
healthi
particip
due
enhanc
express
type
innat
lymphoid
cell
convent
contrast
neither
rv
effect
express
express
cell
major
sourc
product
find
suggest
dysregul
receptor
asthma
provid
mechan
rv
infect
might
exacerb
type
inflamm
rich
tissu
environ
grant
support
nhmrc
cre
sever
asthma
abstract
withdrawn
aim
characteris
peopl
affect
catastroph
event
melbourn
australia
novemb
identifi
individu
patient
characterist
associ
hospit
admiss
inform
research
practic
manag
prevent
increasingli
recognis
potenti
fatal
phenomenon
retrospect
analysi
demograph
patient
present
royal
melbourn
hospit
adult
metropolitan
univers
teach
hospit
melbourn
clinic
characterist
patient
subsequ
attend
outpati
clinic
review
patient
gener
young
adult
mean
age
year
season
rhiniti
univers
sensitis
ryegrass
pollen
patient
requir
hospitalis
patient
prior
diagnosi
asthma
amongst
known
asthmat
preced
event
activ
asthma
symptom
per
cent
patient
receiv
therapi
alon
hospitalis
associ
uncontrol
asthma
symptom
month
prior
event
symptomat
allerg
rhiniti
lower
lung
function
higher
total
ige
higher
peripher
blood
eosinophil
count
measur
review
affect
peopl
season
rhiniti
ryegrass
sensitis
occur
without
prior
histori
asthma
dramat
potenti
rapidli
inund
healthcar
system
poor
asthma
control
earlier
hay
fever
season
associ
hospitalis
inhal
corticosteroid
consid
prior
season
strongli
sensitis
individu
grant
support
author
potenti
conflict
interest
disclos
exercis
benefit
gener
health
howev
impact
asthma
receiv
littl
attent
effect
exercis
intens
examin
popul
previous
found
singl
bout
exercis
decreas
exhal
nitric
oxid
physic
inact
physic
activ
adult
asthma
aim
studi
examin
acut
effect
exercis
intens
airway
inflamm
adult
asthma
examin
whether
differ
usual
exercis
level
randomis
control
trial
adult
asthma
randomis
complet
either
minut
exercis
hrmax
cycl
ergomet
minut
exercis
hrmax
cycl
ergomet
minut
rest
sputum
cell
count
obtain
day
prior
exerciserest
sputum
eosinophil
count
lower
follow
exercis
versu
rest
howev
sputum
eosinophil
count
chang
follow
exercis
versu
rest
particip
report
perform
exercis
caus
breathless
sweat
per
week
signific
decreas
sputum
eosinophil
count
vs
sputum
eosinophil
vs
follow
exercis
compar
rest
particip
becam
breathless
sweati
exercis
chang
sputum
eosinophil
count
sputum
eosinophil
follow
exercis
challeng
studi
demonstr
acut
bout
exercis
reduc
sputum
eosinophil
adult
asthma
chang
evid
physic
inact
particip
suggest
regular
physic
activ
may
protect
airway
inflamm
grant
support
respiratori
research
fellowship
asthma
australia
project
grant
cystic
fibrosi
prior
studi
cystic
fibrosi
transmembran
conduct
regul
cftr
modul
patient
heterozyg
minim
function
mf
cftr
mutat
fail
one
strategi
enhanc
clinic
efficaci
add
second
corrector
establish
correctorpotenti
regimen
safeti
efficaci
ng
corrector
therapi
tc
tezacaftor
tez
ivacaftor
iva
evalu
patient
cf
genotyp
random
studi
phase
phase
tc
conduct
cf
patient
genotyp
latter
week
teziva
pretreat
primari
object
safeti
toler
efficaci
pharmacodynam
effect
assess
absolut
chang
sweat
chlorid
baselin
respect
baselin
characterist
balanc
ng
tc
regimen
well
toler
advers
event
ae
mild
moder
ae
lead
discontinu
includ
increas
alanin
aminotransferaseaspart
aminotransferas
tc
pneumonia
tc
respir
abnormalsputum
increas
placebo
week
signific
improv
baselin
percentag
point
seen
ng
tc
regimen
patient
signific
improv
baselin
percentag
point
seen
tc
top
teziva
patient
vs
teziva
baselin
signific
reduct
baselin
sweat
chlorid
also
seen
tc
regimen
vs
placebo
teziva
alon
first
demonstr
substanti
improv
ng
tc
regimen
patient
cf
genotyp
previou
cftr
modul
fail
patient
cf
genotyp
ongo
studi
guid
develop
tc
regimen
grant
support
sponsor
vertex
pharmaceut
incorpor
conflict
interest
pw
investig
next
gen
clinic
trial
taken
part
advisori
board
vertex
pharmaceut
determin
blood
transcript
gene
signatur
could
use
predict
risk
exacerb
next
month
cf
particip
recruit
stabl
annual
review
follow
month
peripher
blood
rna
collect
paxgen
rna
tube
rna
extract
use
paxgen
blood
rna
kit
qiagen
rna
qualiti
quantiti
assess
use
bioanalys
agil
technolog
transcript
profil
gener
illumina
analys
use
genespr
particip
mean
age
mean
predict
sd
unsupervis
hierarch
cluster
gene
express
profil
reveal
distinct
cluster
cluster
characteris
significantli
lower
predict
higher
residu
volum
predict
lower
bmi
frequent
exacerb
requir
iv
antibiot
increas
presenc
pseudomona
compar
cluster
sever
phenotyp
cluster
associ
reduct
express
entiti
includ
downregul
immun
regulatori
gene
transcript
profil
peripher
blood
predict
diseas
sever
futur
risk
exacerb
next
month
grant
support
na
cystic
fibrosi
cf
result
insulin
defici
birth
progress
cystic
diabet
cfrd
cfrd
signific
impact
lung
function
respiratori
infect
nutrit
lead
increas
mortal
howev
preval
earli
hyperglycaemia
impact
respiratori
tract
infect
young
children
cf
remain
unknown
determin
preval
hyperglycaemia
children
cf
use
continu
glucos
monitor
cgm
correl
hyperglycemia
cgm
presenc
cf
pathogen
neutrophil
percentag
routin
bronchoalveolar
lavag
bal
studi
children
cf
cgm
devic
cgm
medtron
minim
insert
clinic
well
routin
bronchoscopyb
worn
day
cgm
outcom
includ
peak
glucos
time
spent
area
curv
auc
bal
sampl
cultur
cell
count
differenti
determin
regress
analysi
undertaken
examin
relationship
hyperglycaemia
presenc
cf
pathogen
neutrophil
percentag
bal
children
femal
cgm
perform
neutrophil
percentag
result
avail
median
age
year
rang
day
glucos
sd
diabet
rang
glucos
level
particip
posit
cultur
spent
greater
period
time
cgm
mean
time
compar
cultur
neg
particip
greater
glucos
auc
posit
correl
peak
glucos
auc
p
neutrophil
burden
lavag
young
children
cf
demonstr
diabet
rang
hyperglycaemia
cgm
cf
pathogen
like
present
glucos
abnorm
sever
signific
correl
neutrophil
count
hyperglycemia
demonstr
research
underway
determin
whether
abnorm
cgm
cohort
impact
nutrit
pulmonari
inflamm
lung
function
milner
ad
blood
glucos
serum
insulin
level
children
cystic
fibrosi
archiv
diseas
childhood
antoinett
moran
et
al
cystic
diabet
current
trend
preval
incid
mortal
diabet
care
sep
grant
supportdeclar
interest
sh
cfv
grate
fund
assist
nation
health
medic
research
council
australia
australasian
cystic
fibrosi
research
trust
region
diabet
support
scheme
sydney
children
hospit
foundat
australasian
pediatr
endocrin
care
grant
pfizer
industri
support
novo
nordisk
medtron
abbott
diagnost
bp
award
tsanzvertex
cystic
fibrosi
paediatr
clinic
fellowship
sleep
qualiti
peopl
cystic
fibrosi
cf
known
poor
regular
physic
activ
particip
associ
less
declin
lung
function
relationship
sleep
qualiti
physic
activ
peopl
cf
unknown
aim
explor
associ
sleep
pattern
physic
activ
particip
young
adult
cf
secondari
analysi
sleep
activ
data
collect
via
actigraphi
adult
cf
stabl
health
particip
studi
physic
activ
includ
assess
exercis
capac
complet
day
activ
sleep
assess
sensewear
armband
swa
bodymedia
usa
sleep
characterist
deriv
acceleromet
posit
data
registr
sleep
state
swa
determin
energi
expenditur
sleep
activ
data
avail
particip
male
mean
sd
age
year
median
iqr
predict
fragment
sleep
associ
poorer
exercis
capac
time
spent
physic
activ
mvpa
poorer
stepwis
multipl
regress
model
includ
age
sex
bodi
mass
index
model
includ
wake
sleep
onset
waso
signific
predict
total
activ
time
total
mvpa
time
respect
p
less
waso
significantli
predict
total
daili
activ
time
se
trend
toward
signific
predict
greater
mvpa
time
se
greater
total
sleep
time
sleep
effici
relat
better
exercis
capac
lung
function
p
analysi
demonstr
modest
relationship
sleep
paramet
physic
activ
exercis
capac
adult
cf
futur
studi
intervent
promot
physic
activ
particip
group
consid
relationship
sleep
activ
perform
grant
support
nhmrc
earli
career
fellowship
la
trobe
univers
research
collabor
grant
imag
medic
beamlin
imbl
australian
synchrotron
design
world
widest
synchrotron
beam
facilit
clinic
imag
therapeut
applic
human
well
imag
larg
anim
model
group
current
interest
imag
airway
cf
anim
model
display
lung
diseas
cf
pig
hypothesis
abil
lung
clear
inhal
particul
mucociliari
transit
mct
use
outcom
measur
assess
effect
cf
airway
therapi
studi
extend
find
ex
vivo
sheep
pig
tracheal
tissu
studi
previous
perform
imbl
design
determin
whether
design
imbl
suitabl
imag
pig
airway
small
sampl
diamet
high
refract
index
hri
glass
bead
marker
particl
deliv
tracheal
airway
surfac
eight
live
piglet
autom
analysi
algorithm
use
track
quantifi
motion
includ
respons
aerosol
deliveri
hyperton
salin
comput
tomograph
ct
scan
one
pig
also
perform
verifi
ct
capabl
imbl
mct
track
particl
visibl
anim
autom
mct
track
algorithm
abl
identifi
track
particl
ct
whole
anim
success
acquir
visualis
success
made
ct
dataset
due
unexpect
imbl
technic
equip
issu
shutter
bean
sometim
poorli
control
result
high
radiat
dose
anim
studi
demonstr
imbl
suitabl
larg
anim
tracheal
mct
imag
ct
radiat
dose
must
care
reliabl
control
futur
studi
enabl
estim
minimum
achiev
dose
experi
design
acknowledg
wch
foundat
nhmrc
project
grant
http
australian
synchrotron
propos
number
peopl
cystic
fibrosi
cf
live
longer
thu
face
issu
relat
work
aim
studi
peopl
cf
live
western
australia
report
work
statu
absente
absenc
work
due
ill
presente
loss
perform
work
due
ill
ii
explor
factor
relat
work
statu
absente
presente
secondari
analys
larger
studi
conduct
measur
collect
work
statu
absente
presente
world
health
organis
health
perform
questionnair
airflow
obstruct
qualiti
life
hrqol
cf
level
educ
adult
cf
group
work
statu
versu
absenteeismpresente
substanti
versu
substanti
differ
explor
factor
relat
work
statu
absenteeismpresente
evalu
use
logist
regress
particip
yr
percent
predict
sd
work
particip
report
work
sd
hrweek
compar
particip
work
older
median
iqr
yr
versu
yr
higher
level
educ
versu
complet
univers
tertiari
studi
higher
educ
level
associ
reduc
odd
work
unemploy
ci
substanti
absente
substanti
presente
report
particip
respect
report
substanti
absente
wors
hrqol
median
iqr
role
domain
score
substanti
absente
versu
substanti
absente
associ
found
substanti
presente
despit
moder
diseas
sever
particip
report
work
cystic
fibrosi
may
greater
impact
upon
absente
presente
howev
larger
studi
need
determin
reason
greater
impact
grant
support
studi
partial
fund
sir
charl
gairdner
group
research
advisori
council
grant
declar
interest
nil
declar
interest
nil
occup
environment
lung
diseas
popul
health
idiopath
pulmonari
fibrosi
ipf
progress
scar
lung
diseas
unknown
caus
limit
treatment
median
surviv
year
aim
identifi
potenti
occup
environment
exposur
associ
develop
ipf
australia
case
recruit
australian
ipf
registri
patient
complet
questionnair
demograph
smoke
famili
histori
environment
occup
exposur
medic
histori
clinic
radiolog
histopatholog
data
review
multidisciplinari
panel
popul
base
control
recruit
random
digit
diall
frequenc
match
age
sex
state
interview
collect
compar
data
multivari
logist
regress
use
assess
associ
ipf
odd
ratio
confid
interv
ci
adjust
age
sex
smoke
data
case
assess
multidisciplinari
discuss
definit
probabl
possibl
ipf
control
age
case
control
year
case
control
male
current
past
tobacco
smoke
associ
increas
risk
ipf
ci
marijuana
use
appear
protect
famili
histori
pulmonari
fibrosi
associ
fold
increas
risk
ipf
domest
environment
exposur
associ
increas
risk
pet
bird
stand
water
appear
protect
respect
occup
exposur
asbesto
associ
increas
risk
silica
appear
protect
occup
exposur
gase
fume
chemic
dust
associ
ipf
preliminari
find
suggest
burden
ipf
could
reduc
continu
tobacco
control
measur
prevent
ongo
exposur
asbesto
detail
assess
occup
exposur
undertaken
use
finnish
job
exposur
matrix
finjem
nhmrc
longitudin
surveil
firefight
lung
function
highli
valuabl
especi
consid
util
determin
chang
function
follow
disastr
exposur
studi
investig
rate
chang
lung
function
paramet
firefight
howev
produc
mix
find
aim
determin
rate
chang
fvc
contemporari
cohort
profession
south
australian
metropolitan
fire
servic
samf
firefight
spirometri
conduct
stage
avail
consent
firefight
staff
accord
atser
criteria
use
viasi
spirometri
system
examin
serial
fvc
measur
determin
averag
rate
chang
use
linear
mix
effect
model
particip
stage
data
collect
rang
approxim
data
individu
male
firefight
contribut
averag
rang
measur
includ
analysi
fifti
per
cent
includ
firefight
least
three
measur
preliminari
analys
show
proport
firefight
lower
limit
normal
lln
baselin
fvc
longitudin
adjust
baselin
age
height
declin
ci
mlyr
fvc
declin
ci
mlyr
samf
firefight
observ
studi
show
normal
level
fvc
baselin
unsurpris
given
select
part
base
physic
fit
earli
result
indic
cohort
normal
rate
chang
fvc
suggest
lung
function
remain
rel
unaffect
occup
research
support
south
australian
metropolitan
fire
servic
australian
govern
research
train
program
scholarship
fs
fraction
exhal
nitric
oxid
feno
use
measur
eosinophil
airway
inflamm
unknown
appropri
recommend
feno
rang
aborigin
andor
torr
strait
island
patient
aim
assess
distribut
healthi
aborigin
andor
torr
strait
island
feno
result
accord
current
american
thorac
societi
guidelin
measur
feno
use
aerocrin
nioxmino
indigen
children
young
adult
age
year
seven
queensland
commun
questionnair
medic
chart
review
identifi
healthi
particip
respiratori
andor
atop
ill
ever
accept
feno
measur
achiev
children
year
adult
year
particip
histori
respiratori
andor
atopi
condit
exclud
result
healthi
cohort
children
adult
geometr
mean
feno
result
children
adult
respect
tabl
summaris
distribut
healthi
feno
result
ethnic
group
accord
current
rang
although
major
particip
feno
result
within
normal
rang
found
proport
healthi
particip
elev
feno
result
group
greatest
proport
elev
result
seen
torr
strait
island
children
adult
aboriginaltorr
strait
island
children
suggest
recommend
rang
may
appropri
group
investig
still
need
iroc
program
qld
health
cre
indigen
lung
health
children
nhrmc
phd
scholarship
tb
nhmrc
practition
fellowship
ac
asbesto
exposur
increas
risk
lung
cancer
especi
smoker
western
australia
wa
highest
rate
diseas
world
due
crocidolit
mine
pilbara
town
wittenoom
widespread
use
asbesto
throughout
wa
earli
diagnosi
utilis
low
dose
ct
ldct
scan
shown
reduc
mortal
lung
cancer
analys
efficaci
ldct
detect
lung
cancer
popul
period
asbesto
review
program
base
sir
charl
gairdner
hospit
began
perform
annual
ldct
screen
popul
asbesto
relat
lung
diseas
lung
cancer
popul
wittenoom
miner
resid
individu
month
cumul
full
time
exposur
particip
prone
ldct
scan
annual
health
questionnair
includ
smoke
statu
spirometri
ga
transfer
ldct
scan
perform
individu
median
age
year
iqr
male
lung
cancer
diagnos
particip
cohort
stage
b
underw
treatment
cur
intent
underw
lung
cancer
preval
incid
individu
see
tabl
one
particip
die
month
surgeri
found
diseas
oper
particip
treat
cur
reoccurr
date
mesothelioma
diagnos
individu
asbestosi
present
arp
popul
pleural
plaqu
confirm
signific
asbesto
exposur
median
radiat
exposur
per
ldct
iqr
care
control
ldct
screen
program
effect
diagnos
treat
lung
cancer
popul
occup
exposur
asbesto
account
assess
risk
lung
cancer
tabl
characterist
arp
particip
diagnos
lung
cancer
air
pollut
exposur
contribut
develop
chronic
obstruct
pulmonari
diseas
copd
previou
studi
examin
lung
function
beyond
airway
aim
examin
relationship
exposur
nitrogen
dioxid
gaseou
air
pollut
complex
lung
function
measur
australian
data
obtain
tasmanian
longitudin
health
studi
particip
year
age
annual
outdoor
mean
concentr
particip
residenti
address
estim
use
valid
regress
model
multivari
regress
use
spirometri
carbon
monoxid
transfer
factor
tlco
static
lung
volum
continu
outcom
median
exposur
interquartil
rang
part
per
billion
increas
exposur
associ
reduc
tlco
manner
compar
lowest
quartil
exposur
reduct
tlco
equival
predict
highest
quartil
ci
independ
smoke
significantli
lower
current
asthma
p
interact
trend
reduc
tlc
reduct
fvc
past
current
smoker
expos
highest
quartil
pred
p
interact
statist
signific
relationship
ga
trap
rvtlc
provid
evid
moder
advers
associ
exposur
tlco
rel
low
pollut
level
vari
current
asthma
statu
featur
favour
lung
parenchym
process
although
small
airway
narrow
may
mask
reduc
fvc
level
new
knowledg
support
environment
polici
reduc
level
low
feasibl
nhmrc
includ
centr
air
qualiti
health
research
evalu
car
clifford
craig
foundat
asthma
foundat
ta
vic
qld
acceler
adult
lung
function
declin
major
pathway
chronic
obstruct
pulmonari
diseas
sought
investig
associ
interact
life
span
factor
lung
function
declin
middl
age
lung
function
measur
year
particip
tasmanian
longitudin
health
studi
use
multivari
linear
regress
investig
associ
factor
adulthood
current
asthma
smoke
atopi
bmi
bmi
chang
occup
exposur
traffic
relat
air
pollut
childhood
pneumonia
asthma
parent
asthma
parent
smoke
glutathion
gene
polymorph
rate
lung
function
declin
year
interact
factor
also
investig
current
asthma
ci
mlyear
current
smoke
mlyear
atopi
mlyear
year
lifetim
occup
exposur
vapourgasdustfum
mlyear
increas
bmi
period
mlyear
per
increas
independ
associ
acceler
declin
control
age
height
sex
socioeconom
statu
lung
function
baselin
year
current
smoke
mlyear
bmi
chang
mlyear
per
increas
associ
greater
fvc
declin
polymorph
modifi
effect
occup
exposur
heavi
matern
smoke
childhood
modifi
effect
person
smoke
fvc
declin
effect
occup
exposur
signific
carrier
null
genotyp
effect
person
smoke
augment
also
expos
matern
smoke
lung
function
declin
sampl
predominantli
influenc
adult
factor
exposur
matern
smoke
childhood
genet
suscept
may
predispos
peopl
suscept
adulthood
exposur
nation
health
medic
research
council
australia
clifford
craig
medic
research
trust
tasmania
victorian
queensland
tasmanian
asthma
foundat
conflict
interest
primari
care
palli
care
tobacco
person
vapor
aerosolis
liquid
produc
aerosol
inhal
regul
ingredi
differ
flavour
nicotin
concentr
excipi
blend
avail
thousand
supplier
furthermor
mani
ingredi
approv
food
addit
inhal
toxicolog
data
may
unavail
aim
test
properti
rang
aerosol
identifi
potenti
toxic
substanc
ii
see
whether
ingredi
match
label
obtain
australian
us
retail
chemistri
analys
via
aerosol
gener
use
devic
base
innokin
vapor
innokin
cartom
set
aerosol
collect
minut
use
appropri
filter
collect
tube
assess
level
carbonyl
volatil
organ
nicotin
particul
matter
metal
aerosol
mass
size
distribut
measur
use
optic
particl
spectromet
differ
chemic
detect
includ
known
respiratori
irrit
nicotin
detect
appar
juic
seven
metal
identifi
aerosol
includ
titanium
chromium
nickel
also
identifi
carbonyl
howev
formaldehyd
acetaldehyd
aceton
common
sixteen
volatil
organ
identifi
solvent
hexan
ethanol
ubiquit
sampl
aromat
detect
aerosol
contain
particul
matter
huge
vari
level
particl
size
distribut
also
vari
consider
appar
base
excipi
mixtur
properti
aerosol
vari
wide
henc
potenti
impact
health
also
like
vari
importantli
nicotin
found
mani
juic
implic
addict
grant
support
depart
health
wa
telethon
kid
institut
curtin
univers
nh
mrc
accc
tobacco
smoke
prevent
risk
factor
develop
copd
approxim
one
five
patient
attend
gener
practic
smoker
describ
smoke
cessat
intervent
part
interdisciplinari
model
care
radic
aim
reduc
burden
copd
smoke
australian
primari
care
gener
practic
icg
interdisciplinari
care
group
ucg
usual
care
group
patient
age
year
current
smoke
histori
pack
year
andor
manag
copd
invit
particip
particip
ucg
practic
receiv
routin
care
gp
quitlin
referr
appropri
icg
individualis
smoke
cessat
support
coordin
pharmacist
offer
particip
current
smoker
smoke
cessat
support
also
provid
consult
pharmacist
home
medicin
review
particip
copd
pharmacotherapi
recommend
discuss
particip
gp
appropri
exhal
point
preval
abstin
chang
nicotin
depend
month
baselin
outcom
total
particip
rang
demograph
clinic
characterist
recruit
current
smoker
almost
smoke
daili
median
exhal
co
iqr
smoker
icg
practic
variou
stage
tailor
pharmacist
intervent
rang
motiv
counsellingquitlin
referr
advis
nicotin
replac
therapyvareniclin
use
six
month
complet
month
complet
februari
pharmacist
work
gp
assist
smoker
attend
gener
practic
quit
use
pharmacotherapi
approach
support
nhmrc
lung
foundat
australia
boehring
ingelheim
eastern
melbourn
phn
cyril
tonkin
scholarship
hospit
admiss
multipl
pleural
intervent
symptom
relief
often
requir
manag
malign
pleural
effus
mpe
current
literatur
suggest
talc
pleurodesi
indwel
pleural
cathet
ipc
offer
similar
benefit
result
equipois
studi
previous
examin
hospit
mpe
patient
remain
lifespan
principl
endpoint
outcom
signific
patient
often
limit
prognos
random
control
trial
nine
unit
australia
new
zealand
singapor
hong
kong
recruit
mpe
patient
random
ipc
talc
slurri
pleurodesi
minim
australasia
vs
asia
mesothelioma
vs
metastat
malign
trap
lung
vs
primari
endpoint
total
day
hospit
treatment
death
ipc
group
spent
significantli
fewer
day
hospit
pleurodesi
group
median
iqr
vs
day
repres
vs
remain
lifespan
hospit
respect
mean
reduct
hospit
day
dayspati
ipc
vs
pleurodesi
day
reduct
mainli
hospit
median
ipc
vs
pleurodesi
day
p
though
fewer
relat
hospit
day
observ
ipc
treatment
fewer
patient
requir
invas
pleural
drainag
vs
ci
treatment
provid
signific
improv
breathless
assess
visual
analog
score
compar
complic
rate
treatment
mpe
ipc
reduc
lifetim
hospit
day
invas
pleural
procedur
compar
convent
talc
pleurodesi
without
compromis
symptomat
improv
data
inform
patient
decis
treat
option
extrapol
result
use
ipc
instead
talc
slurri
pleurodesi
mpe
save
bed
day
australia
year
grant
support
project
grant
cancer
council
western
australia
sir
charl
gairdner
rac
fellowship
fund
nhmrc
ycgl
rt
cancer
council
wa
rt
rain
foundat
et
declar
rocket
med
ltd
provid
free
ipc
drainag
kit
unrestrict
educ
grant
previou
trial
led
ycgl
ycgl
serv
advisori
board
carefusionbd
sequana
med
ltd
copd
incur
progress
ill
associ
signific
morbid
mortal
accur
determin
prognosi
sever
copd
challeng
diagnos
activ
die
audit
use
diagnost
test
recognis
activ
die
establish
goal
care
goc
palliat
copd
patient
die
hospit
retrospect
audit
consecut
patient
die
copd
australian
teach
hospit
patient
includ
male
median
age
year
median
respiratori
function
fvc
dlco
use
home
oxygen
patient
palli
care
involv
prior
final
admiss
termin
admiss
patient
receiv
averag
episod
venepunctur
arteri
blood
ga
test
chest
radiograph
receiv
increas
diagnost
test
associ
age
admiss
respiratori
medicin
team
icu
admiss
radiolog
evid
pneumonia
admiss
patient
goc
document
palliat
final
admiss
median
day
prior
death
patient
diagnost
test
perform
day
palliat
initi
despit
chang
goc
patient
test
follow
palliat
test
day
die
excess
unnecessari
diagnost
test
perform
one
third
inpati
die
copd
includ
follow
clear
decis
palliat
failur
clinic
diagnos
activ
die
impos
unnecessari
burden
diagnost
test
final
hour
palliat
copd
diagnost
test
nomin
new
investig
award
na
grant
support
na
interdisciplinari
intervent
could
potenti
benefit
patient
copd
primari
care
describ
radic
review
airway
dysfunct
interdisciplinari
care
adult
smoker
model
care
deliv
australian
gener
practic
gener
practic
icg
interdisciplinari
care
group
ucg
usual
care
group
patient
particip
copd
ucg
practic
receiv
routin
care
gp
quitlin
referr
appropri
icg
particip
receiv
radic
model
care
coordin
research
assist
gp
staff
clinic
model
compris
individualis
smoke
cessat
support
home
medicin
review
hmr
consult
pharmacist
pulmonari
rehabilit
specif
train
physiotherapist
primari
endpoint
chang
health
relat
qualiti
life
hrqol
measur
st
georg
respiratori
questionnair
sgrq
month
baselin
outcom
includ
chang
lung
function
dyspnoea
copd
assess
test
cat
score
month
total
patient
copd
includ
icg
ucg
mean
age
year
male
current
smoker
meanmedian
baselin
sgrq
cat
mmrc
score
iqr
total
icg
particip
receiv
hmr
complet
pulmonari
rehabilit
receiv
compon
six
month
complet
month
progress
complet
februari
interdisciplinari
model
care
copd
develop
implement
evalu
gener
practic
hmr
pulmonari
rehabilit
moder
accept
intervent
gp
patient
support
nhmrc
lung
foundat
australia
boehring
ingelheim
eastern
melbourn
phn
cyril
tonkin
scholarship
conflict
interest
fund
receiv
boehring
ingelheim
boehring
ingelheim
involv
project
discuss
plan
progress
review
involv
design
intervent
program
contribut
decis
regard
data
analysi
dissemin
find
lfa
undertook
survey
gain
insight
key
issu
face
consum
carer
understand
lfa
meet
better
meet
need
survey
distribut
via
email
post
consum
lung
diseas
subscrib
lfa
network
survey
complet
repres
respons
rate
approxim
femal
age
year
lung
diseas
carer
respond
indic
see
famili
friend
less
often
feel
isol
societi
thing
love
less
often
lung
diseas
ask
specif
felt
time
diagnosi
felt
less
deserv
help
peopl
medic
condit
felt
shame
guilt
fear
discrimin
felt
stigmatis
view
lung
diseas
felt
support
need
deal
diagnosi
suggest
receiv
addit
lfa
support
respons
highlight
need
psychosoci
support
telephon
onlin
connect
lfa
consum
well
need
addit
educ
seminar
webinar
inform
specif
diseas
treatment
research
peopl
impact
lung
diseas
face
mani
challeng
survey
detail
effect
commun
social
interact
feel
isol
less
contact
love
one
highlight
also
demonstr
shame
stigma
guilt
peopl
may
experi
diagnos
lung
diseas
grant
support
lfa
receiv
financi
support
donor
philanthrop
trust
foundat
fundrais
corpor
partner
cell
immunolog
molecular
biolog
lung
copd
primari
bronchial
epitheli
cell
pbec
characteris
defici
innat
antivir
respons
influenza
viru
infect
lead
heighten
viral
replic
molecular
mechan
underpin
defici
unclear
uniqu
cytoplasm
deacetylas
role
innat
immun
less
well
characteris
studi
aim
determin
function
antivir
immun
expressionfunct
alter
copd
pbec
knockout
plasmid
transfect
human
minim
immortalis
bronchial
epitheli
cell
line
infect
protein
interactionsexpress
level
measur
immunoprecipit
immunoblot
cytometr
bead
array
viral
replic
measur
plaqu
assay
pbec
copd
gold
healthi
control
infect
similar
measur
perform
defici
show
overal
reduct
antivir
respons
immunoprecipit
ip
mass
spectroscopi
identifi
direct
bind
target
import
viral
rna
sensor
found
deacetyl
promot
type
iii
interferon
ifn
induct
express
deacetyl
antivir
respons
reduc
copd
pbec
reduct
express
copd
pbec
due
increas
express
mirna
inhibit
increas
antivir
respons
decreas
viral
replic
copd
healthi
control
pbec
essenti
antivir
signal
influenza
viral
infect
reduc
express
deacetyl
copd
led
defici
antivir
signal
increas
viral
replic
could
restor
specif
inhibit
grant
support
alan
hsu
support
thorac
societi
australia
new
zealand
tsanz
astrazeneca
respiratori
research
fellowship
studi
fund
univers
newcastl
earli
career
research
grant
nh
mrc
nthi
infect
caus
approxim
copd
exacerb
inflamm
declin
normal
intracellular
microb
degrad
autophagi
xenophagi
hypothesis
nthi
exploit
defect
xenophagi
copd
potenti
cigarett
smoke
enabl
infect
propag
airway
epitheli
cell
aec
cultur
bronchial
aec
baec
line
control
copd
donor
differenti
interfac
ali
expos
cigarett
cse
nthi
marker
xenophag
flux
intracellular
nthi
assess
use
western
analysi
immunofluoresc
transmiss
electron
microscopi
tem
figur
tem
baec
control
donor
reveal
detect
nthi
consider
autophag
activ
evidenc
dark
electron
dens
region
within
vesicular
structur
convers
nthi
readili
evid
aec
deriv
copd
donor
close
proxim
similar
vesicular
structur
aec
expos
cse
exhibit
block
autophag
flux
adapt
protein
immunofluoresc
analysi
resolv
intracellular
nthi
within
aec
expos
cse
proxim
autophag
apparatu
marker
importantli
control
ali
cultur
expos
nthi
contain
detect
infect
evid
normal
autophag
activ
wherea
baec
contain
multipl
infect
particl
remain
intact
within
vesicl
tem
analysi
demonstr
expuls
vesicl
nthi
abl
avoid
xenophag
degrad
aec
expos
cse
cultur
aec
may
usurp
defect
autophag
apparatu
mode
persist
extracellular
propag
henc
mode
therapeut
intervent
restor
normal
xenophag
activ
aec
signific
util
improv
clearanc
intracellular
nthi
infect
therebi
decreas
influenc
damag
pathogen
airway
afflict
copd
grant
support
thorac
societi
australia
new
zealandastrazeneca
influenza
signific
global
burden
million
case
per
year
fatal
thu
urgent
need
new
therapeut
toll
like
receptor
pattern
recognit
receptor
drive
power
signal
pathway
help
clear
viru
infect
aim
present
studi
determin
effect
agonist
imiquimod
morbid
lung
inflamm
oxid
stress
antibodi
product
caus
influenza
viru
iav
infect
mice
salin
imiquimod
deliv
intranas
anaesthetis
male
mice
one
day
prior
infect
low
high
dose
mous
adapt
hong
kong
viru
strain
everyday
thereaft
mice
cull
day
analysi
bronchoalveolar
lavag
bal
perform
assess
airway
inflamm
inflammatori
cell
oxid
burst
enhanc
chemiluminesc
addit
bal
fluid
serum
use
determin
antibodi
titr
lung
harvest
use
assess
inflamm
h
e
stain
cytokin
gene
express
qpcr
bodyweight
record
daili
experiment
process
imiquimod
significantli
suppress
bodi
weight
loss
caus
iav
infect
maximum
reduct
start
day
pfumous
p
post
infect
imiquimod
treatment
caus
signific
reduct
airway
inflamm
balf
neutrophil
popul
pfumous
p
effect
macrophag
lymphocyt
popul
oxid
burst
mrna
express
supress
p
p
respect
whilst
mrna
express
unaffect
day
data
show
modest
signific
increas
ige
igm
p
balf
follow
imiquimod
treatment
compar
control
chang
antibodi
titr
within
serum
find
highlight
potenti
imiquimod
therapeut
option
treatment
influenza
diseas
grant
support
nhmrc
australia
project
grant
id
arc
despit
recur
emerg
novel
pathogen
coronavirus
cov
lack
understand
host
immun
respiratori
infect
cov
studi
characteris
innat
immun
respons
differenti
primari
bronchial
epitheli
cell
pbec
infect
relat
human
pbec
grown
air
liquid
interfac
ali
differenti
observ
day
infect
multipl
infect
moi
hour
day
supernat
rna
collect
measur
viral
replic
use
microarray
gene
express
profil
infect
analys
cell
transduc
overexpress
transmembran
protein
ifitm
infect
viral
replic
measur
hour
demonstr
differ
viral
replic
kinet
replic
earlier
effici
peak
hour
associ
delay
robust
activ
innat
host
respons
induct
type
iii
interferon
ifn
stimul
gene
contrast
replic
peak
hour
attenu
level
microarray
data
also
identifi
ifitm
protein
upregul
infect
cell
ifitm
replic
suppress
ifitm
clone
display
similar
replic
kinet
control
replic
unhind
ifitm
protein
studi
demonstr
replic
differenti
pbec
induc
diverg
innat
immun
respons
potenti
link
differ
replic
kinet
understand
interact
less
virul
coronavirus
give
insight
pathogen
mechan
underpin
respiratori
diseas
grant
support
univers
newcastl
research
scholarship
unrsc
infect
exacerb
chronic
inflammatori
lung
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
associ
increment
scar
fibrosi
gradual
decrement
lung
function
central
patholog
pleiotrop
cytokin
transform
growth
tgfb
regul
cell
prolifer
tissu
remodel
lung
fibrosi
previou
studi
demonstr
tgfb
suppress
immun
respons
result
enhanc
viral
infect
utilis
transgen
mous
model
tgfb
establish
acut
chronic
model
inflammatori
lung
diseas
infect
mice
influenza
viru
iav
strain
examin
diseas
sever
inflammatori
immun
respons
viral
load
acut
model
tgfb
day
prior
iav
infect
mice
experienc
sever
bronchiti
pneumonia
increas
inflammatori
cell
infiltr
enhanc
cytokin
chemokin
product
bronchoalveolar
lavag
bal
fluid
compar
mice
normal
tgfb
level
mice
also
demonstr
suppress
innat
immun
respons
associ
enhanc
viral
titr
chronic
model
tgfb
week
result
thicken
respiratori
bronchiol
epithelium
surround
smooth
muscl
emphysemat
appear
within
airspac
resembl
phenotyp
chang
characterist
asthma
copd
preliminari
result
model
demonstr
iav
infect
sever
compar
mice
normal
tgfb
level
transgen
mous
model
provid
us
uniqu
tool
evalu
direct
effect
tgfb
viral
infect
context
chronic
inflammatori
lung
diseas
investig
potenti
therapeut
strategi
combat
diseas
exacerb
grant
support
nhmrc
declar
interest
none
necrosi
airway
epitheli
cell
aec
result
airway
inflamm
characterist
find
cystic
fibrosi
cf
driven
mucu
obstruct
airway
previous
suggest
potenti
respons
respiratori
viral
infect
current
methodolog
measur
apoptot
necrot
cell
death
use
flow
cytometri
aec
adequ
complet
differenti
two
aim
determin
whether
novel
flow
cytometri
methodolog
describ
cell
type
could
optim
adapt
aec
suffici
differenti
apoptot
necrot
aec
cf
aec
permeabilis
infect
human
rhinoviru
hour
moi
incub
limit
environ
hour
cell
collect
stain
analysi
via
flow
cytometri
data
analys
use
gate
process
differenti
six
differ
popul
aec
flow
cytometri
use
abl
differenti
viabl
apoptot
necrot
cell
plu
apoptot
bodi
cellular
debri
stimul
unstimul
epitheli
sampl
flow
cytometri
utilis
conjunct
gate
process
suffici
differenti
six
popul
stimul
unstimul
aec
healthi
diseas
individu
studi
utilis
techniqu
allow
quantif
aec
necrosi
patient
without
cf
aim
investig
differ
mechan
drive
cell
death
airway
inflamm
grant
support
australian
cystic
fibrosi
research
trust
postgradu
studentship
chronic
obstruct
pulmonari
diseas
copd
primari
sourc
airflow
limit
copd
small
airway
sa
fibrosi
obliter
previous
show
epitheli
mesenchym
transit
emt
activ
process
small
airway
contribut
fibrot
pathogenesi
myofibroblast
highli
activ
fibrot
cell
excess
secret
extracellular
matrix
ecm
explor
consequ
sa
myofibroblast
prolifer
relat
physiolog
outcom
airway
remodel
smoker
copd
patient
sa
lung
resect
control
nc
normal
lung
function
smoker
nlf
copd
current
cs
es
stain
fibronectin
cell
enumer
reticular
basement
membran
rbm
lamina
propria
lp
adventitia
repres
per
mm
rbm
respect
area
survey
fibronectin
repres
percentag
chang
measur
includ
lp
adventitia
thick
measur
use
observ
gener
increas
lp
adventitia
thick
patholog
group
compar
nc
similar
increas
myofibroblast
observ
rbm
lp
adventitia
patholog
group
compar
nc
though
chang
promin
higher
lp
increas
myofibroblast
popul
lp
strongli
associ
decreas
lung
function
increas
ecm
protein
fibronectin
deposit
lp
final
observ
emt
marker
express
epitheli
basal
cell
rbm
correl
increas
sa
myofibroblast
airway
thick
first
report
systemat
character
myofibroblast
copd
base
local
statist
correl
lung
function
increas
myofibroblast
popul
also
directli
relat
patholog
chang
ecm
protein
drive
chang
like
emt
activ
basal
epitheli
cell
grant
support
clifford
craig
foundat
launceston
conflict
interest
nil
skelet
muscl
wast
major
comorbid
copd
power
predictor
mortal
current
therapeut
strategi
aim
increas
muscl
mass
augment
protein
synthesi
reduc
protein
degrad
muscl
mass
also
increas
activ
satellit
cell
play
pivot
role
skelet
muscl
regener
howev
role
satellit
cell
copd
fulli
understood
thu
explor
whether
muscl
regener
respons
injur
tibiali
anterior
ta
muscl
impair
mice
expos
cigarett
smoke
cs
male
balbc
mice
expos
room
air
sham
cs
gener
cigarettesday
daysweek
week
week
cs
exposur
right
ta
muscl
injur
inject
barium
chlorid
mice
expos
cs
anoth
day
time
contractil
properti
right
ta
muscl
measur
mice
cull
uninjur
left
ta
injur
right
ta
muscl
dissect
weigh
use
examin
express
gene
associ
muscl
regener
eg
pax
histolog
assess
muscl
injuri
injuri
significantli
decreas
weight
ta
muscl
day
post
injuri
exacerb
mice
p
also
caus
signific
muscl
injuri
demonstr
central
locat
nuclei
alter
tissu
architectur
assess
day
post
injuri
howev
muscl
injuri
even
greater
mice
compar
injur
sham
mice
p
injur
ta
muscl
mice
least
increas
pax
mrna
express
compar
injur
ta
muscl
mice
day
post
injuri
p
moreov
ta
muscl
contractil
function
significantli
impair
injur
mice
compar
injur
mice
p
skelet
muscl
regener
function
impair
experiment
copd
grant
support
nhmrc
australia
project
grant
id
airway
distens
reduc
patient
copd
transform
growth
factor
alpha
increas
serum
copd
patient
produc
airway
remodel
mous
model
hypothesis
overexpress
reduc
airway
distens
aim
determin
effect
regulatori
gene
earli
growth
respons
one
airway
thick
distens
condit
express
airway
transgen
mice
clara
cell
secretori
teto
induc
doxycyclin
dox
mice
homozyg
heterozyg
week
age
mice
fed
dox
chow
control
diet
week
anaesthetis
mechan
ventil
lung
function
measur
use
low
frequenc
forc
oscil
airway
conduct
g
measur
pressur
distens
calcul
chang
conduct
lung
fix
morphometri
stereolog
mice
increas
thick
airway
epithelium
inner
outer
wall
airway
smooth
muscl
layer
increas
thick
epithelium
inner
wall
greater
mice
chang
affect
genotyp
mice
reduc
airway
distens
independ
genotyp
increas
express
within
airway
wall
associ
increas
wall
thick
reduc
airway
distens
effect
larg
unaffect
partial
modif
gene
find
suggest
signal
may
contribut
airflow
limit
copd
reduc
airway
distens
grant
support
nhmrc
declar
interest
statement
none
steroid
mainstay
treatment
target
airway
inflamm
howev
patient
increas
oxid
stress
could
result
resist
steroid
treatment
therefor
combin
resolvin
antioxid
quercetin
q
could
promis
therapeut
strategi
aim
prepar
liposom
formul
q
investig
effect
human
airway
epitheli
cell
blank
q
liposom
prepar
characteris
cell
uptak
studi
perform
use
confoc
microscop
antioxid
activ
liposom
determin
result
demonstr
monomod
size
distribut
nm
nm
nm
blank
q
liposom
respectivelyth
concentr
q
encapsul
found
q
liposom
respect
concentr
liposom
found
pgml
uptak
liposom
q
observ
hour
follow
treatment
liposom
antioxid
activ
q
found
significantli
higher
p
formul
liposom
q
compar
free
q
figur
uptak
q
liposom
cell
hour
follow
treatment
conclus
liposom
formul
demonstr
accept
characterist
inhal
significantli
increas
antioxid
properti
compar
free
q
liposom
formul
could
potenti
improv
therapeut
outcom
steroid
resist
patient
studi
investig
activ
liposom
vitro
vivo
copd
patient
peripher
eosinophilia
may
increas
frequenc
copd
exacerb
respond
better
oral
corticosteroid
reduc
mortal
peripher
eosinophilia
copd
patient
eosinophil
count
white
blood
cell
count
preval
rang
knowledg
littl
epidemiolog
data
australian
copd
patient
concern
peripher
eosinophilia
preval
associ
rehospitalis
rate
steroid
respons
diseas
mortal
rate
literatur
gap
mind
record
patient
present
copd
exacerb
audit
retrospect
determin
preval
peripher
eosinophilia
australian
popul
consecut
patient
spirometri
confirm
copd
admit
institut
copd
exacerb
period
juli
decemb
consid
studi
patient
record
subsequ
follow
june
variabl
record
white
blood
cell
count
absolut
rel
eosinophil
count
readmiss
rate
decompens
type
respiratori
failur
rate
ventil
initi
rate
intens
care
admiss
rate
mortal
rate
patient
includ
analysi
peripher
eosinophilia
use
pearson
coeffici
appear
statist
signific
correl
increas
peripher
eosinophil
count
increas
number
readmiss
decompens
type
respiratori
failur
ventil
initi
rate
intens
care
admiss
rate
mortal
rate
equal
mean
compar
peripher
eosinophilia
without
also
keep
statist
signific
differ
readmiss
rate
preval
peripher
eosinophilia
gold
coast
patient
similar
oversea
cohort
congruenc
find
previou
oversea
studi
gold
coast
patient
eosinophilia
prone
readmiss
increas
type
respiratori
failur
ventil
intens
care
admiss
mortal
peripher
eosinophilia
use
australian
copd
patient
cohort
predict
rehospitalis
rate
futur
studi
look
prospect
evalu
effect
inhal
corticosteroid
readmiss
rate
patient
peripher
eosinophilia
grant
support
none
increas
airway
smooth
muscl
asm
mass
part
overal
structur
chang
observ
copd
correl
sever
diseas
found
neg
impact
lung
function
thu
clear
unmet
clinic
need
find
new
therapi
copd
target
airway
remodel
diseas
progress
apoptosi
kinas
ubiquit
express
activ
variou
stress
stimuli
includ
ro
lp
howev
role
airway
remodel
establish
studi
aim
determin
effect
inhibit
asm
growth
signal
use
asm
cell
copd
patient
known
asm
cell
copd
patient
greater
prolif
capac
varieti
mitogen
vitro
use
human
lung
tissu
sampl
primari
human
asm
cell
obtain
copd
patient
healthi
control
ihc
reveal
increas
express
copd
lung
compar
lung
human
asm
cell
highli
select
nm
oral
avail
inhibitor
result
reduct
mitogen
fb
pdgf
egf
ngml
hour
asm
growth
measur
cyquant
assay
furthermor
sirna
prevent
human
asm
cell
growth
immunoblot
reveal
effect
inhibit
silenc
mediat
jnk
pathway
evid
reduc
phosphoryl
downstream
effector
kinas
respect
effect
signal
collect
find
establish
effect
inhibit
identifi
novel
pathway
target
reduc
prevent
excess
asm
mass
copd
copd
airway
remodel
mitogen
grant
support
ut
chancellor
fellowship
nhmrc
oliv
excess
activ
drive
recurr
inflamm
fibrosi
patient
idiopath
pulmonari
fibrosi
ipf
coagul
factor
promot
heal
damag
also
exert
cellular
effect
coagul
factor
xii
fxii
identifi
potenti
mediat
lung
fibrosi
aim
studi
defin
role
fxii
fibrogenesi
blood
ipf
patient
collect
repeatedli
month
compar
age
healthi
control
plasma
fxii
measur
immunohistochem
analysi
fxii
perform
lung
tissu
ipf
patient
control
ndc
vitro
effect
fxii
primari
ipf
ndc
fibroblast
evalu
cytokin
product
prolifer
migrat
effect
novel
fulli
human
monoclon
antibodi
fxii
evalu
baselin
longitudin
level
fxii
ipf
patient
progress
diseas
elev
compar
stabl
diseas
vs
baselin
vs
longitudin
increas
ipf
compar
healthi
control
baselin
plasma
elev
ipf
patient
compar
healthi
control
pgml
ihc
analysi
reveal
signific
fxii
stain
ipf
lung
tissu
minim
stain
observ
lung
tissu
activ
fxii
induc
product
enhanc
proliferationmigr
primari
lung
fibroblast
migrat
product
effect
inhibit
fxii
elev
lung
progress
ipf
patient
drive
function
fibroblast
antibodi
inhibit
activ
abil
fxii
drive
product
lung
fibroblast
may
contribut
elev
level
seen
ipf
patient
blood
block
fxii
activ
may
novel
avenu
treat
ipf
interstiti
lung
diseas
grant
support
nil
conflict
interest
employe
csl
ltd
lung
transplant
ltx
provid
uniqu
opportun
investig
dynam
virus
present
within
human
pulmonari
virom
transplant
recipi
within
donor
lung
aim
studi
elucid
interact
viral
speci
within
respiratori
virom
ltx
recipi
describ
impact
allograft
function
prospect
longitudin
studi
viral
dynam
ltx
multipl
sampl
type
collect
sampl
process
assay
use
multipl
uniplex
pcr
human
rhinoviru
hrv
respiratori
syncyti
viru
rsv
influenza
b
flu
b
parainfluenza
piv
human
metapneumoviru
clinic
outcom
analys
compar
microbi
detect
consecut
ltx
recruit
swab
explant
lung
posit
virus
despit
recipi
vaccin
neg
recipi
np
day
bal
show
flu
hrv
piv
donor
swab
show
influenza
hrv
donor
transmiss
flu
observ
recipi
bal
posit
sampl
virus
multipl
bal
virus
persist
week
pair
transbronchi
biopsi
viral
pcr
bal
perform
patient
show
evid
acut
cellular
reject
biopsi
grade
grade
grade
virus
detect
bal
collect
concurr
convers
patient
show
evid
cellular
reject
biopsi
viru
posit
viru
neg
analysi
use
fisher
exact
test
tail
indic
signific
correl
viral
detect
presenc
acut
cellular
reject
find
frequent
donor
transmiss
earli
acquisit
virus
particularli
influenza
support
import
respiratori
virom
surveil
ltx
direct
acut
therapi
cohort
viral
presenc
ltx
correl
acut
reject
event
grant
support
na
previous
report
therapeut
effect
augment
endotheli
progenitor
cell
therapi
rat
ph
model
know
littl
direct
cell
integr
pulmonari
endothelium
follow
intraven
inject
thu
attribut
posit
physiolog
effect
cell
therapi
commun
via
secret
factor
exosom
exo
studi
look
compar
protein
profil
via
mass
spectrometri
assess
capac
interact
transport
endotheli
cell
ec
epc
isol
cultur
pah
control
peripher
blood
cell
either
transduc
adtrackluc
untransduc
subsequ
exo
isol
exosom
isol
via
differenti
centrifug
characteris
nanosight
tem
sem
exosom
protein
profil
via
mass
spectrometri
treat
exo
label
use
view
exo
localis
within
target
ec
live
fix
via
confoc
microscopi
incub
ec
wash
cell
lyse
western
blot
analysi
exosom
posit
identifi
via
nanosight
tem
sem
protein
profil
exo
show
differenti
protein
express
pah
vs
control
protein
includ
rel
pah
exo
exosom
interact
ec
demonstr
localis
around
nucleu
cell
live
fix
ec
sampl
addit
express
significantli
increas
cell
treat
differenti
protein
express
exo
deriv
pah
compar
control
epc
shown
addit
characteris
exo
interact
ec
shown
involv
transfer
transduc
epc
ec
result
indic
potenti
role
exo
therapi
grant
support
rah
research
fund
lung
transplant
ltx
recipi
high
risk
lower
respiratori
tract
infect
lrti
secondari
immunosuppress
alter
respiratori
physiolog
make
difficult
clear
secret
inhal
mucoact
agent
alter
mucu
properti
andor
facilit
mucocilliari
clearanc
suppur
lung
diseas
howev
randomis
control
trial
rct
studi
effect
post
ltx
aim
evalu
safeti
efficaci
nebulis
dornas
alfa
compar
isoton
salin
lrti
month
post
ltx
inpati
adult
lrti
sputum
product
follow
bilater
sequenti
ltx
elig
assessor
blind
rct
randomis
stratifi
ltx
indic
fibrosi
cf
particip
receiv
either
isoton
salin
dornas
alfa
nebulis
daili
month
follow
month
symptom
diari
primari
outcom
chang
lung
clearanc
index
lci
measur
washout
secondari
outcom
includ
advers
event
spirometri
qualiti
life
readmiss
length
stay
exacerb
baselin
month
month
particip
group
mean
sd
age
median
iqr
length
stay
day
sinc
ltx
ltx
indic
includ
cf
chronic
obstruct
pulmonari
diseas
signific
differ
lci
time
point
one
month
mean
differ
confid
interv
ci
three
month
mean
differ
ci
favour
dornas
alfa
secondari
outcom
differ
group
result
support
routin
use
dornas
alfa
lrti
ltx
recipi
grant
alfr
research
trust
small
project
grant
professor
carey
laura
denholm
conflict
interest
conflict
interest
declar
lung
fibrosi
consequ
interstiti
lung
diseas
ild
involv
excess
number
activ
lung
fibroblast
elev
muscl
actin
express
pirfenidon
approv
use
patient
idiopath
pulmonari
fibrosi
ipf
common
fatal
idiopath
ild
poor
toler
larg
variat
efficaci
pirfenidon
signific
barrier
best
patient
outcom
studi
aim
investig
whether
fibroblast
test
identifi
patient
like
benefit
pirfenidon
therapi
primari
lung
fibroblast
deriv
apex
base
lung
patient
ipf
patient
ild
normal
donor
whose
lung
deem
unsuit
transplant
ndc
determin
western
gapdh
level
fibroblast
measur
treatment
pirfenidon
presenceabs
transform
growth
sensit
pirfenidon
defin
decreas
level
baselin
treatment
pirfenidon
decreas
level
fibroblast
line
hour
figur
fibroblast
level
correl
extent
declin
respons
pirfenidon
spearman
r
patient
ipf
basal
level
fibroblast
line
correl
forc
vital
capac
fvc
predict
patient
line
deriv
spearman
r
respons
lung
fibroblast
pirfenidon
may
identifi
patient
ipf
would
benefit
said
treatment
data
suggest
patient
high
number
fibroblast
would
particular
benefit
pirfenidon
therapi
although
screen
requir
variat
level
fibroblast
may
reflect
overal
lung
fibrot
burden
correl
fvc
grant
support
none
figur
quantif
asma
level
primari
lung
fibroblast
pre
post
pirfenidon
therapi
primari
fibroblast
deriv
patient
idiopath
pulmonari
fibrosi
ipf
red
dot
donor
without
lung
diseas
ndc
blue
dot
fibroblast
deriv
patient
ipf
express
greater
level
asma
compar
fibroblast
ndc
donor
b
treatment
pirfenidon
pb
decreas
asma
express
lung
fibroblast
dot
experiment
triplic
pulmonari
arteri
hypertens
pah
devast
lung
condit
characteris
pulmonari
vascular
remodel
prolifer
vascular
cell
mutat
causal
link
pah
endotheli
progenitor
cell
epc
cell
differenti
endotheli
cell
play
role
vascular
repair
dysfunct
pah
patient
hypoxia
thought
play
signific
role
diseas
pathogenesi
use
induc
pah
anim
model
diseas
studi
aim
characteris
differ
pah
control
epc
hypox
condit
epc
isol
pah
control
patient
peripher
blood
follow
characteris
expans
cell
expos
either
normoxia
hypoxia
prolifer
apoptosi
assess
use
mtt
assay
flow
cytometri
protein
analysi
conduct
via
western
blot
epc
origin
pah
patient
prolifer
similar
rate
control
epc
normoxia
increas
respect
howev
hypox
condit
prolifer
control
cell
less
pah
cell
increas
respect
preliminari
data
suggest
continu
prolifer
could
due
apoptosi
resist
pah
line
assay
reveal
lower
apoptosi
level
hypoxia
exposur
pah
line
control
line
activ
smad
decreas
hypox
pah
cell
compar
control
epc
isol
peripher
blood
pah
patient
function
differ
hypox
condit
isol
control
subject
notabl
pah
epc
appear
possess
higher
resist
apoptosi
hypoxia
find
suggest
epc
could
play
role
pathogenesi
pah
contribut
aberr
prolifer
apoptosi
vascular
remodel
seen
pah
grant
support
nhmrc
rah
research
fund
ann
woolcock
young
investig
award
acut
hypercapn
respiratori
failur
secondari
exacerb
copd
associ
poor
clinic
outcom
increas
mortal
ventil
niv
part
standard
care
poorli
toler
shown
nasal
high
flow
therapi
nhf
produc
small
reduct
transcutan
tension
stabl
copd
aim
compar
nhf
niv
hypercapn
copd
design
randomis
control
trial
set
singl
centr
institut
new
zealand
recruit
particip
hospit
databas
particip
particip
doctor
diagnosi
copd
fvc
ratio
year
smoke
histori
pack
year
bmi
recent
exacerb
diagnosi
obstruct
sleep
apnea
obes
hypoventil
syndrom
intervent
nhf
bipap
washout
primari
outcom
measur
adjust
baselin
secondari
outcom
includ
toler
proport
particip
decreas
minut
ci
lower
niv
compar
nhf
proport
particip
reduct
niv
versu
nhf
versu
reduct
versu
differ
statist
signific
particip
rate
nhf
significantli
better
eas
applic
comfort
fit
willing
use
futur
stabl
copd
patient
chronic
hypercapnia
niv
result
small
reduct
compar
nhf
uncertain
clinic
signific
nhf
better
toler
nhf
may
therapeut
option
peopl
hypercapn
respiratori
failur
studi
acut
exacerb
copd
requir
grant
support
health
research
council
nz
trial
registr
hospit
aecopd
heterogen
event
divers
aetiolog
hypothes
comprehens
aecopd
evalu
would
reveal
clinic
phenotyp
amongst
aecopd
nasopharyng
viral
pcr
sputum
cultur
protein
chest
troponin
pro
brain
natriuret
peptid
hospit
anxieti
depress
scale
had
use
construct
cumul
aetiolog
phenotyp
aecopd
use
simpl
acronym
aairway
viral
infect
bbacteri
infect
ccoinfect
ddepressionanxieti
eembol
pulmonari
ffailur
cardiac
ggener
environ
xunknown
aetiolog
identifi
among
uniqu
aecopd
admiss
divers
often
multifactori
aetiolog
identifi
aetiolog
baselin
lung
function
symptom
similar
across
exacerb
subtyp
infect
exacerb
associ
lower
eosinophil
p
exacerb
lower
ph
niv
requir
higher
v
bacteri
aecopd
patient
identifi
aetiolog
x
gener
frequent
exacerb
sever
acut
present
prompt
stabil
admiss
day
common
group
viral
v
bacteri
v
v
subclin
cardiac
dysfunct
highli
preval
infect
aecopd
elev
elev
overal
anxietydepress
preval
aetiolog
subgroup
overal
popul
had
meansd
surviv
month
post
discharg
lower
versu
viral
aecopd
hospit
aecopd
multidimension
multifactori
subtyp
infect
type
identifi
signific
differ
comorbid
health
care
util
laboratori
paramet
inpati
manag
post
exacerb
surviv
anxietydepress
cardiac
dysfunct
appear
preval
underdiagnos
clinic
orient
methodolog
provid
feasibl
framework
clinician
research
address
aecopd
complex
target
therapeut
intervent
grant
support
project
support
unrestrict
educ
grant
glaxosmithklin
treatment
agonist
may
overcom
symptom
sever
asthma
relaxin
rhrlx
receptor
agonist
exert
cardioprotect
effect
acut
heart
failur
elicit
vascular
relax
via
nitric
oxid
signal
although
previous
establish
bronchodil
efficaci
rat
airway
lam
et
al
effect
speci
potenti
enhanc
relax
yet
explor
compar
bronchodil
effect
relaxin
alon
combin
agonist
isoprenalin
iso
salbutamol
sal
multipl
speci
tracheal
ring
bronchi
dissect
andor
precis
cut
lung
slice
pcl
contain
intrapulmonari
airway
prepar
mice
rat
guinea
pig
marmoset
human
lung
unus
donor
rhrlx
alon
combin
iso
sal
ad
airway
mch
rhrlx
nm
elicit
partial
relax
rat
airway
rapid
pcl
trachea
ineffect
direct
bronchodil
guinea
pig
trachea
mous
pcl
rhrlx
markedli
increas
potenc
iso
rat
pcl
without
increas
maximum
relax
sal
guinea
pig
trachea
sal
elicit
partial
relax
mous
pcl
synerg
evid
rhrlx
sal
maximum
relax
rhrlx
respons
sal
rhrlxsal
n
p
preliminari
data
show
rhrlx
elicit
relax
potenti
relax
marmoset
human
small
airway
rhrlx
elicit
airway
relax
speci
enhanc
respons
small
larg
airway
salbutamol
across
speci
test
sinc
rhrlx
increas
potenc
salbutamol
investig
warrant
defin
therapeut
potenti
asthma
therapi
human
lung
particularli
respons
current
dilat
therapi
limit
grant
support
nhmrc
project
grant
influenza
virus
caus
respiratori
tract
infect
lead
fatal
outcom
viru
spread
alveolar
space
predominantli
observ
high
pathogen
influenza
viru
strain
shown
influenza
virus
irrespect
strain
caus
burst
reactiv
oxygen
speci
ro
product
via
oxidas
occur
endosom
evid
endosom
target
oxidas
inhibitor
call
cholestenol
conjug
abrog
diseas
caus
season
strain
influenza
viru
iav
mice
aim
determin
effect
treatment
lung
patholog
induc
highli
pathogen
strain
iav
male
mice
treat
daili
via
intranas
administr
dmso
control
period
mice
infect
pfu
strain
iav
pb
control
post
initi
drug
treatment
analys
day
bronchoalveolar
lavag
bal
fluid
collect
mice
use
assess
airway
inflamm
histopatholog
analysi
lung
assess
use
h
e
stain
score
alveol
inflammatori
cell
infiltr
peribronchiolar
inflamm
superoxid
gener
bal
measur
use
enhanc
chemiluminesc
chang
cytokin
viral
mrna
express
lung
quantifi
use
qpcr
treatment
significantli
p
reduc
airway
inflamm
neutrophil
influx
pulmonari
inflamm
measur
degre
alveol
inflammatori
cell
infiltr
peribronchiolar
inflamm
addit
attenu
ro
gener
influenza
viral
mrna
express
mice
spatial
inhibit
endosom
compart
could
use
potenti
treatment
strategi
highli
pathogen
influenza
viru
infect
grant
support
nhmrc
australia
project
grant
id
arc
et
al
natur
commun
articl
number
base
limit
avail
data
current
recommend
empir
treatment
bronchiectasi
exacerb
children
azithromycin
attract
altern
long
reduc
dose
schedul
good
safeti
profil
children
test
primari
hypothesi
oral
azithromycin
within
margin
achiev
resolut
exacerb
treatment
children
bronchiectasi
conduct
multicentr
parallel
group
rct
trial
centr
start
exacerb
children
randomis
receiv
either
mgkg
bd
placebo
azithromycin
placebo
primari
outcom
resolut
exacerb
defin
return
baselin
studi
power
margin
detect
resolut
rate
secondari
outcom
qualiti
life
durat
exacerb
generalis
linear
model
use
calcul
rel
differ
group
baselin
characterist
group
azithromycin
similar
resolut
compar
group
rel
risk
ci
fall
within
calcul
margin
group
differ
durat
exacerb
day
ci
compar
begin
exacerb
also
within
margin
ci
azithromycin
treat
exacerb
bronchiectasi
children
azithromycin
may
prefer
select
set
eg
adher
howev
use
need
balanc
risk
treatment
failur
within
compar
induc
macrolid
resist
grant
support
nhmrc
project
grant
number
vg
support
nhmrc
pg
scholarship
abc
support
nhmrc
practition
fellowship
persist
airflow
limit
pal
may
develop
older
asthma
howev
mechan
unknown
reduc
lung
elast
recoil
may
contribut
occur
age
may
occur
asthma
neutrophil
airway
inflamm
also
common
older
peopl
asthma
aim
determin
relationship
lung
elast
recoil
airway
inflamm
airflow
limit
hypothesis
reduc
lung
elast
recoil
neutrophil
airway
inflamm
associ
pal
older
asthmat
adult
asthma
treat
standardis
high
dose
inhal
corticosteroidlong
act
beta
agonist
two
month
underw
standard
lung
function
lung
elast
recoil
measur
use
oesophag
balloon
deriv
indic
loss
lung
elast
recoil
increas
k
reduc
ba
bronchoscopi
obtain
bronchoalveolar
lavag
fluid
bal
differenti
leukocyt
count
cytokin
measur
spearman
correl
assess
multipl
linear
regress
use
adjust
age
bmi
diseas
durat
nineteen
subject
male
age
year
asthma
durat
year
demonstr
moder
pal
fvc
reduc
lung
elast
recoil
demonstr
subject
median
iqr
k
ba
correl
neg
k
independ
age
bmi
diseas
durat
neutrophil
airway
inflamm
demonstr
neutrophil
lung
elast
recoil
correl
bal
neutrophil
count
cytokin
loss
lung
elast
recoil
contribut
pal
older
asthma
may
due
lung
tissu
chang
addit
airway
remodel
despit
lack
relationship
airway
inflamm
exploratori
studi
underli
cellular
mechan
requir
investig
altern
paradigm
lung
remodel
would
potenti
implic
prevent
pal
popul
grant
support
univers
sydney
bridg
grant
tol
propos
altern
smoke
nicotin
replac
therapi
confus
around
safeti
efficaci
smoke
cessat
aid
stem
contradictori
find
across
multipl
studi
aim
studi
determin
inflammatori
respons
chronic
obstruct
pulmonari
diseas
copd
cell
realist
physiolog
condit
primari
human
airway
smooth
muscl
cell
stimul
increas
concentr
nicotin
nicotin
tobacco
menthol
flavour
vaper
empir
extract
hour
mtt
assay
perform
determin
cytotox
elisa
use
assess
product
cell
isol
explant
resect
lung
tissu
copd
patient
smoker
without
copd
extract
cytotox
cell
cytotox
increas
aerosol
creat
higher
temperatur
extract
stimul
product
compar
unstimul
control
p
cell
peopl
copd
hyperrespons
nicotin
tobacco
flavour
stimul
significantli
greater
product
copd
cell
compar
cell
p
product
stimul
potenti
contribut
patholog
copd
cytotox
caus
cell
death
ineffect
repair
seen
airway
parenchyma
copd
increas
would
contribut
proinflammatori
environ
lung
data
suggest
copd
patient
use
smoke
cessat
aid
cigarett
replac
none
tol
mani
preschool
asthma
experi
diseas
remiss
first
year
life
may
offer
window
opportun
modifi
outcom
explor
relationship
likelihood
remiss
asthma
control
two
year
follow
diagnost
asthma
preschool
assembl
retrospect
birth
cohort
children
born
four
canadian
provinc
quebec
manitoba
saskatchewan
british
columbia
preschool
asthma
defin
one
hospitalis
medic
visit
within
period
asthma
children
age
less
year
remiss
assum
two
year
without
drug
claim
medic
visit
hospit
main
exposur
asthma
control
year
follow
diagnosi
measur
valid
pediatr
pharmacoepidemiolog
asthma
control
index
ppaci
ascertain
consecut
period
cohort
exit
occur
death
loss
medic
drug
coverag
date
last
avail
data
within
provinc
cox
regress
model
serv
estim
strength
associ
ppaci
stabil
year
post
diagnosi
remiss
adjust
potenti
confound
covari
name
demograph
eg
sex
social
assist
diseas
characterist
eg
age
atopi
therapi
eg
first
control
therapi
aggreg
result
million
live
birth
provinc
children
less
year
met
definit
asthma
male
age
less
year
diagnosi
pool
rate
remiss
ci
poorer
asthma
control
year
follow
diagnosi
associ
increment
lower
likelihood
asthma
remiss
tabl
adjust
demograph
diseas
characterist
provinc
poorer
asthma
control
two
year
follow
diagnosi
associ
increment
lower
rate
remiss
better
asthma
control
appear
promis
target
modifi
outcom
asthmat
preschool
studi
fund
canadian
respiratori
research
network
canadian
respiratori
research
network
crrn
support
grant
canadian
institut
health
research
cihr
circulatori
respiratori
health
canadian
lung
associ
cla
canadian
thorac
societi
ct
british
columbia
lung
associ
industri
partner
canada
ltd
astrazeneca
canada
inc
novarti
canada
ltd
funder
role
studi
design
data
collect
analysi
prepar
manuscript
tol
emiss
fire
open
cut
coal
mine
caus
markedli
increas
concentr
fine
particul
matter
latrob
valley
victoria
australia
approxim
six
week
aim
evalu
impact
infant
year
age
exposur
mine
fire
emiss
lung
function
measur
three
year
fire
hourli
fire
deriv
atmospher
transport
model
daili
averag
maximum
assign
particip
residenti
address
fire
lung
function
evalu
use
forc
oscil
techniqu
fot
gener
z
score
resist
rr
two
measur
reactanc
follow
reactanc
frequenc
xr
area
reactanc
curv
ax
use
generalis
linear
model
adjust
matern
smoke
pregnanc
matern
stress
fire
assess
associ
exposur
lung
function
children
mean
age
sd
year
includ
median
iqr
daili
exposur
averag
maximum
baselin
mean
sd
z
score
rr
xr
ax
increas
averag
maximum
respect
independ
associ
z
score
ax
coeffici
ci
averag
maximum
measur
lung
function
matern
smoke
strongli
associ
ax
matern
stress
fire
protect
exposur
coal
mine
fire
emiss
infanc
may
associ
reduc
lung
reactanc
research
requir
valid
find
depart
health
human
servic
victoria
author
declar
compet
interest
tol
preval
chronic
obstruct
pulmonari
diseas
copd
extens
studi
howev
limit
evid
exist
role
lung
diffus
capac
carbon
monoxid
dlco
manag
copd
variou
predict
equat
use
interpret
dlco
recent
global
lung
initi
gli
establish
new
refer
equat
calcul
dlco
aim
assess
preval
low
dlco
younger
smoker
normal
spirometri
use
gli
predict
equat
perform
analysi
subject
spirometri
tlco
measur
respiratori
laboratori
monash
lung
sleep
monash
health
subject
includ
male
femal
age
year
normal
spirometri
signific
smoke
histori
ct
scan
use
assess
preval
parenchym
lung
diseas
group
initi
roca
roca
j
predict
equat
use
calcul
lower
limit
normal
lln
subsequ
result
reanalys
gli
equat
set
data
compar
screen
lung
function
test
identifi
subject
age
normal
spirometri
signific
smoke
histori
cohort
subject
group
tlco
lower
limit
normal
use
roca
equat
subject
low
dlco
higher
preval
emphysema
bronchiectasi
ct
scan
gli
equat
appli
markedli
lower
preval
low
dlco
subject
cohort
dlco
lln
low
transfer
factor
carbon
monoxid
dlco
preval
amongst
younger
smoker
normal
spirometri
low
tlco
may
import
earli
indic
potenti
lung
damag
copd
na
cystic
fibrosi
evalu
lumacaftor
lum
ivacaftor
iva
combin
therapi
lung
morpholog
ct
scan
patient
age
year
cystic
fibrosi
cf
homozyg
mutat
baselin
ct
scan
obtain
patient
lumiva
placebo
phase
trial
ct
scan
complet
activ
treatment
placebo
patient
ct
scan
obtain
total
lung
capac
residu
volum
rv
ct
scan
score
independ
reader
blind
patient
time
point
inform
use
brodi
score
evalu
extent
sever
multipl
aspect
cf
lung
diseas
includ
bronchiectasi
air
trap
score
present
mean
sd
statist
test
perform
preliminari
studi
mean
total
ct
score
sum
subcompon
score
decreas
mean
chang
sd
lumiva
group
increas
placebo
group
mean
bronchiectasi
score
decreas
lumiva
group
increas
placebo
group
addit
suggest
sever
ectat
bronchi
decreas
size
patient
activ
treatment
mean
air
trap
score
decreas
activ
group
increas
placebo
group
first
report
describ
ct
lung
find
cftr
correctorpotenti
therapi
patient
year
age
homozyg
exploratori
analysi
bronchiectasi
air
trap
score
improv
patient
treat
lumiva
worsen
placebo
group
data
suggest
lumiva
may
reduc
cf
chang
lung
morpholog
support
need
studi
grant
support
sponsor
vertex
pharmaceut
incorpor
conflict
interest
cew
receiv
grant
incom
per
patient
basi
conduct
studi
person
fee
travel
support
vertex
pharmaceut
incorpor
conduct
studi
also
receiv
person
fee
travel
support
novarti
pharmaceut
research
grant
novo
nordisk
grant
incom
per
patient
basi
conduct
studi
vertex
pharmaceut
incorpor
ablynx
nv
outsid
submit
work
low
attenu
region
lar
chest
ct
import
compon
lung
diseas
reflect
small
airway
diseas
cystic
fibrosi
cf
howev
extent
lar
revers
young
children
unknown
aim
assess
localis
chang
lar
distribut
time
relat
diseas
outcom
hypothesis
proport
lar
irrevers
young
children
cf
indic
clinic
sever
children
arest
cf
cohort
contribut
ct
scan
clinic
data
annual
consecut
visit
localis
chang
lar
distribut
assess
use
specialis
imag
analysi
softwar
match
ct
lung
imag
two
time
point
measur
lung
volum
proport
new
larnew
revers
larrevers
stabl
larstabl
lar
linear
mix
effect
model
adjust
age
multipl
visit
assess
differ
lar
outcom
associ
clinic
predictor
includ
age
pancreat
suffici
bronchiectasi
extent
determin
method
pulmonari
inflamm
infect
measur
bronchoalveolar
lavag
entir
cohort
compris
ct
scan
cf
patient
mean
age
rang
year
approxim
total
lar
stabl
time
log
larnew
p
log
larrevers
p
significantli
higher
log
larstabl
log
larnew
invers
correl
pancreat
suffici
log
larrevers
associ
presenc
neutrophil
previou
year
p
log
larstabl
associ
pancreat
suffici
previou
detect
neutrophil
inflamm
lar
present
earli
life
around
lar
irrevers
time
progress
lar
associ
pancreat
insuffici
neutrophil
inflamm
children
cf
suggest
role
lar
secondari
imag
endpoint
grant
support
european
respiratori
societi
research
fellowship
studi
show
signific
proport
infant
cystic
fibrosi
cf
diminish
lung
function
within
first
year
life
howev
unknown
whether
lung
function
test
infanc
potenti
predict
wors
prognosi
determin
infant
like
benefit
treatment
earli
life
studi
aim
investig
whether
diminish
lung
function
detect
infant
diagnos
follow
newborn
screen
associ
wors
lung
function
lung
function
assess
individu
cf
diagnos
newborn
screen
year
school
age
year
rais
volum
rapid
compress
rvrtc
techniqu
multipl
breath
washout
mbw
test
perform
infanc
spirometri
mbw
perform
model
use
determin
outcom
rvrtc
forc
expiratori
volum
second
fvc
well
lung
clearanc
index
lci
mbw
test
associ
fvc
measur
spirometri
lci
age
fvc
lci
infanc
associ
zfvc
lci
coeffici
confid
interv
model
shown
lung
function
measur
infanc
associ
lung
function
outcom
factor
respiratori
infect
clinic
statu
investig
may
better
predictor
wors
lung
function
grant
support
nhmrc
conflict
interest
author
conflict
interest
declar
ntm
emerg
respiratori
infect
peopl
cystic
fibrosi
cf
one
speci
mycobacterium
abscessu
complex
mabsc
caus
concern
mode
acquisit
unknown
preval
potabl
water
may
risk
factor
peopl
cf
studi
investig
ntm
recov
potabl
water
system
princ
charl
hospit
tpch
queensland
home
water
collect
shower
sink
tap
two
respiratori
ward
tpch
across
five
time
point
water
collect
home
queensland
four
group
peopl
cf
activ
mabsc
respiratori
infect
year
sinc
posit
sputum
cultur
peopl
cf
past
mabsc
respiratori
infect
year
sinc
posit
sputum
cultur
peopl
cf
never
infect
ntm
peopl
lung
diseas
hospit
home
water
sampl
filter
inocul
growth
media
incub
week
dna
extract
presumpt
ntm
isol
sent
whole
genom
sequenc
water
sampl
recov
presumpt
ntm
isol
hospit
home
date
presumpt
ntm
isol
sequenc
two
isol
contamin
isol
hospit
water
identifi
mycobacterium
kansasii
mabsc
unidentifi
mycobacterium
mycobacterium
avium
isol
home
water
identifi
mabsc
kansasii
unidentifi
mycobacterium
avium
water
isol
compar
cf
mabsc
respiratori
isol
well
environment
isol
ntm
speci
found
potabl
water
system
home
hospit
domin
ntm
speci
kansasii
hospit
water
mabsc
home
water
grant
support
cystic
fibrosi
foundat
therapeut
usa
princ
charl
hospit
foundat
australia
advanc
queensland
cystic
fibrosi
cf
characteris
chronic
lung
infect
often
pseudomona
aeruginosa
requir
repeat
aminoglycosid
therapi
aminoglycosid
recognis
caus
acut
chronic
damag
inner
ear
sensorineur
hear
loss
snhl
especi
higher
frequenc
studi
examin
hear
cf
adult
westmead
hospit
compar
pure
tone
audiometri
pta
high
frequenc
audiometri
hfa
asymptomat
cf
adult
recruit
outpati
cf
clinic
quiet
room
pta
examin
frequenc
whilst
hfa
test
frequenc
hear
loss
sever
categoris
follow
slight
moder
sever
profound
record
worst
consecut
frequenc
standard
high
rang
total
cf
adult
mean
sd
age
year
recruit
standard
pta
detect
hear
loss
ear
show
slight
moder
sever
impair
hfa
detect
hear
loss
slight
moder
sever
profound
impair
hear
loss
standard
frequenc
exhibit
similar
wors
abnorm
high
frequenc
older
patient
show
hear
abnorm
standard
high
frequenc
preliminari
result
suggest
hfa
sensit
standard
pta
measur
potenti
hear
loss
cf
popul
comparison
result
cumul
dose
aminoglycosid
undertaken
studi
grant
support
studi
support
novarti
peripher
insert
central
cathet
picc
integr
role
manag
pulmonari
exacerb
cystic
fibrosi
cf
allow
effect
deliveri
intraven
antibiot
inpati
outpati
set
repeat
use
picc
line
howev
incid
complic
rise
one
complic
deep
venou
thrombosi
dvt
treatment
prove
challeng
set
haemoptysi
cf
relat
liver
diseas
retrospect
audit
undertaken
sir
charl
gairdner
hospit
picc
line
insert
patient
cf
januari
februari
object
assess
current
practic
picc
insert
ii
determin
frequenc
dvt
inform
obtain
comput
record
includ
basic
patient
demograph
prior
histori
haemoptysi
venou
thrombosi
complic
outcom
total
picc
insert
patient
male
femal
took
place
studi
period
percent
patient
histori
haemoptysi
one
fifth
prior
histori
dvt
pulmonari
embolu
major
patient
picc
line
insert
radiologist
rest
perform
nurs
practition
symptomat
dvt
pulmonari
embol
occur
audit
show
rate
dvt
adult
attend
wa
adult
cf
centr
equivoc
report
literatur
well
recognis
factor
includ
picc
size
thrombot
state
patient
cf
histori
dvt
impact
likelihood
dvt
follow
audit
plan
assess
role
enoxaparin
prophylaxi
particularli
outpati
set
aim
minimis
risk
picc
associ
dvt
grant
dr
anna
tai
recipi
follow
grant
glenn
brown
memori
grant
institut
respiratori
health
wa
conquer
cf
program
grant
institut
respiratori
health
wa
tsanz
vertex
adult
cystic
fibrosi
fellowship
conflict
interest
nil
grant
support
intervent
pulmonolog
broncholog
breathless
common
patient
pleural
effus
pathophysiolog
unclear
pleas
comprehens
studi
assess
physiolog
symptom
respons
pleural
effus
drainag
aim
identifi
etiolog
factor
correl
breathless
ii
determin
incid
factor
influenc
symptomat
benefit
fluid
drainag
consecut
patient
symptomat
pleural
effus
undergo
therapeut
drainag
recruit
includ
patient
characterist
degre
breathless
use
three
separ
grade
system
walk
distanc
capac
spirometri
diaphragm
morpholog
motion
ultrasonographi
patient
median
age
male
commonli
malign
effus
heart
failur
effus
effus
hemithorax
cxr
median
iqr
ml
drain
breathless
measur
improv
significantli
effus
drainag
visual
analog
score
minim
clinic
import
score
borg
score
p
respiratori
heart
rate
increas
fvc
improv
p
abnorm
diaphragmat
morpholog
flatten
invers
motion
paralys
paradox
common
normal
patient
respect
report
signific
relief
breathless
va
pathophysiolog
breathless
patient
pleural
effus
complex
multifactori
drainag
pleural
effus
improv
symptom
function
capac
spirometri
normalis
diaphragm
morpholog
motion
grant
support
nhmrc
fellowship
rt
ycgl
sj
pe
wa
cancer
council
rt
ycgl
wacpcn
fellowship
sm
conflict
interest
author
declar
conflict
interest
pleural
fluid
ph
glucos
level
recommend
current
guidelin
investig
workup
pleural
effus
paramet
reduc
inflammatori
andor
metabol
activ
condit
whether
pleural
fluid
ph
glucos
level
provid
duplic
inform
independ
knowledg
unclear
aim
investig
relationship
pleural
fluid
ph
glucos
level
unselect
pleural
effus
incid
discord
level
set
pleural
servic
three
centr
spain
uk
australia
data
clinic
inform
pleural
fluid
ph
glucos
level
collect
analys
assess
relationship
ph
glucos
use
smooth
curv
restrict
cubic
spline
model
ii
concord
ph
glucos
vari
level
assess
pleural
fluid
sampl
separ
four
categori
malign
bacteri
infect
tb
pleuriti
benign
effus
mean
ph
sd
median
glucos
rang
mmoll
linear
regress
model
relationship
glucos
ph
restrict
cubic
spline
show
linear
p
nonlinear
effect
p
sampl
concord
ph
glucos
level
ie
cutoff
respect
concord
lowest
tb
group
highest
benign
pleuriti
group
patient
low
ph
high
glucos
like
diabet
diabet
vs
low
glucos
high
ph
p
bacteri
infect
pleural
fluid
ph
glucos
correl
concord
major
case
either
test
level
use
aid
diagnos
infect
pleural
fluid
glucos
interpret
care
diabetichyperglycaem
patient
studi
aim
examin
whether
differ
needl
obtain
adequ
tissu
diagnosi
ancillari
test
well
compar
safeti
retrospect
review
case
done
lyell
mcewin
hospit
june
septemb
includ
case
done
needl
comparison
randomli
select
number
case
use
needl
data
collect
includ
patient
demograph
data
diagnosi
base
fine
needl
aspir
fna
sampl
averag
size
lymph
node
biopsi
number
needl
pass
sampl
adequaci
immunohistochemistri
ihc
molecular
mutat
test
case
primari
lung
adenocarcinoma
egfr
alk
sampl
qualiti
procedur
complic
data
result
analys
compar
statist
use
fisher
test
needl
diagnost
yield
needl
p
sampl
adequaci
obtain
ihc
compar
group
p
group
molecular
mutat
test
achiev
patient
primari
lung
adenocarcinoma
averag
size
lymph
node
significantli
larger
group
compar
group
cf
p
howev
slight
increas
bleed
group
cf
p
signific
differ
needl
size
use
regard
diagnost
yield
sampl
adequaci
molecular
mutat
test
howev
studi
signific
differ
sampl
adequaci
ihc
test
come
slight
increas
risk
bleed
grant
support
nil
declar
interest
nil
refer
nil
indwel
pleural
cathet
ipc
effect
treatment
recurr
especi
malign
pleural
effus
pleural
infect
though
uncommon
remain
physician
major
concern
use
ipc
intrapleur
tpadnas
therapi
revolution
care
pleural
infect
use
pleural
infect
subject
prior
report
singl
centr
retrospect
review
patient
pleural
infect
treat
tpadnas
tertiari
pleural
unit
demograph
intervent
outcom
treatment
describ
treatment
success
defin
surviv
hospit
discharg
avoid
surgeri
data
present
percentag
median
iqr
appropri
nineteen
patient
male
age
year
receiv
intrapleur
tpadnas
malign
effus
mesothelioma
cell
lung
carcinoma
median
time
ipc
insert
diagnosi
pleural
infect
day
median
day
one
patient
die
cancer
progress
fever
dyspnoea
decreas
fluid
drainag
commonest
present
complaint
staphylococcu
aureu
bacilli
common
organ
found
pleural
fluid
cultur
tpadnas
therapi
success
cure
case
remain
two
patient
underw
surgeri
inadequ
clinic
improv
three
patient
requir
addit
chest
drain
thoracentesi
crp
improv
iul
iul
outpati
wcc
respect
pleural
opac
cxr
improv
patient
pleurodesi
develop
patient
allow
ipc
remov
length
hospit
stay
day
signific
complic
includ
bleed
associ
tpadnas
therapi
observ
intrapleur
tpadnas
therapi
safe
administ
via
ipc
pleural
infect
provid
high
cure
rate
grant
support
nhmrc
fellowship
rt
ycgl
wa
cancer
council
rt
ycgl
wacpcn
fellowship
sm
declar
rocket
med
ltd
provid
free
ipc
drainag
kit
unrestrict
educ
grant
previou
trial
led
ycgl
ycgl
serv
advisori
board
carefusionbd
lung
therapeut
inc
sequana
med
ltd
bronchoscop
lung
volum
reduct
blvr
via
endobronchi
valv
ebv
insert
accept
treatment
patient
sever
emphysema
common
complic
ebv
insert
pneumothorax
report
incid
aim
studi
determin
previou
pleural
injuri
paraseptalpanlobular
emphysema
morpholog
subtyp
would
contribut
pneumothorax
risk
insert
ebv
insert
blvr
occur
adelaid
south
australia
period
septemb
examin
centr
royal
adelaid
hospit
queen
elizabeth
hospit
chestcar
clinic
emphysema
subtyp
determin
evalu
ct
chest
scan
presenc
pleural
injuri
determin
assess
patient
previou
pneumothorax
pleural
instrument
pleural
plaquesnodul
ct
chest
scan
procedur
complet
within
studi
timefram
procedur
result
pneumothorax
mean
age
ebv
insert
year
ebv
insert
occur
male
patient
statist
analysi
undertaken
via
logist
regress
previou
pleural
injuri
significantli
increas
risk
pneumothorax
confid
interv
p
gender
age
ebv
insert
paraseptalpanlobular
emphysema
subtyp
significantli
increas
pneumothorax
risk
first
australian
studi
examin
risk
factor
pneumothorax
incid
ebv
insert
previou
pleural
injuri
significantli
increas
pneumothorax
risk
ebv
insert
data
contribut
abil
predict
pneumothorax
patient
evalu
ebv
insert
thu
allow
improv
risk
assess
facilit
discharg
plan
insert
plan
studi
evalu
possibl
risk
factor
includ
quantit
ct
score
pleural
adhes
grant
support
none
talc
pleurodesi
tp
indwel
pleural
cathet
ipc
recogn
treatment
malign
pleural
effus
mpe
advantag
combin
potenti
provid
best
fluid
control
facilit
earli
ipc
remov
minim
hospit
long
term
ipc
cost
complic
pilot
studi
new
treatment
algorithm
epitom
patient
symptomat
mpe
requir
definit
treatment
offer
inpati
ipc
unless
contraind
insert
upon
complet
drainag
usual
overnight
cxr
perform
lung
full
talc
slurri
instil
via
ipc
patient
discharg
follow
day
daili
ipc
drainag
use
day
longer
continu
reduct
drainag
volum
ipc
remov
pleurodesi
success
defin
fluid
drainag
consecut
drainag
without
signific
residu
effus
imag
patient
trap
lung
contraind
talc
discharg
ipc
drainag
symptomat
data
present
median
iqr
patient
mpe
male
median
age
metastat
cancer
mesothelioma
includ
median
volum
litr
drain
within
hour
ipc
insert
sixteen
patient
fulfil
criteria
receiv
talc
instil
via
ipc
usual
one
day
insert
median
total
hospit
day
nine
patient
achiev
pleurodesi
median
day
underw
cathet
remov
evid
recurr
median
day
talc
administ
patient
due
trap
lung
prior
fail
talc
pleurodesi
etc
complic
talc
includ
revers
tube
blockag
fever
subsequ
develop
symptomat
locul
success
manag
tube
drainag
intrapleur
tpa
epitom
protocol
combin
ipc
talc
pleurodesi
feasibl
safe
potenti
advantag
individu
therapi
grant
support
nhmrc
fellowship
rt
ycgl
wa
cancer
council
rt
ycgl
wacpcn
fellowship
sm
declar
rocket
med
ltd
provid
free
ipc
drainag
kit
unrestrict
educ
grant
previou
trial
led
ycgl
ycgl
serv
advisori
board
carefusionbd
sequana
med
ltd
pulmonari
physiolog
sleep
obstruct
sleep
apnoea
osa
common
associ
signific
morbid
mortal
object
preval
data
australia
particularli
women
busselton
western
australia
preval
osa
respiratori
disturb
index
estim
men
men
women
index
ahi
particip
without
known
osa
assess
osa
preval
busselton
healthi
age
studi
comprehens
health
studi
sex
age
year
resid
busselton
shire
elector
roll
born
invit
particip
particip
dual
channel
apnealink
devic
home
sleep
studi
issu
particip
collect
suitabl
analysi
preval
osa
defin
ahi
obtain
apnealink
autom
event
score
algorithm
relat
demograph
data
assess
moder
sever
osa
defin
ahi
respect
preval
osa
ahi
men
women
see
tabl
increas
osa
sever
associ
increas
bmi
alcohol
use
sex
sleepi
men
compar
ahi
ahi
associ
hypertens
sex
p
current
depress
men
vs
diabet
vs
cancer
vs
women
preval
osa
busselton
increas
preval
women
higher
previous
report
differ
comorbid
observ
grant
support
nation
health
medic
research
council
nhmrc
offic
scienc
depart
health
govern
western
australia
equip
consum
support
resm
scienc
centr
current
evid
indic
inspiratori
load
engag
cortic
mechan
defend
ventil
cortic
contribut
breath
determin
via
presenc
bereitschaft
readi
potenti
low
amplitud
neg
begin
inspir
chronic
obstruct
pulmonari
diseas
copd
chang
lung
chest
wall
respiratori
muscl
induc
inspiratori
load
hypothesis
cortic
contribut
quiet
breath
copd
cortic
contribut
inspiratori
threshold
load
relat
dyspnoea
major
symptom
copd
electroencephalograph
activ
eeg
record
copd
patient
male
age
healthi
control
young
quiet
breath
inspiratori
threshold
load
maxim
inspiratori
pressur
two
blind
observ
evalu
presenc
bereitschaftspotenti
prior
inspir
ensembl
averag
epoch
eeg
cz
fcz
dyspnoea
rate
use
modifi
borg
scale
incid
cortic
contribut
quiet
breath
significantli
greater
copd
patient
young
p
p
control
cortic
contribut
inspiratori
threshold
load
associ
higher
borg
score
young
p
control
p
copd
patient
p
studi
provid
evid
age
rather
copd
associ
cortic
contribut
quiet
breath
cortic
contribut
inspiratori
threshold
load
may
associ
sever
dyspnoea
least
healthi
young
peopl
grant
support
al
hudson
support
lung
foundat
australiaboehring
ingelheim
copd
research
fellowship
despit
advanc
technolog
continu
posit
airway
pressur
cpap
treatment
obstruct
sleep
apnea
osa
well
valid
benefit
qualiti
life
health
outcom
long
term
adher
remain
major
challeng
remot
access
cloud
base
technolog
becom
standard
featur
new
cpap
devic
current
featur
may
optim
utilis
improv
complianc
patient
experi
cpap
sought
determin
whether
remot
base
assess
cpap
usag
regular
interv
follow
telephon
assess
could
improv
cpap
usag
epworth
sleepi
score
ess
patient
commenc
cpap
therapi
osa
sleep
servic
sought
prospect
assess
consecut
patient
commenc
cpap
therapi
osa
patient
cpap
usag
remot
assess
week
post
commenc
telephon
assess
standardis
questionnair
carri
interv
cpap
usag
per
night
cpap
usag
final
ess
compar
consecut
retrospect
control
current
preliminari
data
includ
target
patient
intervent
group
mean
age
year
sd
vs
bodi
mass
index
bmi
vs
apnea
hypopnea
index
ahi
vs
eventshour
baselin
ess
vs
control
intervent
group
respect
signific
differ
cpap
usag
control
group
intervent
group
vs
hour
sd
vs
hour
vs
hour
vs
hour
respect
addit
signific
differ
chang
ess
score
vs
respect
regular
interv
remot
base
assess
cpap
usag
osa
addit
usual
care
improv
cpap
usag
ess
grant
support
nil
syndrom
ds
associ
multipl
health
issu
includ
obstruct
sleep
apnoea
osa
dysmorph
craniofaci
featur
inher
ds
predispos
osa
aim
studi
ascertain
preval
sever
osa
ds
adult
identifi
possibl
barriersenabl
treatment
compar
demograph
polysomnographi
psg
indic
continu
posit
airway
pressur
cpap
prescript
rate
adher
ds
adult
match
group
adult
refer
sleep
studi
repatri
gener
hospit
data
collect
electron
record
ds
patient
osa
identifi
case
review
compar
randomli
select
match
gender
age
bodi
mass
index
bmi
studi
date
day
group
comparison
conduct
use
independ
sampl
u
test
continu
data
fisher
test
categor
variabl
ds
match
patient
gender
age
versu
year
bmi
versu
ds
osa
compar
p
patient
ds
patient
osa
commenc
cpap
p
ds
sever
osa
total
apnoea
hypopnoea
index
median
iqr
versu
control
cpap
adher
month
averag
hour
use
ds
versu
control
control
similar
intens
follow
visit
first
year
cpap
initi
ds
versu
control
ds
patient
higher
intens
supervis
overnight
better
cpap
complianc
ds
patient
significantli
sever
osa
reduc
cpap
adher
research
requir
elucid
barrier
treatment
potenti
solut
improv
cpap
complianc
amongst
ds
patient
osa
grant
support
nil
declar
interest
nil
pulmonari
function
test
pft
main
tool
evalu
function
respiratori
system
howev
use
alon
hardli
lead
diseas
diagnosi
base
artifici
intellig
ai
aim
develop
smart
softwar
improv
clinic
read
lung
function
suggest
respiratori
diseas
diagnosi
possibl
data
subject
respiratori
symptom
taken
belgian
hospit
develop
algorithm
final
diagnosi
healthi
asthma
copd
ild
neuromuscular
diseas
chest
wall
pleural
diseas
pulmonari
vascular
diseas
obstruct
diseas
obtain
clinic
histori
lung
function
addit
test
confirm
expert
panel
solut
incorpor
clinic
set
valid
accuraci
algorithm
random
sampl
new
subject
final
softwar
diagnos
compar
diagnost
opinion
pulmonologist
differ
european
hospit
provid
pft
clinic
data
new
subject
develop
softwar
present
high
accuraci
detect
lung
diseas
possibl
diseas
categori
valid
high
accuraci
maintain
real
clinic
set
extern
multicentr
valid
autom
diagnos
accuraci
superior
suggest
diagnos
pulmonologist
mean
accuraci
great
disagr
reader
observ
low
kappa
score
ai
use
identifi
differ
lung
diseas
due
superior
work
consist
softwar
provid
power
decis
support
system
daili
clinic
routin
grant
support
vlaio
flander
mechan
ventil
lifesav
therapi
patient
respiratori
failur
contribut
mortal
induc
inflamm
lead
multisystem
organ
failur
differ
region
lung
shown
heterogen
respond
mechan
ventil
howev
associ
variat
region
lung
distens
region
lung
inflamm
unknown
aim
studi
assess
associ
healthi
lung
ventil
two
group
adult
balbc
mice
n
per
group
h
use
protect
low
tidal
volum
moder
posit
end
expiratori
pressur
peep
injuri
high
tidal
volum
zero
peep
ventil
strategi
rna
level
gene
quantifi
region
qpcr
array
gene
express
correl
region
frc
tidal
volum
distens
frc
tidal
volum
frc
tidal
volum
obtain
analysi
velocimetri
dynam
phase
contrast
lung
imag
baselin
two
hour
ventil
two
gene
differenti
region
express
vari
ventil
strategi
p
express
gene
posit
correl
region
tidal
volum
distens
p
correl
express
also
vari
ventil
strategi
p
appear
associ
frc
tidal
volum
distens
demonstr
associ
region
gene
express
tidal
volum
result
provid
critic
insight
region
lung
respons
mechan
ventil
particular
result
highlight
import
balanc
tidal
volum
contribut
lung
inflamm
potenti
patient
outcom
grant
support
studi
fund
nhmrc
grant
asthma
allergi
although
signific
progress
made
asthma
manag
patient
sever
asthma
sa
associ
increas
morbid
mortal
econom
burden
within
group
patient
prescrib
continu
oral
corticosteroid
oc
achiev
maintain
asthma
control
howev
primari
care
subset
patient
may
exist
poor
asthma
manag
practic
thu
less
sever
diseas
reli
oc
achiev
asthma
control
instead
regular
inhal
prevent
medic
aim
studi
identifi
pattern
medic
take
behaviour
describ
respiratori
statu
peopl
asthma
primari
care
allow
develop
framework
identifi
patient
base
asthma
sever
medic
record
patient
data
utilis
commun
pharmaci
databas
correl
analysi
regress
model
employ
determin
potenti
predictor
asthmat
oral
corticosteroid
user
base
asthma
sever
lung
function
symptom
control
comorbid
adher
inhal
techniqu
medic
manag
fifteen
percent
asthmat
recruit
prescrib
oc
last
month
percent
oc
user
classifi
poor
asthma
control
identifi
potenti
barrier
determin
brief
medic
questionnair
svarstad
bl
et
al
incorrect
inhal
techniqu
signific
relationship
found
oc
user
ownership
asthma
action
plan
p
exist
depress
eczema
potenti
poor
asthma
control
p
poor
lung
function
test
higher
prescrib
rate
inhal
combin
therapi
p
includ
higher
rate
visit
doctor
regard
asthma
research
uncov
heterogen
group
peopl
asthma
primari
care
less
sever
diseas
put
risk
exacerb
due
medic
take
behaviour
better
understand
behaviour
individu
context
manag
abl
tailor
intervent
patient
reflect
current
guidelin
svarstad
b
l
et
al
brief
medic
questionnair
tool
screen
patient
adher
barrier
adher
patient
educ
coun
sever
asthma
substanti
impair
qualiti
life
may
impair
workplac
product
although
rare
quantifi
aim
studi
compar
workplac
impair
sever
asthma
time
identifi
characterist
associ
presente
sever
asthma
patient
enrol
sever
asthma
databas
sawd
ongo
observ
registri
patient
sever
refractori
asthma
control
asthma
site
across
australia
new
zealand
singapor
year
femal
particip
provid
baselin
clinic
questionnair
data
everi
month
month
workplac
absente
time
absent
work
presente
impair
work
activ
impair
impair
daili
activ
outsid
work
past
week
deriv
valid
half
particip
employ
baselin
quarter
worker
report
absente
report
presente
peopl
sever
compar
asthma
time
like
report
presente
ci
time
like
report
daili
activ
impair
ci
poorer
asthma
control
exacerb
previou
year
associ
greater
absente
presente
activ
impair
p
worsen
asthma
control
score
associ
increas
presente
time
time
interact
particip
sever
asthma
wors
asthma
control
p
qualiti
life
p
depress
symptom
anxieti
symptom
associ
greater
odd
presente
impair
work
function
import
compon
diseas
burden
sever
asthma
optimis
workplac
product
requir
improv
asthma
control
attent
mental
health
absente
presente
may
key
metric
assess
intervent
efficaci
among
peopl
sever
asthma
work
age
grant
support
sawd
support
gsk
roch
az
novarti
boehring
ingelheim
reilli
et
al
pharmacoeconom
glucocorticoid
gc
remain
central
treatment
asthma
therapeut
respons
impair
sever
asthma
asthma
exacerb
laboratori
found
per
se
impair
gc
activ
key
mediat
viral
gc
insensit
airway
epithelium
key
clock
compon
implic
signal
also
regul
gc
activ
current
studi
demonstr
target
prevent
gc
insensit
attenu
viru
mimic
poli
c
inflammatori
respons
differenti
express
assess
ihc
human
asthmat
cohort
gc
respons
bronchial
epitheli
cell
interfac
ali
primari
human
bronchial
epitheli
cell
hbec
presenc
assess
poli
c
inflammatori
respons
cell
assess
elisa
potenti
involv
experiment
set
determin
use
pharmacolog
genet
sirna
approach
express
significantli
higher
airway
wall
sever
asthmat
compar
asthma
healthi
subject
cell
suppress
gre
activ
endogen
gene
express
prevent
poli
c
cytokin
attenu
inhibit
use
sirna
identifi
novel
target
therapeut
potenti
restor
efficaci
gc
sever
asthma
asthma
exacerb
grant
support
nhmrc
asthma
australia
improv
diagnost
tool
predict
airway
inflammatori
phenotyp
futur
exacerb
frequenc
asthma
requir
previous
demonstr
sputum
gene
express
signatur
biomark
could
predict
inflammatori
phenotyp
corticosteroid
respons
stabl
asthma
recent
demonstr
azithromycin
treatment
uncontrol
asthma
significantli
reduc
asthma
exacerb
amaz
clinic
trial
aim
test
whether
predict
airway
inflammatori
futur
exacerb
phenotyp
subpopul
amaz
clinic
trial
also
test
whether
week
azithromycin
treatment
alter
express
compar
placebo
patient
produc
adequ
sputum
differenti
cell
count
pcr
marker
baselin
week
treatment
logist
regress
roc
analysi
perform
baselin
result
compar
predict
valu
convent
biomark
airway
inflammatori
phenotyp
futur
exacerb
frequenc
significantli
predict
airway
inflammatori
subtyp
baselin
outperform
system
biomark
peripher
blood
eosinophil
pbe
fraction
exhal
nitric
oxid
feno
significantli
predict
futur
exacerb
phenotyp
numer
superior
biomark
examin
sputum
eosinophil
sputum
neutrophil
pbe
feno
identifi
patient
would
go
experi
frequent
sever
exacerb
azithromycin
treatment
significantli
alter
express
compar
placebo
affect
predict
exacerb
phenotyp
use
sputum
use
diagnost
tool
inflammatori
phenotyp
predict
futur
frequent
sever
exacerb
retain
predict
capac
asthma
suggest
novel
therapeut
mechan
independ
known
inflammatori
factor
grant
support
work
support
nhmrc
mf
hold
nhmrc
research
fellowship
within
cre
sever
asthma
pgg
hold
nhmrc
practition
fellowship
kjb
hold
lung
foundat
australia
boehring
ingelheim
copd
research
fellowship
sever
asthma
characteris
frequent
exacerb
lead
poor
asthma
control
worsen
qualiti
life
tthe
major
exacerb
trigger
viral
respiratori
tract
infect
poorli
control
asthma
associ
impair
antivir
immun
respons
treatment
sever
allerg
asthma
omalizumab
monoclon
antibodi
ige
shown
improv
asthma
control
reduc
exacerb
risk
sought
determin
treatment
omalizumab
result
improv
antivir
innat
immun
respons
influenza
iav
rhinoviru
rv
recruit
adult
poorli
control
allerg
asthma
atop
one
aeroallergen
maxim
dose
inhal
corticosteroid
long
act
bronchodil
persist
poor
asthma
symptom
control
exacerb
requir
oral
corticosteroid
serum
total
ige
compar
healthi
age
match
control
asthma
atopi
particip
assess
prior
commenc
treatment
omalizumab
month
later
time
effect
treatment
assess
blood
drawn
peripher
blood
monocyt
pbmc
isol
pbmc
expos
hour
iav
rv
respons
assess
elisabead
arraywith
releas
interferon
ifn
baselin
visit
subject
sever
allerg
asthma
compar
healthi
control
demonstr
impair
releas
respons
iav
p
rv
follow
month
treatment
demonstr
improv
asthma
symptom
control
continu
treatment
clinic
respond
signific
increas
seen
iav
trend
toward
improv
rv
adult
sever
allerg
asthma
demonstr
impair
system
innat
immun
respons
iav
rv
treatment
omalizumab
result
improv
asthma
control
associ
improv
innat
antivir
respons
grant
support
treatabl
trait
tt
propos
new
approach
airway
diseas
manag
howev
support
data
current
limit
aim
determin
identif
tt
possibl
use
sever
asthma
registri
assess
preval
sever
compar
asthma
assess
relationship
tt
futur
exacerb
risk
sever
asthma
databas
observ
registri
sever
asthma
patient
comparison
group
patient
asthma
site
australasia
year
femal
particip
characteris
enrol
follow
month
publish
map
registri
data
field
preval
determin
bayesian
model
averag
appli
identifi
trait
best
predict
futur
exacerb
risk
seven
pulmonari
extrapulmonari
behaviour
trait
identifi
pulmonari
extrapulmonari
trait
express
sever
asthma
p
trait
significantli
common
sever
asthma
incomplet
revers
airflow
limit
vs
frequent
exacerb
vs
p
neutrophil
airway
inflamm
vs
obes
vs
p
system
inflamm
vs
p
reflux
vs
polypharmaci
vs
aspergillu
sensitis
vs
p
patient
sever
asthma
report
exacerb
median
iqr
irr
p
addit
trait
associ
increas
exacerb
risk
p
previou
exacerb
polypharmaci
sleep
apnea
depress
best
predict
exacerb
risk
systemat
characteris
asthma
may
use
assess
tt
report
trait
predict
exacerb
risk
confirm
greater
burden
associ
sever
asthma
trial
evalu
efficaci
tt
approach
need
gibson
etal
lancet
agusti
etal
erj
grant
support
sawd
support
gsk
roch
az
novarti
boehring
ingelheim
cell
immunolog
molecular
biolog
lung
asthma
chronic
inflammatori
airway
diseas
character
recurr
attack
breathless
wheez
pathogenesi
asthma
complex
still
unclear
unfold
protein
respons
upr
endoplasm
reticulum
er
recent
identifi
play
decis
role
inflammatori
diseas
worsen
asthmat
condit
brought
stimuli
oxid
stress
pathogen
infect
allergen
exposur
induc
er
stress
activ
upr
activ
arm
upr
induc
differ
inflammatori
pathway
dysregul
innat
immun
respons
howev
upr
associ
asthma
unclear
investig
upr
signatur
differ
inflammatori
phenotyp
asthma
use
human
clinic
sampl
broncho
alveolar
lavag
fluid
balf
endobronchi
biopsi
induc
sputum
sampl
collect
eosinophil
neutrophil
paucigranulocyt
asthma
patient
healthi
individu
express
upr
associ
gene
balf
cell
biopsi
sampl
analys
qpcr
upr
relat
protein
express
analys
immunoblot
upr
gene
express
sputum
cell
analys
microarray
upr
gene
chop
lung
immun
cell
significantli
induc
p
eosinophil
asthma
neutrophil
asthma
demonstr
increas
trend
chop
protein
express
significantli
higher
eosinophil
neutrophil
group
microarray
data
sputum
cell
demonstr
upregul
variou
upr
gene
mostli
eosinophil
asthma
group
paucigranulocyt
mix
granulocyt
group
upr
gene
express
lung
biopsi
show
signific
differ
group
howev
bronchial
epitheli
cell
bec
treat
asthma
allergen
demonstr
increas
trend
upr
upr
heighten
eosinophil
neutrophil
asthma
airway
immun
cell
major
role
regul
upr
airway
asthma
b
cell
implic
develop
lung
fibrosi
previous
demonstr
b
mice
protect
bleomycin
blm
lung
fibrosi
suggest
b
cell
import
regul
fibrosi
hypothesis
effect
involv
b
immun
regul
effect
therapi
wildtyp
mice
lung
fibrosi
immun
cell
composit
examin
mice
given
two
dose
antibodi
genentech
inc
usa
isotyp
control
ip
either
day
prior
day
bleomycin
day
day
treatment
follow
initi
fibrosi
extent
fibrosi
measur
day
fac
analysi
blood
taken
day
day
reveal
almost
complet
deplet
b
cell
circul
wildtyp
mice
howev
extent
fibrosi
assess
use
imag
hplc
analysi
hydroxyprolin
level
significantli
differ
treatment
group
histolog
analysi
reveal
abund
b
cell
plasma
cell
lung
mice
fac
analysi
identifi
expans
day
cell
lung
bleomycin
treat
mice
day
although
antibodi
deplet
follicular
b
cell
effect
fibrosi
residu
plasma
cell
b
abund
lung
mice
activ
b
cell
subset
may
contribut
fibrot
phenotyp
grant
support
work
fund
nhmrc
project
grant
british
lung
foundat
grant
obes
appear
protect
effect
lung
patholog
inflammatori
respons
copd
howev
underli
relationship
obes
diet
diseas
outcom
copd
fulli
understood
studi
explor
relationship
dietari
polyunsatur
fatti
acid
pufa
arachidon
acid
aa
airway
inflamm
remodel
primari
human
pulmonari
fibroblast
vitro
peopl
without
copd
also
effect
bodi
mass
index
bmi
inflammatori
respons
assess
primari
human
lung
fibroblast
deriv
copd
patient
patient
challeng
aa
releas
cytokin
measur
use
elisa
messeng
rna
mrna
express
extracellular
matrix
ecm
protein
fibronectin
fn
collagen
col
tenascin
tnc
measur
use
quantit
pcr
found
challeng
aa
result
increas
releas
fibroblast
howev
p
p
releas
copd
lower
compar
regress
analysi
reveal
relationship
bmi
cytokin
releas
copd
aa
reduc
basal
fn
p
col
p
mrna
express
fibroblast
copd
patient
studi
demonstr
aa
commonli
found
obes
diet
affect
inflammatori
process
ecm
deposit
copd
copd
cell
compar
cell
hyporespons
aa
suggest
copd
meal
rich
pufa
potent
induct
inflammatori
respons
compar
lung
diseas
howev
reduc
capac
produc
ecm
protein
could
neg
affect
heal
process
like
manifest
perturb
excess
tissu
remodel
copd
class
iii
histon
deacetylas
hdac
sirtuin
import
regul
senesc
age
inflamm
chromatin
histon
therebi
silenc
inflammatori
gene
transcript
report
increas
steroid
resist
senesc
cell
patient
copd
hypothes
express
would
reduc
cell
copd
treatment
activ
resveratrol
agent
prevent
nad
deplet
theophyllin
would
upregul
express
reduc
cytokin
express
steroid
resist
cell
blood
collect
copd
patient
age
match
control
express
cytokin
determin
cell
cultur
presenc
resveratrol
theophyllin
prednisolon
use
flow
cytometri
decreas
express
identifi
cell
compar
counterpart
patient
control
eg
vs
loss
associ
increas
product
steroid
resist
express
upregul
presenc
resveratrol
theophyllin
associ
decreas
steroid
resist
product
cell
steroid
resist
cell
associ
decreas
express
combin
resveratrol
andor
theophyllin
treatment
increas
express
restor
steroid
sensit
inhibit
cytokin
product
cell
may
reduc
system
inflamm
copd
grant
support
women
higher
incid
asthma
compar
men
exacerb
women
often
sever
correl
high
estrogen
level
use
experiment
anim
model
asthma
observ
femal
rat
experiment
asthma
also
develop
sever
exacerb
compar
male
rat
aim
studi
investig
femal
sex
hormon
estrogen
impact
asthma
respons
identifi
immunolog
mechan
effect
implant
pellet
male
rat
prior
investig
male
respond
compar
untreat
male
femal
use
multi
paramet
flow
cytometri
investig
proport
activ
antigen
present
dendrit
cell
respond
effector
regulatori
cell
airway
allergen
discov
estrogen
suffici
induc
diseas
phenotyp
exacerb
male
rat
interestingli
male
femal
rat
also
display
signific
differ
cell
ratio
airway
drain
lymph
node
directli
impact
estrogen
exposur
addit
femal
estrogen
treat
male
rat
male
rat
display
sign
recruit
cell
airway
follow
allergen
like
contribut
exacerb
respons
data
suggest
estrogen
suffici
induc
femal
like
asthma
symptom
male
rat
appear
alter
cell
balanc
promot
allerg
respons
grant
support
studi
fund
asthma
foundat
western
australia
telethon
kid
institut
swedish
societi
medic
research
small
molecul
correct
cftr
product
function
greatli
improv
cf
outcom
rarer
mutat
hinder
lack
appropri
primari
cultur
model
modifi
primari
airway
epitheli
cell
aec
children
cf
modifi
express
fluoresc
marker
allow
function
cftr
assess
would
provid
screen
platform
compar
methodolog
achiev
stabl
fluoresc
primari
aec
primari
aec
obtain
children
cf
bronchial
brush
cultur
use
condit
reprogram
methodolog
cell
transfect
plasmid
via
devic
altern
aec
transduc
retrovir
vector
fluoresc
tag
hour
cell
express
fluoresc
select
fluoresc
activ
cell
sort
fac
flow
cytometri
expand
cultur
assess
stabil
gene
express
primari
aec
amen
three
methodolog
transfect
effici
best
electropor
protocol
achiev
slightli
higher
effici
replic
defici
retroviru
effect
posit
cell
differ
transfect
effici
observ
cf
aec
cell
could
success
cultur
fac
select
aec
transduc
retrovir
vector
maintain
fluoresc
two
passag
cultur
retrovir
vector
could
stabli
induc
fluoresc
primari
aec
construct
retrovir
vector
contain
yfp
gene
valid
cftr
function
assay
across
rang
cftr
mutat
grant
support
bhp
billiton
telethon
kid
institut
blue
sky
research
grant
chronic
obstruct
pulmonari
diseas
copd
chronic
obstruct
pulmonari
diseas
copd
second
lead
caus
avoid
hospit
admiss
australia
date
nation
data
exist
compar
recommend
clinic
practic
guidelin
inpati
manag
acut
exacerb
actual
practic
aim
compar
contemporari
manag
recommend
guidelin
prospect
audit
copd
hospit
admiss
five
tertiari
care
hospit
five
state
australia
conduct
standardis
audit
tool
use
collect
data
telephon
day
discharg
assess
readmiss
data
assess
guidelin
prospect
data
obtain
admiss
patient
octob
age
year
male
caucasian
mean
number
comorbid
per
patient
hypertens
gastrointestin
diseas
ischaem
heart
diseas
psychiatricanxietydepress
disord
preval
half
live
home
anoth
patient
readmit
within
day
inpati
death
death
within
day
discharg
concord
recommend
vari
prescript
oral
corticosteroid
rang
antibiot
therapi
perform
chest
high
howev
perform
spirometri
rang
written
inpati
prescript
acut
oxygen
therapi
rang
referr
pulmonari
rehabilit
rang
poor
import
gap
manag
seen
nation
compar
clinic
practic
guidelin
grant
support
nil
declar
interest
declar
conflict
interest
relat
project
examin
associ
specif
type
physic
activ
pa
mortal
risk
peopl
chronic
obstruct
pulmonari
diseas
copd
prospect
cohort
studi
use
peopl
copd
age
year
identifi
health
survey
england
scottish
health
survey
cohort
walk
domest
pa
sportexercis
assess
baselin
classifi
three
group
particip
type
pa
refer
group
median
level
activ
cohort
low
equal
median
level
activ
cohort
high
median
metabol
equival
met
walk
domest
pa
sportexercis
cox
proport
hazard
model
use
examin
associ
pa
mortal
risk
particip
copd
includ
analysi
mean
age
sd
mean
predict
men
year
death
associ
mortal
risk
demonstr
walk
sportexercis
domest
pa
compar
refer
group
particip
high
walk
group
reduc
mortal
risk
hazard
ratio
hr
confid
interv
ci
particip
high
sportexercis
group
hr
ci
signific
mortal
risk
reduct
observ
low
group
walk
sportexercis
walk
structur
exercis
encourag
peopl
copd
gain
mortal
benefit
effect
domest
pa
mortal
remain
unclear
grant
support
es
fund
nation
institut
health
research
uk
award
code
nation
health
medic
research
council
award
code
dataset
acquisit
process
harmonis
approxim
peopl
chronic
obstruct
pulmonari
diseas
copd
refer
pulmonari
rehabilit
desatur
exercis
aim
determin
whether
supplementari
oxygen
exercis
train
effect
medic
air
improv
exercis
capac
qualiti
life
peopl
copd
desatur
walk
test
randomis
control
trial
randomis
independ
conceal
alloc
blind
particip
exercis
trainer
assessor
analysi
particip
randomis
either
oxygen
group
og
air
group
ag
group
receiv
respect
ga
concentr
via
nasal
prong
litresminut
exercis
train
treadmil
cycl
exercis
three
timesweek
eight
week
primari
outcom
measur
endur
shuttl
walk
test
eswt
chronic
respiratori
questionnair
crq
studi
ethic
approv
trial
registr
particip
male
mean
sd
age
year
predict
recruit
complet
og
ag
chang
week
signific
eswt
crq
total
crq
dyspnoea
eswt
og
mean
differ
ci
ag
crq
og
point
pt
ag
pt
crq
og
pt
ag
pt
p
group
differ
p
outcom
exercis
capac
qualiti
life
improv
significantli
group
greater
benefit
train
supplement
oxygen
medic
air
largest
rigor
rct
report
find
grant
support
nhmrc
project
grant
flame
studi
demonstr
superior
indacaterolglycopyrronium
daili
reduc
exacerb
improv
lung
function
health
statu
versu
salmeterolfluticason
sever
copd
patient
histori
assess
effect
indacaterolglycopyrronium
versu
salmeterolfluticason
rate
risk
moder
sever
exacerb
subset
gold
group
patient
histori
exacerb
hospit
exacerb
flame
studi
flame
random
studi
patient
sever
copd
predict
normal
histori
exacerb
previou
year
random
receiv
either
indacaterolglycopyrronium
salmeterolfluticason
rate
time
moder
sever
exacerb
analyz
subset
gold
group
patient
patient
random
categor
gold
group
mean
predict
normal
valu
patient
ic
screen
indacaterolglycopyrronium
demonstr
superior
efficaci
salmeterolfluticason
reduc
rate
moder
sever
exacerb
rate
ratio
tabl
indacaterolglycopyrronium
delay
moder
sever
exacerb
compar
salmeterolfluticason
median
day
versu
tabl
patient
treat
indacaterolglycopyrronium
lower
risk
moder
sever
exacerb
compar
salmeterolfluticason
tabl
effect
indacaterolglycopyrronium
versu
salmeterolfluticason
moder
sever
exacerb
subset
gold
group
patient
histori
exacerb
hospit
exacerb
indacaterolglycopyrronium
superior
salmeterolfluticason
reduc
rate
risk
moder
sever
exacerb
subset
gold
group
patient
histori
exacerb
hospit
exacerb
confirm
use
prefer
treatment
option
copd
patient
high
risk
exacerb
grant
support
novarti
pharma
ag
basel
wedzicha
ja
et
al
n
engl
j
med
famili
aggreg
chronic
lung
condit
may
result
combin
genet
suscept
exposur
risk
factor
throughout
life
use
approach
investig
factor
contribut
relationship
parent
respiratori
diseas
histori
reduc
lung
health
rlh
adulthood
use
data
british
birth
cohort
studi
cohort
particip
characteris
term
rlh
presenc
respiratori
symptom
airway
obstruct
parent
histori
respiratori
diseas
offspr
age
factor
evalu
matern
smoke
live
smoker
social
class
respiratori
ill
smoke
statu
occup
exposur
dust
fume
operationalis
life
period
birth
childhood
adulthood
path
analysi
use
investig
mediat
role
factor
relationship
parent
respiratori
diseas
histori
rlh
adjust
gender
asthma
recent
chest
infect
within
cohort
parent
respiratori
histori
offspr
rlh
parent
respiratori
histori
posit
associ
rlh
matern
smoke
pregnanc
person
smoke
adulthood
social
class
occup
exposur
dust
fume
factor
relat
parent
histori
rlh
mediat
pathway
test
indic
sequenc
matern
adulthood
smoke
contribut
model
fit
indirect
effect
explain
parent
relationship
associ
parent
histori
respiratori
diseas
offspr
rlh
partli
mediat
sequenc
exposur
matern
smoke
smoker
adulthood
larg
proport
relationship
parent
remain
unexplain
smoke
suggest
assess
parent
histori
respiratori
diseas
may
provid
insight
earlier
diagnosi
intervent
grant
support
australian
govern
research
train
program
scholarship
lsk
li
examin
associ
four
activ
phenotyp
mortal
cardiometabol
risk
factor
peopl
chronic
obstruct
pulmonari
diseas
copd
prospect
cohort
analys
peopl
copd
age
year
current
identifi
scottish
health
survey
group
one
follow
activ
phenotyp
base
activ
level
couch
potato
insuffici
activ
high
sit
time
andor
domest
physic
activ
pa
light
mover
insuffici
activ
domest
pa
sedentari
exercis
suffici
activ
high
sit
time
busi
bee
suffici
activ
low
sit
time
suffici
activ
involv
adher
pa
recommend
metabol
equival
met
hour
per
week
low
sit
time
defin
minut
recreat
screen
time
per
day
associ
phenotyp
mortal
cardiometabol
outcom
made
use
cox
proport
hazard
model
binari
logist
regress
model
respect
sampl
compris
particip
mean
age
sd
year
male
year
death
copd
particip
avail
data
compar
couch
potato
reduc
risk
mortal
busi
bee
hazard
ratio
confid
interv
ci
trend
toward
reduct
mortal
risk
phenotyp
reduc
risk
diabet
busi
bee
compar
couch
potato
odd
ratio
ci
analysi
demonstr
mortal
benefit
reduc
risk
diabet
peopl
copd
sit
time
low
pa
guidelin
adher
indic
health
benefit
pa
import
measur
activ
outcom
copd
popul
grant
support
nil
declar
interest
nil
nomin
award
physiotherapi
conflict
interest
nil
pulmonari
physiolog
sleep
copd
lung
hyperinfl
reduc
inspiratori
reserv
therebi
limit
exercis
respiratori
system
reactanc
xr
measur
forc
oscil
techniqu
fot
reflect
heterogen
airway
narrow
closur
copd
may
relat
clinic
import
outcom
hypothes
xr
relat
qualiti
life
hyperinfl
exercis
capac
copd
copd
subject
royal
north
shore
hospit
pulmonari
rehabilit
depart
underw
spirometri
plethysmograph
lung
volum
st
georg
respiratori
questionnair
sgrq
walk
distanc
xr
measur
fot
tidal
breath
follow
deep
inspir
mean
xr
record
xmean
xr
inspir
xinsp
expiratori
decreas
xr
index
expiratori
flow
limit
efli
inspiratori
capac
deriv
fot
sgrq
repeat
rehabilit
complet
month
later
particip
old
predict
xinsp
correl
sgrq
ic
p
unrel
baselin
efli
unrel
either
ic
xinsp
improv
significantli
respect
ic
chang
baselin
xinsp
baselin
efli
predict
improv
month
complet
rehabilit
respect
reactanc
inspir
xinsp
efli
reflect
differ
aspect
mechan
impair
respiratori
system
copd
differ
clinic
correl
correl
xinsp
qualiti
life
hyperinfl
suggest
may
use
clinic
paramet
manag
copd
deserv
evalu
larger
prospect
studi
efli
add
inform
xinsp
within
context
present
studi
therefor
separ
xr
inspiratori
expiratori
compon
may
clinic
use
use
mean
valu
copd
grant
support
nhmrc
postgradu
scholarship
compar
physiolog
power
approach
help
understand
relationship
structur
function
kangaroo
exhibit
uniqu
breath
mechan
hop
respir
depend
motion
forc
less
activ
contract
diaphragm
ask
structur
mechan
properti
kangaroo
airway
might
accommod
respiratori
pressur
gener
hop
studi
compar
mechan
structur
properti
airway
kangaroo
sheep
latter
subject
movement
air
bronchial
segment
kangaroo
sheep
mount
organ
bath
chamber
curv
obtain
theophyllin
airway
stiff
calcul
chang
pressur
normal
volum
volumeiniti
volum
close
pressur
pressur
requir
airway
collaps
airway
wall
morpholog
also
assess
data
stiff
kangaroo
airway
less
sheep
kangaroo
sheep
p
theophyllin
caus
reduct
sheep
airway
stiff
p
effect
kangaroo
airway
stiff
suggest
role
smooth
muscl
tone
former
kangaroo
airway
also
requir
less
neg
pressur
collaps
compar
sheep
airway
kangaroo
sheep
p
kangaroo
airway
thicker
inner
p
thinner
outer
wall
p
compar
sheep
airway
total
thick
cartilag
compar
group
greater
number
p
smaller
p
cartilag
plate
kangaroo
airway
kangaroo
airway
low
stiff
collaps
compar
sheep
airway
fragment
cartilag
plate
absenc
smooth
muscl
tone
contribut
lower
stiff
low
airway
stiff
may
maintain
function
residu
capac
hop
respons
larg
variat
respiratori
pressur
grant
support
na
declar
interest
statement
none
lung
copd
demonstr
expiratori
flow
limit
airway
closur
ventil
heterogen
reactanc
hz
measur
forc
oscil
techniqu
fot
influenc
pathophysiolog
phenomena
also
depend
lung
volum
presenc
airway
closur
oscil
pressur
wave
abl
penetr
lung
segment
may
relat
total
thorac
ga
volum
alveolar
volum
va
measur
diffus
capac
test
estim
commun
ga
volum
dilut
breath
hold
ratio
va
plethysmograph
total
lung
capac
tlc
vatlc
therefor
reduc
obstruct
airway
diseas
due
incomplet
ga
mix
ga
trap
hypothesis
would
relat
vatlc
tlc
copd
subject
copd
male
mean
rang
age
mean
sd
pred
test
use
fot
thorasi
tremoflo
normal
tidal
breath
spirometri
bodi
plethysmographi
diffus
capac
test
perform
accord
standard
qualiti
criteria
spearman
rank
correl
coeffici
determin
adjust
known
covari
publish
refer
equat
moder
correl
vatlc
r
p
va
r
p
tlc
adjust
known
covari
remain
moder
correl
vatlc
r
p
va
tlc
vatlc
correl
sever
airflow
obstruct
measur
ratio
r
p
copd
measur
fot
normal
tidal
breath
reflect
commun
lung
volum
rather
total
lung
volum
fot
therefor
may
compliment
tradit
lung
function
measur
six
minut
walk
test
remain
commonli
use
clinic
measur
exercis
capac
pulmonari
hypertens
ph
whilst
maxim
exercis
test
use
cardiopulmonari
exercis
test
cpet
remain
gold
standard
estim
exercis
capac
test
much
less
common
clinic
practic
purpos
studi
compar
physiolog
respons
cpet
group
ph
subject
eighteen
individu
group
iiv
ph
patient
function
class
complet
cpet
cycl
ergomet
separ
day
test
ga
exchang
measur
use
calibr
portabl
metabol
system
cortex
metamax
oxygen
uptak
carbon
dioxid
product
ventil
heart
rate
hr
oxygen
puls
end
tidal
carbon
dioxid
oxygen
satur
breathless
borg
averag
final
compar
cpet
subgroup
particip
end
exercis
lactat
hla
also
measur
use
portabl
lactat
analys
lactat
scout
mean
peak
power
achiev
particip
w
whilst
mean
distanc
signific
differ
cpet
peak
cpet
vs
vs
hr
vs
puls
vs
mlbeat
vs
vs
mmhg
vs
peak
vs
breathless
vs
lactat
vs
significantli
higher
p
cpet
found
physiolog
respons
cpet
group
ph
particip
similar
would
suggest
similar
peak
exercis
challeng
ph
popul
grant
support
offic
health
medic
research
queensland
pulmonari
rehabilit
pr
cycl
train
recommend
peak
oxygen
uptak
measur
cardiopulmonari
exercis
test
cpet
howev
access
cpet
limit
estim
equival
intens
walk
distanc
use
publish
equat
associ
substanti
variat
studi
aim
investig
whether
submaxim
cycl
exercis
test
smct
prescrib
appropri
cycl
train
intens
whether
initi
train
intens
estim
smct
similar
retrospect
data
collect
patient
attend
pr
previou
month
patient
routin
perform
walk
test
baselin
complet
smct
second
exercis
session
subsequ
exercis
session
cycl
train
prescrib
peak
work
watt
achiev
smct
initi
intens
consid
appropri
patient
could
complet
minut
prescrib
report
dyspnoea
andor
rpe
score
borg
score
patient
male
chronic
lung
diseas
copd
ild
includ
mean
sd
age
metr
smct
peak
work
watt
eight
one
percent
patient
achiev
target
intens
found
initi
workload
easi
unabl
maintain
target
intens
moder
correl
work
rate
predict
watt
smct
watt
r
p
estim
cycl
train
intens
watt
appropri
train
patient
chronic
lung
diseas
prescrib
cycl
exercis
intens
smct
peak
work
achiev
appropri
train
intens
toler
patient
prescrib
work
rate
smct
result
similar
train
load
although
smct
may
provid
accur
cycl
train
intens
grant
support
nil
increas
dietari
fat
associ
increas
risk
asthma
airway
hyperrespons
singl
high
fat
meal
reduc
efficaci
salbutamol
suggest
dietari
fatti
acid
may
alter
airway
smooth
muscl
asm
contractil
therefor
aim
determin
effect
fatti
acid
vitro
bovin
tracheali
smooth
muscl
respons
relax
contractil
stimuli
oleic
acid
linol
acid
acid
palmit
acid
stearic
acid
elaid
acid
compar
bovin
tracheali
muscl
strip
n
mount
tissu
bath
warm
aerat
kreb
solut
experi
done
presenc
tetradotoxin
test
sensit
relax
stimuli
muscl
strip
contract
acetylcholin
half
maxim
effect
concentr
addit
vehicl
fatti
acid
cumul
curv
isoproterenol
perform
test
sensit
contractil
stimuli
separ
muscl
strip
incub
vehicl
fatti
acid
cumul
curv
acetylcholin
perform
relax
experi
asm
forc
follow
acetylchoin
affect
addit
fatti
acid
similarli
effect
fatti
acid
concentr
isoproterenol
ranova
p
contract
experi
baselin
forc
unalt
addit
fatti
acid
similarli
effect
fatti
acid
acetylcholin
ranova
p
dietari
fatti
acid
alter
bovin
tracheali
asm
function
grant
support
dgc
support
european
respiratori
societi
research
fellowship
strtf
respiratori
infecti
diseas
piperacillin
pip
tazobactam
taz
commonli
use
treatment
pleural
infect
pleural
pharmacokinet
howev
report
develop
valid
rapid
sensit
tandem
spectrometri
assay
quantif
piptaz
drug
extract
human
plasma
pleural
fluid
protein
precipit
methanol
contain
intern
standard
sulbactam
sampl
mix
methanol
contain
vortex
centrifug
supernat
dilut
mobil
phase
contain
ammonium
bicarbon
water
chromatograph
separ
achiev
use
acquiti
beh
column
method
appli
two
patient
pleural
infect
six
pleural
fluid
blood
sampl
obtain
electrospray
ionis
posit
mode
multipl
reaction
monitor
mrm
use
pip
transit
mz
mz
respect
neg
mode
taz
sul
transit
mz
mz
linear
observ
concentr
pip
taz
respect
complet
method
valid
perform
accord
us
fda
guidelin
select
specif
precis
accuraci
matrix
effect
stabil
result
within
accept
limit
patient
time
maximum
concentr
cmax
pip
taz
pleural
fluid
delay
compar
plasma
cmax
pip
pleural
fluid
reach
patient
cmax
achiev
plasma
patient
respect
two
case
notabl
differ
profil
drug
pleural
fluid
differ
system
elimin
piptaz
assay
feasibl
use
futur
pharmacokinet
studi
grant
support
nhmrc
cancer
council
wa
cancer
australia
nsw
dust
diseas
board
ycgl
sir
charl
gairdner
research
advisori
group
np
ycgl
daj
wa
cancer
palli
care
network
df
bronchiectasi
relat
cystic
fibrosi
bex
increasingli
recognis
caus
chronic
lung
diseas
occur
isol
lung
diseas
includ
asthma
copd
set
bronchiectasi
associ
signific
health
care
utilis
impact
australia
new
zealand
poorli
understood
includ
indigen
popul
aim
describ
impact
bex
inpatinet
hospit
care
set
multicentr
australian
new
zealand
retrospect
audit
hospit
admiss
data
relat
patient
bex
admit
five
hospit
melbourn
sydney
alic
spring
australia
auckland
new
zealand
undertaken
number
length
stay
lo
respiratori
admiss
determin
melbourn
alic
spring
auckland
addit
inform
obtain
regard
requir
ventilatori
support
data
regard
hospitalis
present
health
care
utilis
bex
substanti
number
admiss
vari
substanti
site
cummul
lo
averag
lo
also
vari
australian
patient
longer
lo
compar
nz
patient
indigen
australian
patient
shorter
lo
compar
counterpart
despit
frequent
admiss
overal
greater
hospitalis
day
lo
compar
copd
rang
day
australia
frequenc
admiss
bex
like
major
factor
drive
health
care
utilis
utilis
ventilatori
support
vari
countri
particularli
high
indigen
australian
impact
optim
level
admiss
frequenc
lo
ventilatori
support
susequ
represent
hospit
qualiti
life
surviv
focu
investig
grant
support
australia
bronchiectasi
consortium
lung
foundat
australia
drug
resist
tuberculosi
tb
emerg
problem
rifampicin
resist
rare
usual
seen
resist
mdr
tb
rifampicin
rmr
tb
less
common
world
health
organ
recommend
treat
per
mdr
tb
guidelin
requir
prolong
treatment
second
line
agent
includ
intraven
aminoglycosid
associ
increas
risk
toxic
cost
evid
support
recommend
lack
predict
mdr
tb
regimen
commonli
use
queensland
confirm
carri
studi
examin
clinic
featur
treatment
regimen
outcom
queensland
australia
retrospect
case
seri
identifi
case
queensland
data
gather
notifi
condit
system
databas
use
medic
record
twelv
case
identifi
mean
age
year
patient
oversea
born
nine
case
pulmonari
diseas
drug
suscept
test
confirm
isol
resist
rifampicin
sensit
first
line
agent
isoniazid
pyrazinamid
ethambutol
complet
data
treatment
outcom
avail
case
patient
treat
mdr
tb
regimen
patient
complet
treatment
queensland
cure
mean
durat
treatment
month
major
patient
treat
first
line
agent
plu
moxifloxacin
ad
regimen
case
patient
receiv
intraven
amikacin
studi
confirm
rare
queensland
manag
mdr
tb
regimen
gener
extend
regimen
first
line
agent
fluroquinolon
use
regimen
achiev
good
outcom
cure
rate
manag
requir
studi
determin
optim
treatment
regimen
howev
base
data
extend
cours
mdr
type
regimen
necessari
grant
support
nil
mortal
pleural
infect
pi
remain
high
mani
patient
die
success
treatment
pi
studi
report
longer
term
outcom
caus
death
one
us
studi
report
mortal
rapid
score
recent
introduc
risk
stratif
tool
pi
encompass
paramet
age
renal
function
pleural
fluid
purul
infect
sourc
serum
albumin
aim
valid
rapid
score
singl
centr
cohort
examin
longer
term
outcom
caus
mortal
case
pi
treat
nambour
gener
hospit
juli
juli
review
pi
defin
posit
pleural
fluid
gram
stain
cultur
complic
parapneumon
effus
data
date
censor
juli
extract
hospit
record
electron
patholog
databas
mortal
caus
death
record
gp
practic
contact
confirm
death
data
case
includ
mean
age
male
pi
cultur
posit
mortalti
mortal
case
stratifi
rapid
score
low
medium
high
mortal
group
mortal
group
caus
death
case
discharg
deceas
year
includ
chronic
liver
diseas
malign
myocardi
infarct
bowel
obstruct
cellul
aspir
pneumonia
patient
median
comorbid
time
pi
cohort
rapid
score
accur
stratifi
low
risk
group
poor
longer
term
outcom
post
pi
like
relat
signific
patient
address
manag
time
pi
import
sever
influenza
infect
children
chronic
lung
diseas
result
unschedul
hospit
present
substanti
burden
health
system
nation
influenza
burden
data
children
chronic
lung
diseas
limit
data
crucial
monitor
burden
diseas
evalu
effect
influenza
vaccin
program
conduct
retrospect
cohort
studi
measur
impact
influenza
hospitalis
rate
children
chronic
lung
diseas
perform
retrospect
cohort
studi
use
link
administr
data
children
born
new
south
wale
complet
decemb
cohort
divid
two
group
children
chronic
lung
diseas
includ
children
asthma
bronchopulmonari
dysplasia
cystic
fibrosi
congenit
lung
disord
ii
children
primari
outcom
episod
influenza
associ
hospitalis
icd
code
incid
rate
influenza
hospitalis
calcul
use
poisson
estim
calcul
confid
interv
around
incid
cohort
compris
children
chronic
lung
diseas
children
adjust
influenza
hospitalis
children
chronic
lung
diseas
ci
children
ci
rate
children
chronic
lung
diseas
rang
similar
male
femal
children
chronic
lung
diseas
ci
boy
ci
girl
studi
demonstr
children
chronic
diseas
least
five
time
risk
hospitalis
influenza
children
futur
studi
investig
effect
univers
vaccin
program
children
may
help
reduc
burden
grant
support
work
fund
rotari
club
sydney
cove
cerebr
palsi
allianc
conflict
interest
author
conflict
interest
pseudomona
aeruginosa
pa
domin
respiratori
pathogen
peopl
cystic
fibrosi
cf
releas
viabl
aerosol
cough
aerosol
travel
least
metr
remain
airborn
least
minut
research
determin
peopl
chronic
lung
condit
releas
pa
cough
aerosol
project
aim
determin
peopl
bronchiectasi
ncfb
chronic
obstruct
pulmonari
diseas
copd
releas
pa
aerosol
cough
twenti
particip
ncfb
copd
pa
lung
infect
recruit
particip
underw
test
two
valid
devic
measur
pa
viabil
distanc
min
durat
voluntari
cough
aerosol
test
sampl
use
andersen
cascad
impactor
quantit
sputum
count
aerosol
cultur
perform
total
number
coloni
form
unit
cfu
determin
twenti
particip
mean
sd
age
year
predict
bmi
recruit
day
test
particip
cultur
pa
sputum
nine
particip
complet
five
cough
test
viabl
pa
detect
cough
aerosol
particip
particip
particip
minut
particip
minut
particip
produc
pa
cough
aerosol
minut
concentr
pa
sputum
correl
pa
cfu
aerosol
cultur
pa
releas
viabl
cough
aerosol
peopl
ncfb
copd
although
lower
cfu
compar
peopl
cf
result
highlight
import
respiratori
hygien
infect
control
strategi
hospit
grant
support
princ
charl
hospit
foundat
advanc
queensland
asthma
allergi
overus
saba
compromis
asthma
control
increas
burden
diseas
especi
among
symptom
studi
assess
percept
control
depend
reliev
medic
among
patient
take
saba
alon
internet
survey
particip
current
asthma
age
year
use
question
rang
strongli
disagre
strongli
agre
survey
captur
attitud
asthma
asthma
treatment
asthma
control
assess
use
asthma
control
test
act
respond
poor
symptom
control
compar
user
symptom
almost
time
like
agreestrongli
agre
felt
anxiou
without
reliev
vs
respect
p
almost
twice
like
feel
anxiou
without
reliev
around
trigger
vs
respect
p
addit
vs
symptom
like
agreestrongli
agre
reli
reliev
asthma
vs
respect
p
reliev
vs
respect
p
half
respond
group
agreedstrongli
agre
reliev
gave
control
asthma
vs
respect
patient
poor
symptom
control
appear
overli
reliant
saba
compar
patient
asthma
optim
asthma
control
popul
requir
prevent
treatment
half
respond
view
reliev
mean
achiev
control
asthma
given
public
messag
control
asthma
aim
encourag
prevent
use
may
inadvert
give
opposit
messag
mani
peopl
data
call
question
paradigm
current
use
terminolog
interact
better
patient
thought
belief
may
effect
grant
support
astrazeneca
conflict
interest
studi
fund
research
grant
astrazeneca
last
year
provid
medic
write
support
medic
commun
agenc
boehring
ingelheim
novarti
unrel
topic
present
research
intrauterin
growth
restrict
iugr
associ
increas
risk
asthma
later
life
development
chang
airway
structur
function
may
impact
suscept
subsequ
diseas
studi
use
matern
mous
model
iugr
assess
chang
airway
smooth
muscl
asm
contractil
thick
male
femal
adult
offspr
pregnant
balbc
mice
hous
hypox
condit
gestat
day
gd
iugr
group
follow
hypox
exposur
mice
return
normox
environ
second
group
pregnant
mice
hous
normox
condit
throughout
pregnanc
control
weight
offspr
record
week
age
point
euthan
tracheasectomi
perform
trachea
segment
studi
organ
bath
chamber
measur
isometr
forc
product
carbachol
subsequ
fix
morphometri
maxim
activ
tension
stress
calcul
forc
normalis
segment
length
asm
area
respect
iugr
offspr
lighter
birth
control
iugr
p
remain
lighter
week
age
compar
control
control
iugr
p
activ
tension
p
stress
p
reduc
male
iugr
offspr
compar
control
differ
asm
thick
statist
differ
activ
tension
stress
iugr
femal
offspr
despit
reduct
asm
thick
p
sensit
asm
contractil
agonist
alter
iugr
persist
effect
iugr
matur
airway
wall
favour
reduc
contract
asm
layer
includ
lower
asm
contractil
male
offspr
thinner
asm
layer
femal
offspr
find
suggest
alter
develop
fetal
airway
impact
suscept
futur
airway
diseas
chang
asm
structur
function
grant
support
nhmrc
declar
interest
statement
none
abnorm
small
airway
implic
primari
caus
function
impair
obstruct
airway
diseas
contract
airway
smooth
muscl
asm
layer
absenc
exogen
stimulu
term
intrins
tone
may
contribut
airflow
limit
aim
studi
assess
underli
structur
determin
asm
intrins
tone
peripher
human
airway
subject
year
undergo
lung
resect
surgeri
recruit
baselin
lung
function
assess
prior
surgeri
peripher
airway
dissect
resect
tissu
cut
bronchial
ring
ringssubject
measur
forc
organ
bath
chamber
curv
construct
kcl
mm
establish
optimum
length
lo
contract
subsequ
adapt
repeat
kcl
stimul
experi
perform
lo
tension
mnmm
ring
determin
complet
relax
theophyllin
fix
stereolog
section
stain
use
masson
trichom
techniqu
rel
fraction
asm
vvasm
ecm
vvecm
within
asm
layer
measur
point
count
muscl
tension
convert
stress
normalis
muscl
thick
subject
pred
bronchial
ring
exhibit
mean
intrins
stress
intrins
stress
neg
correl
vvecm
p
posit
correl
vvasm
p
also
trend
decreas
pred
increas
intrins
stress
associ
lung
function
vvecm
vvasm
presenc
intrins
stress
peripher
asm
layer
determin
underli
layer
composit
increas
greater
muscl
fraction
decreas
ecm
fraction
respect
propos
muscl
composit
affect
lung
function
regul
intrins
tone
grant
support
nhmrc
diet
may
contribut
poor
lung
function
turn
develop
andor
progress
chronic
inflammatori
lung
diseas
studi
assess
relationship
dietari
inflammatori
index
measur
inflammatori
potenti
diet
lung
function
aim
investig
relationship
sampl
adult
random
sampl
adult
year
inner
melbourn
assess
spirometri
questionnair
dii
calcul
particip
food
frequenc
questionnair
regress
method
use
model
relationship
dii
quintil
lung
function
outcom
adjust
age
gender
height
energi
intak
bmi
asthma
atopi
smoke
asthma
statu
also
examin
effect
modifi
associ
dii
dii
fvc
differ
asthma
statu
respect
current
asthmat
diet
highest
dii
quintil
mean
lower
lowest
dii
quintil
ci
mean
fvc
lower
ci
remit
asthmat
diet
highest
dii
quintil
mean
lower
lowest
dii
quintil
ci
mean
fvc
lower
ci
never
asthma
associ
dii
lung
function
measur
also
associ
dii
asthma
categori
diet
associ
poorer
lung
function
current
remit
asthmat
associ
causal
argu
low
inflammatori
diet
peopl
histori
asthma
grant
support
nhmrc
niddk
usa
vocal
cord
dysfunct
vcd
often
mistaken
sever
asthma
accur
diagnosi
crucial
difficult
treatment
complex
dedic
essenti
examin
optim
overal
manag
vcd
multidisciplinari
team
mdt
clinic
initi
operation
type
clinic
yet
describ
patient
suspect
vcd
refer
respiratori
physician
ent
surgeon
clinic
staf
respiratori
physician
ent
surgeon
laryngologist
speech
therapist
respiratori
nurs
specialist
patient
complet
questionnair
spirometri
dynam
ct
larynx
prior
review
review
team
histori
obtain
physic
examin
conduct
laryngoscopi
perform
diagnosi
vcd
base
detect
ct
larynx
laryngoscopi
inspiratori
paradox
vocal
cord
movement
pvcm
least
one
occas
team
final
review
data
like
diagnosi
formul
treatment
select
consult
patient
total
patient
report
establish
asthma
diagnosi
vcd
establish
case
elect
access
speech
therapi
servic
base
symptom
speech
therapi
gaug
unsuccess
patient
individu
elect
botulinum
toxin
inject
second
group
case
diagnosi
vcd
consid
unlik
group
patient
poorli
control
asthma
patient
diagnos
third
group
patient
vcd
strongli
suspect
confirm
patient
offer
speech
therapi
success
achiev
case
vcd
mdt
clinic
establish
provid
integr
multidisciplinari
approach
diagnosi
manag
vcd
experi
indic
strategi
feasibl
employ
optimis
manag
problemat
condit
grant
support
monash
lung
sleep
institut
monash
health
treatabl
trait
propos
new
paradigm
airway
diseas
manag
aim
determin
preval
trait
sever
asthma
copd
compar
healthi
control
compar
trait
preval
diagnost
label
particip
sever
asthma
copd
healthi
control
recruit
cross
section
studi
underw
multidimension
assess
characteris
treatabl
trait
recruit
sever
asthma
copd
healthi
control
particip
overal
age
year
femal
copd
particip
older
compar
sever
asthma
healthi
control
p
predict
lower
copd
compar
sever
asthma
healthi
control
p
possibl
trait
significantli
identifi
copd
sever
asthma
compar
healthi
control
p
signific
differ
copd
sever
asthma
p
howev
number
comorbid
differ
diseas
group
copd
versu
sever
asthma
trait
preval
copd
compar
sever
asthma
dyspnoea
p
exert
desatur
p
p
airflow
limit
p
sever
asthma
significantli
p
musculoskelet
problem
p
obes
p
diseas
p
dermat
p
common
sever
asthma
system
inflamm
copd
p
p
respect
preval
frequent
chest
infect
pathogen
colonis
smoke
dysfunct
breath
reflux
anxieti
depress
differ
copd
sever
asthma
studi
confirm
heterogen
copd
sever
asthma
multidimension
assess
chronic
airway
diseas
allow
detect
trait
target
use
precis
medicin
approach
trial
test
approach
need
advanc
manag
grant
support
nhmrc
hunter
medic
research
institut
univers
newcastl
john
hunter
hospit
charit
trust
declar
interest
interest
declar
cell
immunolog
molecular
biolog
lung
malign
pleural
mesothelioma
mpm
incur
cancer
pleura
difficult
diagnos
biomark
earlier
andor
easier
diagnosi
urgent
need
power
gene
regul
microrna
becom
popular
diagnost
target
due
stabl
express
within
bodi
studi
examin
microrna
mpm
control
sampl
howev
still
unclear
microrna
potenti
biomark
mpm
approxim
patient
develop
pleural
effus
ideal
sourc
diagnost
target
sampl
collect
minim
invas
biomark
potenti
microrna
mpm
frozenfresh
effus
yet
determin
hypothesis
microrna
express
effus
potenti
biomark
mpm
taqman
openarray
profil
quantit
pcr
use
analys
microrna
cohort
cohort
effus
cell
supernat
sampl
mpm
lung
adenocarcinoma
benign
pleural
diseas
patient
potenti
microrna
biomark
analys
second
cohort
cohort
mpm
lung
adenocarcinoma
sampl
microrna
express
determin
significantli
differ
diseas
volcano
plot
chang
p
microrna
combin
analys
use
logist
regress
diagnost
effici
assess
use
receiv
oper
characterist
curv
effus
cell
signatur
base
combin
diagnosi
mpm
identifi
cohort
auc
valid
cohort
auc
microrna
express
effus
cell
potenti
biomark
differenti
mpm
lung
adenocarcinoma
grant
support
work
support
grant
dust
diseas
board
nsw
mauric
blackburn
sir
charl
gairdner
hospit
research
committe
mutsaer
support
cancer
council
wa
research
fellowship
declar
interest
conflict
interest
emerg
evid
suggest
upper
lower
airway
unifi
diseas
set
patholog
process
one
region
airway
would
affect
function
entir
airway
howev
direct
evid
support
extrem
limit
infer
fact
respiratori
tract
continu
line
epitheli
cell
clinic
observ
improv
outcom
lower
airway
diseas
follow
manag
upper
airway
diseas
directli
test
hypothesi
perform
predominantli
match
nasal
bronchial
epitheli
brush
children
without
atopi
asthma
use
combin
differenti
gene
express
gene
analys
determin
similar
transcript
landscap
upper
lower
airway
overal
report
homolog
diverg
two
site
independ
diseas
phenotyp
atopi
identifi
sixteen
modul
gene
enrich
specif
biolog
function
conserv
across
nasal
bronchial
epithelium
howev
almost
half
differenti
express
two
region
find
suggest
part
upper
lower
airway
share
similar
transcript
composit
also
exhibit
signific
differ
reflect
function
signific
interest
biomark
develop
data
suggest
certain
set
nasal
epitheli
cell
may
inform
lower
airway
diseas
thu
consider
clinic
implic
grant
support
asthma
australia
conflict
interest
conflict
interest
increas
evid
highlight
cellular
senesc
contribut
idiopath
pulmonari
fibrosi
ipf
dna
damag
respons
ddr
senesc
also
lead
escal
mitochondri
superoxid
product
reinforc
senesc
studi
characteris
senesc
lung
fibroblast
ipf
patient
control
delin
role
mitochondria
senesc
stabil
fibroblast
senesc
assess
use
composit
set
marker
includ
express
activ
measur
pcr
cytochem
stain
respect
ddr
detect
format
nuclear
foci
use
immunofluoresc
secretori
phenotyp
sasp
characteris
measur
increas
cytokin
product
inflammatori
gene
express
elisa
nanostr
technolog
respect
mitochondri
dysfunct
monitor
increas
mitochondri
stress
mass
superoxid
use
fluorogen
dye
orang
mitotrack
green
mitosox
respect
even
earli
passag
exhibit
intensifi
ddr
sasp
mitochondri
dysfunct
dna
damag
agent
etoposid
augment
senesc
accompani
heighten
mitochondri
stress
mass
superoxid
product
howev
effect
mitochondri
perturb
rotenon
also
evok
ddr
senesc
inhibit
regul
mitochondri
function
incub
antioxid
cystein
attenu
senesc
exhibit
featur
mitochondri
dysfunct
reinforc
senesc
phenotyp
understand
mechan
mitochondria
contribut
fibroblast
senesc
ipf
potenti
import
therapeut
implic
grant
support
nhmrc
research
grant
mucu
overproduct
patient
asthma
link
increas
hospitalis
morbid
notch
famili
receptor
protein
regul
airway
mucu
product
via
differenti
mechan
direct
cell
toward
secretori
ciliat
morpholog
howev
littl
known
regard
notch
role
mucu
product
follow
differenti
examin
impact
inhibit
notch
signal
mucu
product
fulli
differenti
primari
bronchial
epitheli
cell
pbec
control
subject
well
patient
asthma
hypothes
notch
inhibit
downregul
mucu
product
pbec
donor
cohort
grown
interfac
ali
cultur
day
promot
multicellular
differenti
time
cell
treat
dibenzazepin
dbz
potent
inhibitor
notch
signal
apic
line
fluid
collect
everi
assess
releas
complet
experi
sampl
also
collect
protein
mrna
histolog
analysi
assess
direct
role
sirna
knockdown
also
perform
monolay
cultur
human
epitheli
cell
dbz
treatment
significantli
reduc
express
releas
phenotyp
assess
qpcr
elisa
ihc
western
blottingqpcr
reveal
signific
reduct
intracellular
domain
mrna
pbec
donor
phenotyp
sirna
knockdown
significantli
reduc
protein
final
goblet
cell
marker
protein
unchang
across
treatment
inhibit
reduc
express
secret
differenti
pbec
independ
goblet
cell
number
reduct
depend
occur
pbec
asthmat
suggest
regul
product
outsid
notch
well
characteris
role
secretori
cell
differenti
grant
support
nhmrc
project
grant
fibrosi
thicken
airway
smooth
muscl
asm
layer
compon
airway
remodel
attribut
increas
ecm
fraction
asm
shown
epigenet
chang
occur
copd
immun
cell
peripher
lung
tissu
known
airway
mesenchym
cell
reprogram
project
aim
identifi
differenti
express
ecm
protein
investig
effect
epigenet
inhibit
protein
express
primari
human
asm
cell
isol
lung
tissu
copd
smoke
patient
asm
cell
grown
cultur
stimul
histon
deacetylas
inhibitor
trichostatin
tsa
extra
termin
domain
bet
protein
inhibitor
histon
acetyltransferas
inhibitor
curcumin
cell
lysat
collect
hour
treatment
microarray
analys
carri
identifi
basal
differ
express
ecm
epigenet
gene
target
copd
smoker
qpcr
carri
confirm
microarray
analys
determin
effect
epigenet
inhibitor
asm
cell
copd
patient
show
augment
tnc
express
respons
stimul
compar
cell
smoker
without
copd
inhibit
tsa
effect
tnc
express
cell
patient
group
whilst
inhibit
express
copd
treatment
significantli
abrog
express
copd
group
whilst
express
abrog
copd
tnc
express
significantli
repress
curcumin
treatment
group
differ
respons
suscept
smoker
copd
group
highlight
epigenet
differ
diseas
target
histon
acetyl
may
therapeut
option
small
airway
fibrosi
copd
airway
epithelium
key
driver
asthma
pathogenesi
partli
due
dysregul
respons
injuri
notch
signal
potenti
crosstalk
integrin
modul
epitheli
cell
migrat
repair
therefor
hypothesis
aberr
notch
signal
asthmat
epithelium
would
result
defect
repair
airway
epitheli
cell
aec
via
regul
integrin
tracheobronchi
airway
brush
age
rang
male
asthmat
male
children
utilis
aec
isol
cultur
notch
receptor
ligand
gene
express
investig
qpcr
arbitrari
unit
au
notch
signal
cultur
inhibit
gamma
secretas
inhibitor
dapt
ester
linear
wound
perform
aec
assess
repair
incucyt
essen
bioscienc
integrin
protein
express
investig
western
notch
receptor
ligand
found
express
ex
vivo
aec
asthmat
children
howev
gene
express
differenti
express
aec
asthmat
children
downregul
p
upregul
p
follow
vitro
wound
mrna
level
induc
within
aec
children
howev
earlier
induct
au
au
post
wound
observ
aec
asthmat
children
global
inhibit
notch
signal
result
reduct
wound
repair
inabl
close
wound
observ
maxim
dose
furthermor
notch
signal
inhibit
result
reduct
integrin
protein
express
nm
dapt
integrin
protein
express
find
suggest
dysregul
express
notch
signal
molecul
conjunct
role
regul
integrin
express
contribut
defect
wound
repair
asthmat
airway
epithelium
grant
support
nhmrc
apa
uwa
centr
cell
therapi
regen
medicin
phd
scholarship
fiona
staniforth
asthma
foundat
wa
phd
scholarship
chronic
obstruct
pulmonari
diseas
copd
peopl
chronic
obstruct
pulmonari
diseas
copd
report
poor
sleep
qualiti
associ
increas
morbid
mortal
vari
report
effect
pulmonari
rehabilit
pr
sleep
qualiti
aim
assess
effect
pr
object
measur
sleep
qualiti
peopl
copd
secondari
analysi
data
collect
part
rct
compar
pr
copd
sleep
qualiti
assess
object
use
sensewear
armband
swa
bodymedia
usa
worn
day
pr
programm
sleep
characterist
deriv
acceleromet
posit
data
registr
sleep
state
swa
determin
energi
expenditur
particip
male
age
year
predict
pair
pre
post
pr
sleep
data
twenti
particip
receiv
pr
alloc
pr
median
interquartil
rang
sleep
onset
latenc
sol
minut
total
sleep
time
tst
minut
wake
sleep
onset
waso
minut
sleep
effici
se
low
signific
differ
seen
sleep
paramet
sol
tst
waso
se
pr
p
intervent
group
p
within
pr
group
associ
sleep
paramet
measur
qualiti
life
function
pr
attend
greater
proport
pr
session
moder
associ
tst
end
rehabilit
sleep
qualiti
measur
object
use
actigraphi
improv
pr
programm
individu
copd
whether
ongo
particip
regular
exercis
train
beyond
durat
pr
may
influenc
sleep
qualiti
yet
determin
grant
support
nhmrc
project
grant
earli
career
fellowship
lung
foundat
australia
la
trobe
univers
research
collabor
grant
gold
copd
strategi
treatment
choic
guid
patient
classif
base
assess
symptom
exacerb
histori
previou
strategi
also
includ
lung
function
investig
effect
classif
analysi
efficaci
tiotropiumolodaterol
gold
stage
ab
patient
copd
patient
phase
iii
replic
tonado
studi
receiv
class
gold
ab
cd
exacerb
histori
lung
function
exacerb
histori
criteria
distinct
b
possibl
mmrc
dyspnoea
scale
copd
assess
test
use
st
georg
respiratori
questionnair
sgrq
transit
dyspnoea
index
tdi
analys
patient
classifi
gold
ab
criteria
guidelin
superior
monotherapi
sgrq
tdi
ab
popul
tabl
use
exacerb
histori
alon
gold
rather
combin
lung
function
result
patient
classifi
gold
ab
lead
statist
power
investig
differ
monotherapi
use
strategi
greater
impact
sgrq
tdi
monotherapi
gold
ab
patient
tabl
grant
support
studi
fund
boehring
ingelheim
declar
interest
statement
dl
conflict
interest
declar
relat
present
gtf
serv
consult
astrazeneca
boehring
ingelheim
meda
mylan
novarti
pearl
therapeut
sunovion
therav
verona
also
receiv
honoraria
boehring
ingelheim
glaxosmithklin
sunovion
meda
fv
lg
employe
boehring
ingelheim
fm
noth
disclos
rb
receiv
reimburs
attend
scientif
confer
andor
fee
speak
andor
consult
astrazeneca
boehring
ingelheim
chiesi
glaxosmithklin
novarti
nycom
pfizer
hw
receiv
grantsresearch
support
almiral
astrazeneca
cilag
janssen
chiesi
boehring
ingelheim
bayer
glaxosmithklin
novarti
roch
takeda
sterna
pharmceut
well
honoraria
consult
fee
almiral
astrazeneca
boehring
ingelheim
berlinchemi
chiesi
glaxosmithklin
novarti
peopl
mild
chronic
obstruct
pulmonari
diseas
copd
experi
exercis
intoler
dyspnoea
poor
qualiti
life
howev
role
pulmonari
rehabilit
group
unclear
randomis
control
trial
aim
explor
effect
pulmonari
rehabilit
pr
peopl
mild
copd
peopl
mild
copd
predict
smoke
histori
packet
year
randomis
either
pr
one
home
visit
seven
telephon
call
attent
control
weekli
social
telephon
call
walk
distanc
modifi
medic
research
council
mmrc
dyspnoea
score
chronic
respiratori
questionnair
crq
score
compar
group
post
intervent
total
particip
femal
mean
age
sd
year
predict
metr
includ
particip
randomis
pr
particip
attend
averag
eight
schedul
session
rang
three
eight
session
group
show
improv
exercis
capac
symptom
qualiti
life
time
howev
differ
primari
outcom
mean
differ
metr
confid
interv
ci
metr
six
month
metr
ci
metr
pr
particip
like
clinic
import
improv
crq
emot
function
home
pr
vs
control
p
crq
total
score
vs
howev
differ
symptom
aspect
qualiti
life
peopl
mild
copd
pulmonari
rehabilit
improv
exercis
capac
qualiti
life
weekli
social
telephon
call
grant
support
eiren
luca
foundat
institut
breath
sleep
pragmat
randomis
control
trial
aim
determin
whether
comprehens
pulmonari
rehabilit
cpr
includ
cognit
behaviour
therapi
cbt
sensat
breathless
significantli
improv
health
outcom
beyond
achiev
cpr
alon
peopl
copd
pred
gold
grade
block
randomis
eight
week
cpr
without
cbt
breve
primari
six
minut
walk
test
hospit
anxieti
depress
scale
had
secondari
outcom
breathless
daili
life
multidimension
dyspnoea
profil
mdp
qualiti
life
chronic
respiratori
questionnair
crq
habitu
daili
activ
accelerometri
assess
one
six
month
post
intervent
differ
group
assess
latent
growth
model
chang
without
covari
age
sex
bmi
gold
grade
comorbid
smoke
statu
cprp
attend
use
intent
treat
itt
per
protocol
pp
commenc
intervent
valid
approach
signific
particip
mean
age
sd
male
pred
enrol
trial
pp
analysi
except
crq
mdp
subdomain
score
group
differ
significantli
either
trajectori
assess
point
primari
secondari
outcom
itt
pp
without
covari
itt
improv
favour
cprp
breve
unadjust
model
p
wherea
reduct
respons
favour
cprp
alon
adjust
model
p
pp
without
adjust
covari
differ
group
crq
mdp
favour
cprp
alon
p
percept
p
emot
respons
p
cohort
peopl
particip
cprp
clear
addit
short
longer
term
benefit
combin
cprp
cbt
breathless
grant
support
studi
support
nation
health
medic
research
council
project
grant
clinic
trial
registr
australian
new
zealand
clinic
trial
registri
pauciti
literatur
document
respiratori
high
depend
unit
hdu
outcom
present
demograph
outcom
data
patient
undergo
care
austin
hospit
respiratori
hdu
provid
singl
organ
support
patient
acut
respiratori
failur
retrospect
audit
describ
admiss
respiratori
hdu
januari
decemb
logist
regress
use
identifi
factor
relat
mortal
patient
mean
age
year
sd
underw
hdu
admiss
patient
male
mean
hdu
length
stay
lo
day
sd
ci
main
precipit
caus
respiratori
failur
exacerb
chronic
obstruct
pulmonari
diseas
infect
admiss
manag
hypox
respiratori
failur
treat
ventil
niv
admiss
occur
follow
ward
met
call
averag
hdu
lo
day
sd
ci
patient
admiss
surviv
hospit
discharg
higher
charlson
comorbid
score
associ
higher
mortal
ci
hdu
high
turnov
patient
includ
call
care
outcom
gener
good
howev
increas
comorbid
reflect
higher
charlson
score
associ
mortal
proport
hypoxaem
patient
receiv
niv
rais
opportun
review
current
practic
grant
support
none
patient
antitrypsin
defici
aatd
develop
pulmonari
emphysema
prematur
rapid
random
trial
show
treatment
zemairarespreeza
slow
emphysema
progress
base
observ
data
show
reduc
loss
subgroup
patient
current
guidelin
recommend
treatment
predict
howev
relationship
effect
treatment
lung
structur
preserv
unclear
aim
assess
effect
treatment
relat
baselin
predict
measur
chang
comput
tomographi
ct
lung
densiti
patient
random
rapid
baselin
predict
chang
annual
ct
lung
densiti
declin
rate
activ
placebo
treat
patient
calcul
year
random
slope
intercept
model
baselin
treatment
group
covari
use
analys
influenc
treatment
effect
baselin
lung
function
impair
affect
chang
lung
densiti
pn
regress
line
flat
activ
treatment
associ
lung
densiti
preserv
p
regress
line
parallel
placebo
treat
patient
regress
line
rate
annual
lung
densiti
declin
vs
baselin
flat
interact
treatment
group
baselin
data
demonstr
patient
aatd
treat
therapi
deriv
equal
benefit
term
lung
tissu
preserv
independ
grant
support
rapid
trial
programm
prepar
abstract
support
csl
behr
intervent
pulmonolog
broncholog
assess
diagnost
accuraci
consciou
sedat
cs
compar
gener
anaesthet
ga
bronchoscop
procedur
report
analysi
prospect
randomis
patient
group
patient
undergo
therapeut
diagnost
procedur
within
rbwh
consid
trial
entri
random
procedur
includ
standard
bronchoscopi
endobronchi
ultrasound
ebu
transbronchi
node
aspir
tbna
ebu
guid
sheath
patient
random
either
cs
ga
stratifi
charlson
comorbid
index
ga
defin
use
laryng
mask
airway
andor
propofol
usag
diagnosi
obtain
bronchoscopi
compar
final
clinic
diagnosi
patient
randomis
receiv
cs
diagnost
procedur
ebu
tbna
ga
group
number
respect
final
diagnosi
malign
made
case
cs
group
case
ga
group
diagnost
procedur
signific
differ
diagnost
accuraci
cs
ga
vs
regard
ebu
tbna
diagnost
accuraci
vs
lymph
node
sampl
cs
group
paratrach
subcarin
hilar
node
sampl
ga
group
paratrach
subcarin
hilar
averag
pass
per
node
respect
cs
case
drug
use
midazolam
mean
dose
fentanyl
varieti
anaesthet
agent
use
ga
group
signific
differ
regard
mean
fentanyl
dosag
cs
vs
ga
cs
inferior
ga
term
diagnost
accuraci
includ
ebu
tbna
wide
rang
nodal
station
grant
support
nil
cryobiopsi
emerg
techniqu
mount
utilis
set
diffus
parenchym
lung
diseas
dpld
neoplasia
safeti
usag
pattern
cryobiopsi
well
establish
australian
set
tertiari
institut
routin
perform
cryobiopsi
gener
anaesthesia
endotrach
intub
fluoroscopi
guid
cryoprob
via
erbecryo
routin
bronchial
blocker
balloon
deploy
thu
set
establish
safeti
usag
pattern
cryobiopsi
servic
follow
institut
ethic
approv
conduct
retrospect
audit
institut
cryobiopsi
regist
novemb
record
miss
electron
record
supplement
hand
search
contact
referr
result
two
author
cd
ls
verifi
third
pl
present
patient
underw
cryobiopsi
audit
period
biopsi
perform
per
patient
target
follow
right
lower
lobe
right
upper
lobe
left
lower
lobe
left
upper
lobe
endobronchi
predomin
indic
cryobiopsi
suspect
dpld
possibl
malign
account
remain
case
mean
fvc
predict
lowest
dlco
predict
lowest
day
discharg
achiev
uncompl
case
stay
overnight
social
reason
case
sever
bleed
bleed
moder
control
endobronchi
intervent
case
case
pneumothorac
requir
intercost
cathet
insert
physician
agre
strongli
agre
cryobiopsi
help
patient
cryobiopsi
suggest
diagnost
dpld
infect
malign
abnorm
present
refer
surgic
lung
biopsi
cryobiopsi
appear
accept
safeti
profil
good
diagnost
yield
key
word
cryobiopsi
bronchoscopi
interstiti
lung
diseas
grant
support
nil
forcep
biopsi
guid
sheet
locat
lesion
use
radial
probe
ebu
establish
techniqu
diagnosi
solitari
pulmonari
modul
spn
yield
howev
drop
significantli
lesion
concentr
furthermor
forcep
often
provid
small
sampl
occasion
fall
short
provid
inform
requir
malign
use
cryoprob
combin
radial
ebu
could
potenti
provid
larger
sampl
increas
yield
lesion
patient
underw
radial
ebu
cryobiopsi
diagnosi
spn
concord
macquari
univers
hospit
sydney
includ
studi
retrospect
audit
undertaken
obtain
demograph
baselin
physiolog
procedur
data
complic
length
stay
record
yield
determin
histopatholog
clinic
data
total
patient
femal
mean
age
year
far
includ
studi
procedur
perform
gener
anesthesia
rigid
intub
use
case
lesion
locat
case
use
ebu
radial
probe
one
eccenter
lesion
target
locat
upper
lobe
averag
biopsi
obtain
case
pneumothorax
sever
bleed
observ
two
patient
stay
overnight
procedur
averag
diamet
specimen
definit
malign
patholog
diagnos
case
overal
yield
radial
ebu
cryobiopsi
feasabl
altern
diagnosi
spn
yield
compar
previous
report
techniqu
howev
larger
specimen
obtain
cryobiopsi
could
potenti
provid
invalu
data
malign
condit
grant
support
histolopatholog
often
requir
achiev
multidisciplinari
diagnosi
diffus
parenchym
lung
diseas
surgic
lung
biopsi
slb
remain
gold
standard
associ
signific
morbid
mortal
recent
emerg
transbronchi
cryobiopsi
tbcb
potenti
altern
slb
promis
less
complic
compar
yield
divid
world
intervent
pulmonolog
numer
public
report
differ
occasion
contradict
outcom
despit
rel
popular
tbcb
region
far
publish
seri
australia
patient
underw
tbcb
concord
macquari
univers
liverpool
hospit
sydney
diagnosi
diffus
parenchym
lung
diseas
august
june
includ
retrospect
audit
undertaken
obtain
demograph
baselin
physiolog
procedur
data
complic
length
stay
record
diagnost
valu
tbcb
assess
histopatholog
clinic
impact
biopsi
specimen
review
singl
investig
record
size
presenc
artefact
percentag
alveolar
area
presenc
pleura
proxim
airway
structur
total
patient
male
averag
age
enrol
studi
case
perform
gener
anaesthesia
rigid
bronchoscop
access
averag
biopsi
obtain
lobe
patient
discharg
home
day
averag
length
stay
night
pneumothorax
observ
patient
sever
endobronchi
bleed
death
report
within
day
procedur
histopatholog
data
well
yield
current
analys
preliminari
data
suggest
tbcb
rel
safe
procedur
accept
yield
could
consid
altern
slb
grant
support
emphysema
lead
caus
disabl
death
current
medic
treatment
show
certain
limit
advanc
stage
diseas
also
limit
evid
australian
set
regard
therapeut
intervent
reduc
hyperinfl
includ
endobronchi
valv
insert
ebv
studi
examin
outcom
ebv
insert
patient
sever
emphysema
royal
brisban
women
hospit
retrospect
review
patient
sever
emphysema
underw
ebv
insert
primari
outcom
chang
exercis
toler
measur
walk
test
qualiti
life
qol
measur
st
georg
respiratori
questionnair
sgrq
direct
question
variabl
interest
measur
placement
patient
includ
studi
femal
age
rang
year
median
year
sixteen
patient
complic
patient
multipl
complic
three
patient
readmit
within
day
die
mainli
due
mortal
rate
pre
post
valu
obtain
patient
sgrq
patient
qol
data
patient
patient
complet
data
show
improv
mean
valu
sgrq
lung
function
mean
sgrq
reduc
unit
increas
metr
mean
increas
residu
volum
tlc
reduc
respect
signific
improv
qol
report
patient
report
improvementslight
improv
ebv
effect
safe
therapi
improv
lung
function
exercis
capac
qol
select
patient
emphysema
studi
larger
popul
need
confirm
find
grant
support
nil
conflict
interest
none
sever
emphysema
endobronchi
valv
qualiti
life
random
control
trial
bronchial
thermoplasti
bt
proven
reduc
symptom
sever
asthma
mechan
achiev
still
uncertain
improv
spirometri
observ
studi
postul
bt
might
improv
lung
mechan
alter
airway
resist
small
airway
lung
way
measur
studi
aim
evalu
chang
measur
ga
trap
particularli
residu
volum
rv
prospect
cohort
consecut
patient
sever
asthma
list
bt
two
tertiari
institut
frankston
hospit
macquari
univers
hospit
evalu
three
time
point
name
baselin
week
month
post
complet
procedur
evalu
medic
usag
symptom
score
asthma
control
questionnair
exacerb
histori
obtain
lung
function
evalu
spirometri
ii
ga
diffus
dlco
iii
static
lung
volum
bodi
plethysmographi
improv
baselin
month
p
daili
reliev
salbutamol
usag
improv
puff
per
day
p
exacerb
frequenc
mainten
oral
corticosteroid
usag
also
significantli
declin
p
chang
spirometr
paramet
demonstr
dlco
also
unalt
bt
treatment
howev
signific
reduct
ga
trap
observ
rv
fall
predict
predict
pair
test
signific
improv
tlc
frc
also
observ
chang
evid
week
time
period
maintain
month
chang
rv
neg
correl
baselin
indic
greatest
improv
evid
obstruct
patient
bronchial
thermoplasti
appear
improv
ga
trap
effect
greatest
sever
obstruct
patient
improv
may
relat
chang
mechan
properti
small
airway
measur
spirometri
grant
support
nil
lung
cancer
copd
smoke
play
vital
role
develop
nsclc
local
progress
metastasi
nsclc
associ
epitheli
mesenchym
transit
emt
implic
copd
pathogenesi
investig
emt
biomark
vimentin
epitheli
activ
marker
egfr
vascular
marker
collagen
surgic
resect
tissu
patient
nsclc
squamou
cell
carcinoma
compar
correspond
airway
egfr
vimentin
express
higher
tumour
cell
peripher
lead
edg
nsclc
compar
central
locat
tumour
cell
subject
p
collagen
express
blood
vessel
egfr
express
relat
differenti
statu
p
tnm
stage
p
nsclc
moreov
emt
marker
lead
edg
significantli
relat
airway
emt
activ
peripher
edg
vascular
squamou
significantli
relat
larg
airway
rbm
vascular
p
egfr
protein
express
remark
high
peripher
lead
edg
nsclc
relat
tumour
characterist
associ
poor
prognosi
relationship
tumour
express
airway
epithelium
rbm
provid
background
util
airway
chang
clinic
set
grant
support
studi
fund
nation
health
medic
research
council
nhmrc
grant
conflict
interest
author
declar
conflict
interest
lung
cancer
screen
high
fals
posit
rate
carri
potenti
neg
psycholog
impact
report
qualiti
life
hrqol
first
year
screen
queensland
lung
cancer
screen
studi
qlcss
qlcss
screen
healthi
volunt
age
extens
current
former
smoke
histori
pack
year
quit
year
prior
scan
result
defin
base
month
scan
fp
lung
year
tp
fals
neg
global
health
statu
physic
mental
function
assess
use
recal
period
baselin
month
month
month
baselin
screen
scan
use
short
form
version
contain
twelv
question
aggreg
summari
measur
mental
compon
summari
mc
physic
compon
summari
pc
calcul
use
factor
weight
deriv
us
gener
popul
sampl
mc
pc
rang
higher
valu
indic
better
health
minim
import
differ
determin
clinic
meaning
differ
mid
half
standard
deviat
sd
mean
respons
questionnair
tabl
baselin
mean
sd
mc
pc
respect
mc
gener
popul
norm
pc
norm
small
chang
mid
seen
fp
neg
group
figur
larger
chang
seen
tp
group
howev
number
respons
small
screen
associ
small
measur
chang
global
hrqol
clinic
meaning
differ
particip
neg
fp
scan
grant
support
nhmrc
queensland
govern
smart
state
grant
princ
charl
hospit
foundat
tabl
respond
time
point
baselin
scan
result
figur
mean
chang
physic
compon
score
mental
compon
score
baselin
light
criteria
gold
standard
distinguish
exud
transud
pleural
effus
sensit
specif
use
pleural
fluid
cholesterol
improv
diagnost
accuraci
compar
light
criteria
unclear
studi
aim
determin
level
pleural
fluid
cholesterol
triglycerid
b
use
distinguish
exud
transud
pleural
fluid
prospect
collect
consecut
pleural
effus
case
fluid
analys
accredit
laboratori
pathwest
wa
protein
lactat
dehydrogenas
ldh
cholesterol
triglycerid
aetiolog
effus
independ
verifi
base
clinic
radiolog
patholog
assess
effus
class
exud
transud
base
final
aetiolog
exud
mainli
due
malign
includ
lung
breast
mesothelioma
effus
pleural
infect
benign
pleuriti
transud
secondari
heart
failur
hepat
hydrothorax
periton
dialys
exud
higher
pleural
fluid
protein
median
iqr
gdl
ldh
mmoll
cholesterol
mmoll
triglycerid
mmoll
compar
transud
fluid
protein
ldh
cholesterol
triglycerid
cholesterol
triglycerid
highest
malign
mean
sd
respect
parapneumon
effus
strong
spearman
correl
found
fluid
cholesterol
protein
p
well
fluid
serum
protein
ratio
p
exud
identifi
high
discrimin
accuraci
sensit
specif
fluid
protein
ldh
cholesterol
modifi
combin
pleural
fluid
cholesterol
triglycerid
level
higher
exud
particularli
malign
parapneumon
effus
combin
fluid
protein
ldh
cholesterol
criteria
use
distinguish
exud
transud
grant
support
nhmrc
cancer
council
wa
rt
ycgl
jc
cancer
australia
nsw
dust
diseas
board
ycgl
jc
sir
charl
gairdner
research
advisori
group
ycgl
conflict
interest
author
declar
conflict
interest
investig
feasibl
efficaci
exercis
improv
physic
function
bodi
composit
outcom
patient
malign
pleural
diseas
mpd
patient
mpd
recruit
complet
exercis
train
intervent
exercis
intervent
includ
progress
resist
exercis
train
three
timesweek
outcom
assess
baselin
includ
muscular
strength
maximum
leg
press
function
capac
walk
test
physic
function
time
go
bodi
composit
dxa
scan
qualiti
life
health
survey
rate
intervent
burden
accept
likert
scale
much
pair
wilcoxon
sign
rank
test
use
assess
chang
time
mean
particip
age
sd
year
major
mesothelioma
ecog
perform
statu
male
sarcopen
particip
complet
intervent
complet
assess
median
adher
supervis
exercis
rang
median
rate
trial
evalu
high
ie
measur
intervent
burden
low
ie
item
post
intervent
signific
improv
found
mean
walk
distanc
ci
p
maximum
leg
press
kg
ci
p
time
go
sec
ci
p
chair
rise
sec
ci
p
appendicular
lean
massheight
squar
ci
p
outcom
mental
health
subscal
chang
significantli
median
chang
iqr
p
progress
resist
exercis
train
feasibl
intervent
measur
health
benefit
patient
mpd
grant
support
cancer
council
western
australia
edith
cowan
univers
conflict
interest
author
declar
conflict
interest
radial
endobronchi
ultrasound
ebu
bronchoscopi
conjunct
examin
rose
procedur
routin
achiev
adequ
diagnost
yield
identifi
malign
cell
studi
aim
improv
diagnost
valu
ebu
bronchial
brush
screen
specimen
molecular
chang
identifi
therapeut
target
specif
assess
feasibl
use
ebu
bronchial
brush
detect
differenti
express
tumour
marker
use
taqman
low
densiti
array
tlda
singl
pass
radial
ebu
brush
cell
lung
cancer
nsclc
patient
collect
follow
rose
confirm
malign
site
royal
melbourn
hospit
final
diagnos
includ
adenocarcinoma
squamou
cell
carcinoma
scc
control
benign
brush
collect
confirm
interstiti
lung
diseas
patient
isol
dna
rna
individu
brush
use
tlda
gene
express
analysi
determin
fold
chang
sever
tumour
marker
pten
rictor
met
next
gener
sequenc
ng
use
illumina
trusight
panel
statist
signific
assess
perform
mann
whitney
test
compar
unpair
group
fold
chang
valu
higher
p
p
rictor
p
p
malign
brush
rel
benign
brush
accord
tumour
type
fold
increas
p
rictor
p
met
p
observ
adenocarcinoma
vs
scc
level
higher
fold
p
pten
level
lower
fold
p
scc
vs
adenocarcinoma
malign
natur
lesion
confirm
ng
identifi
common
mutat
patient
kra
egfr
find
demonstr
target
profil
identifi
molecular
abnorm
ebu
bronchoscopi
brush
collect
rose
confirm
malign
lesion
investig
warrant
whether
use
clinic
guid
individualis
therapeut
option
grant
support
nation
health
medic
research
council
nhmrc
australian
research
council
arc
preclin
studi
demonstr
radiat
act
immun
stimulu
facilit
immun
mediat
enabl
respons
impact
previou
radiat
therapi
chest
efficaci
safeti
nivolumab
patient
advanc
cell
lung
cancer
nsclc
unknown
consecut
seri
patient
receiv
nivolumab
advanc
nsclc
basi
month
period
januari
june
larg
unit
identifi
outcom
patient
receiv
radiat
therapi
chest
part
previou
treatment
prior
commenc
nivolumab
rt
group
compar
age
gender
tumour
histolog
perform
statu
match
cohort
patient
receiv
previou
radiat
therapi
group
rt
group
receiv
mean
sd
median
month
prior
commenc
nivolumab
median
progress
free
surviv
pf
month
ci
rt
group
compar
month
ci
group
median
overal
surviv
month
ci
rt
group
compar
month
ci
group
diseas
respons
initi
assess
follow
start
nivolumab
includ
nine
patient
stabl
diseas
partial
respons
rt
group
compar
five
group
median
four
cycl
therapi
rate
immun
relat
complic
rt
group
respect
rt
group
higher
mean
smoke
pack
year
studi
demonstr
novel
find
previou
radiat
therapi
chest
result
significantli
higher
pf
patient
treat
nivolumab
advanc
nsclc
trend
toward
higher
rate
immun
relat
advers
effect
seen
rt
group
may
due
increas
activ
immunotherapi
patient
grant
support
nil
oliv
phase
iii
trial
nintedanib
significantli
reduc
annual
rate
fvc
declin
versu
placebo
patient
ipf
versu
mlyear
extens
trial
patient
complet
treatment
visit
could
receiv
nintedanib
patient
receiv
nintedanib
placebo
bd
end
receiv
nintedanib
bd
patient
receiv
nintedanib
placebo
bd
receiv
nintedanib
bd
bd
base
discuss
patient
investig
dose
reduct
bd
allow
manag
advers
event
bd
permit
assess
influenc
nintedanib
dose
fvc
declin
annual
rate
fvc
declin
week
assess
patient
subgroup
treat
nintedanib
bd
bd
slope
fvc
declin
calcul
use
avail
fvc
measur
collect
baselin
week
first
patient
enrol
juli
analys
descript
base
data
snapshot
octob
patient
treat
receiv
bd
bd
dose
respect
adjust
annual
fvc
declin
week
mlyear
patient
treat
nintedanib
bd
bd
dose
respect
annual
rate
fvc
declin
subgroup
consist
annual
rate
fvc
declin
week
treat
patient
mlyear
annual
rate
fvc
declin
similar
patient
treat
nintedanib
bd
bd
efficaci
nintedanib
reduc
diseas
progress
maintain
patient
ipf
requir
dose
adjust
manag
advers
event
grant
support
trial
fund
boehring
ingelheim
declar
interest
statement
ng
receiv
speaker
fee
boehring
ingelheim
astrazeneca
menarini
novarti
consult
fee
boehring
ingelheim
roch
bc
receiv
grant
person
fee
support
rocheintermun
boehring
ingelheim
person
fee
support
sanofi
grant
cardif
lvl
medimmun
person
fee
astrazeneca
mk
receiv
grant
person
fee
roch
boehring
ingelheim
glaxosmithklin
gilead
promet
alkerm
grant
actelion
respivert
synairgen
person
fee
astrazeneca
genoa
bw
noth
disclos
mq
ws
employe
boehring
ingelheim
lr
serv
scientif
advisori
board
intermun
boehring
ingelheim
fibrogen
glaxosmithklin
anthera
genentech
medimmun
takeda
ucb
promedior
trial
princip
investig
boehring
ingelheim
intermun
gilead
roch
takeda
ucb
receiv
research
grant
intermun
biogen
italian
ministri
health
italian
nation
drug
agenc
wellcom
trust
speaker
fee
intermun
boehring
ingelheim
cipla
idiopath
pulmonari
fibrosi
ipf
aggress
frequent
form
idiopath
interstiti
pneumonia
progress
ipf
variabl
individu
establish
quantit
tool
exist
assess
develop
work
aim
integr
inform
volumetr
imag
pulmonari
function
test
use
predict
comput
model
hypothesi
abnorm
volumetr
suffici
explain
increas
lung
stiff
decreas
dlco
tissu
region
hrct
imag
patient
ipf
quantit
analys
tissu
abnorm
classifi
use
calip
lung
informat
patholog
evalu
rate
softwar
tissu
densiti
td
distribut
volum
tissu
classifi
reticular
normal
emphysema
lung
calcul
classifi
data
map
statist
shape
model
allow
consist
comparison
region
tissu
properti
patient
within
one
patient
differ
time
point
ventil
distribut
ga
exchang
simul
comput
model
parameteris
subject
lung
tissu
characteris
predict
relationship
match
dlco
diseas
distribut
fibrosi
usual
consist
higher
td
compar
normal
tissu
present
predominantli
lower
lobe
honeycomb
reticular
contrast
emphysema
lower
densiti
appear
predominantli
upper
lobe
model
predict
ventil
distribut
dlco
show
mismatch
occur
due
redistribut
ventil
away
diseas
region
contribut
observ
dlco
decreas
quantit
analysi
spatial
distribut
ipf
diseas
coupl
function
model
provid
potenti
tool
improv
assess
contributor
declin
ipf
patient
statu
time
declin
dlco
function
region
lung
stiff
due
diseas
locat
combin
redistribut
ventil
normal
lung
tissu
grant
support
multidisciplinari
meet
mdm
model
care
recommend
tsanz
diagnosi
initi
manag
interstiti
lung
diseas
ild
order
ensur
equiti
access
requir
expertis
establish
princ
charl
hospit
tpch
brisban
facilit
telemedicin
activ
particip
site
elsewher
queensland
review
case
present
juli
june
includ
minimum
expert
thorac
physician
radiologist
histopathologist
referr
clinician
institut
discuss
femal
mean
age
year
outsid
tpch
includ
privat
practic
mean
fvc
carbon
monoxid
diffus
capac
overal
case
classifi
idiopath
pulmonari
fibrosi
ipf
combin
pulmonari
fibrosi
emphysema
major
elig
antifibrot
medic
classifi
connect
tissu
diseas
chronic
hypersensit
pneumon
whilst
remain
unclassifi
patient
surgic
lung
biopsi
slb
review
perform
prior
first
mdm
present
patient
first
present
diagnosi
ipf
prior
slb
case
comput
tomographi
hrct
report
usual
interstiti
pneumonia
uip
possibl
uip
inadequ
imag
slb
show
definit
uip
pattern
possibl
uip
uip
pattern
hrct
initi
case
present
investig
recommend
includ
surgic
lung
biopsi
hrct
bronchoscopi
extend
autoimmun
screen
telemedicin
model
feasibl
facilit
equiti
access
patient
clinician
low
volum
ild
caseload
absenc
expertis
preclud
local
establish
grant
support
roch
pharmaceut
declar
interest
none
exercis
train
deliv
signific
improv
function
exercis
capac
symptom
qualiti
life
across
rang
interstiti
lung
diseas
ild
extent
individu
experi
clinic
signific
benefit
studi
aim
establish
proport
patient
achiev
minim
import
differ
mid
walk
distanc
dyspnoea
fatigu
domain
chronic
respiratori
questionnair
crq
data
particip
ild
idiopath
pulmonari
fibrosi
ipf
asbestosi
connect
tissu
ild
ild
aetiolog
randomis
either
eight
week
supervis
exercis
train
usual
care
review
compar
percentag
patient
achiev
mid
ild
crq
dyspnoea
point
crq
fatigu
point
exercis
train
control
group
entir
ild
popul
subgroup
ipf
asbestosi
ild
use
pearson
follow
exercis
train
least
third
particip
achiev
improv
exceed
mid
increas
ipf
asbestosi
subgroup
respect
see
tabl
compar
control
group
greater
percentag
particip
achiev
improv
exceed
mid
crq
dyspnoea
fatigu
entir
ild
sampl
ipf
asbestosi
significantli
greater
control
group
crq
fatigu
improv
exceed
mid
limit
like
occur
crq
dyspnoea
fatigu
third
half
particip
ild
achiev
clinic
meaning
improv
follow
exercis
train
includ
ipf
devast
ild
fatigu
appear
respons
chang
dyspnoea
grant
support
abstract
fund
at
foundationpulmonari
fibrosi
foundat
nation
health
medic
research
council
eiren
luca
foundat
institut
breath
sleep
tabl
percentag
particip
achiev
mid
follow
intervent
tyrosin
kinas
inhibitor
may
associ
increas
risk
arteri
thromboembol
event
efficaci
safeti
treatment
nintedanib
versu
placebo
patient
idiopath
pulmonari
fibrosi
assess
phase
ii
tomorrow
trial
phase
iii
trial
exclus
criteria
includ
myocardi
infarct
previou
month
unstabl
angina
previou
month
stroke
previou
year
assess
effect
cardiovascular
cv
risk
baselin
cv
safeti
nintedanib
incid
rate
major
advers
cv
event
mace
subgroup
patient
histori
atherosclerot
cv
diseas
cvd
andor
cv
risk
factor
hypertens
dyslipidemia
bodi
mass
index
currentform
smoke
diabet
baselin
higher
cv
risk
patient
histori
atherosclerot
cvd
cv
risk
factor
baselin
lower
cv
risk
analys
use
pool
data
tomorrow
trial
baselin
patient
nintedanib
placebo
higher
cv
risk
patient
nintedanib
placebo
lower
cv
risk
patient
higher
cv
risk
incid
rate
ci
mace
per
nintedanib
placebo
group
respect
figur
patient
lower
cv
risk
incid
rate
ci
mace
per
nintedanib
placebo
group
respect
figur
pool
data
tomorrow
trial
incid
major
advers
cv
event
similar
nintedanib
placebo
group
patient
higher
lower
cv
risk
baselin
figur
grant
support
studi
fund
boehring
ingelheim
declar
interest
statement
tc
receiv
unrestrict
educ
grant
travel
assist
serv
advisori
board
boehring
ingelheim
roch
product
ltd
receiv
unrestrict
educ
grant
intermun
pharmaceut
serv
advisori
board
astra
zeneca
receiv
institut
grant
centacor
immunework
actelion
nation
institut
health
conduct
clinic
trial
ipf
support
nation
institut
health
nation
heart
lung
blood
institut
mw
receiv
speaker
advisori
board
fee
paid
institut
intermun
boehring
ingelheim
roch
unrestrict
research
grant
paid
institut
intermun
roch
mk
receiv
grant
person
fee
roch
boehring
ingelheim
gsk
gilead
promet
alkerm
grant
actelion
respivert
synairgen
person
fee
astrazeneca
genoa
fb
receiv
grant
honoraria
rochegenentech
intermun
boehring
ingelheim
serendex
sekisui
diagnost
lm
dw
employe
boehring
ingelheim
declin
forc
vital
capac
fvc
declin
walk
distanc
respiratori
hospit
event
associ
diseas
progress
mortal
ipf
incid
multipl
event
context
studi
patient
pt
receiv
antifibrot
treatment
pirfenidon
pfd
unknown
determin
incid
multipl
progress
event
proport
pt
death
subsequ
progress
event
first
month
pfd
treatment
vs
placebo
pbo
pt
pool
phase
iii
trial
pfd
n
pbo
n
analyz
incid
event
defin
rel
declin
predict
fvc
absolut
declin
respiratori
hospit
death
caus
incid
progress
event
driven
declin
fvc
total
event
pfd
vs
pbo
pfd
vs
pbo
lower
proport
pt
event
pfd
vs
pbo
vs
p
figur
death
follow
progress
event
occur
less
often
pfd
vs
pbo
vs
p
figur
multipl
progress
event
death
first
subsequ
progress
event
pool
capac
ascend
phase
trial
n
ascend
pfd
significantli
reduc
incid
multipl
progress
event
death
subsequ
progress
event
month
vs
pbo
multipl
approach
may
relev
design
futur
ipf
clinic
trial
f
roch
ltdgenentech
inc
medicin
practic
increas
awar
deleteri
health
impact
physic
inact
peopl
chronic
obstruct
pulmonari
diseas
copd
coupl
technolog
develop
permit
accur
measur
led
dramat
increas
studi
aim
improv
physic
activ
particip
systemat
review
aim
evalu
effect
intervent
promot
physic
activ
peopl
copd
randomis
control
trial
intervent
design
increas
physic
activ
peopl
copd
use
object
measur
physic
activ
identifi
cochran
airway
group
specialis
regist
march
two
review
author
independ
assess
studi
inclus
risk
bia
undertook
data
extract
result
primari
outcom
stepsday
program
complet
use
publish
data
refer
screen
paper
assess
includ
studi
report
stepsday
greatest
improv
seen
physic
activ
counsel
pedomet
compar
counsel
alon
studi
mean
differ
ci
stepsday
telecoach
compar
advic
alon
studi
stepsday
signific
improv
also
demonstr
telephon
counsel
pedomet
compar
pedomet
alon
studi
stepsday
endobronchi
valv
compar
usual
care
studi
stepsday
deterior
step
count
seen
follow
sing
class
compar
film
workshop
studi
stepsday
risk
select
detect
bia
gener
low
high
unclear
rate
report
bia
rang
intervent
particularli
involv
physic
activ
counsel
improv
physic
activ
measur
daili
step
result
suggest
target
intervent
may
use
improv
physic
activ
peopl
copd
grant
support
nhmrc
postgradu
research
scholarship
atb
whilst
arteri
blood
ga
abg
gold
standard
diagnosi
respiratori
failur
metabol
disturb
peripher
venou
blood
ga
analysi
pvbg
increasingli
use
sought
compar
perform
accuraci
test
diagnos
target
condit
perform
extens
electron
manual
search
literatur
consecut
seri
studi
directli
compar
index
test
pvbg
refer
standard
abg
languag
restrict
appli
includ
studi
provid
outcom
data
specifi
target
condit
ph
use
gener
accept
cut
point
qualiti
assess
conduct
use
tool
statist
analysi
util
tabl
outcom
posit
neg
result
stata
softwar
statacorp
publish
protocol
avail
cochran
databas
systemat
review
articl
identifi
articl
search
strategi
follow
remov
duplic
studi
meet
inclus
criteria
howev
could
provid
suffici
data
statist
analysi
two
author
evalu
qualiti
studi
gener
consid
low
risk
bia
respiratori
failur
studi
demonstr
poor
accuraci
pvbg
compar
abg
diagnost
odd
ratio
dor
confid
interv
isol
hypercarbia
studi
metabol
disturb
studi
pvbg
perform
well
dor
ci
dor
ci
abl
perform
hypercapnia
pvbg
show
high
sensit
low
specif
high
fals
posit
rate
limit
data
suggest
pvbg
use
diagnos
metabol
disturb
respiratori
failur
isol
hypercarbia
pvbg
high
sensit
poor
specif
grant
support
nil
intern
guidelin
recommend
comput
tomographi
pulmonari
angiographi
ctpa
gold
standard
imag
modal
suspect
pulmonari
embol
pe
royal
colleg
radiologist
suggest
pe
detect
ctpa
scan
appropri
request
ctpa
import
establish
accur
diagnosi
minim
unnecessari
test
radiat
exposur
intern
waikato
hospit
guidelin
recommend
probabl
score
assay
stratifi
patient
prior
perform
ctpa
aim
determin
overal
department
diagnost
yield
ctpa
waikato
hospit
also
aim
identifi
whether
ctpa
order
accord
current
guidelin
medic
record
consecut
patient
underw
ctpa
suspect
pe
march
may
retrospect
review
patient
demograph
referr
sourc
clinic
risk
factor
level
diagnost
yield
addit
ctpa
find
record
util
ctpa
imag
obtain
use
either
siemen
slice
ct
scanner
result
compar
intern
guidelin
well
similar
local
studi
patient
pe
orthopaed
highest
yield
follow
respiratori
gener
surgeri
accord
well
score
patient
low
risk
high
risk
done
patient
patient
group
two
patient
low
well
score
neg
receiv
ctpa
neither
pe
patient
refer
cardiolog
none
posit
scan
review
one
patient
ctpa
request
inappropri
low
well
score
done
diagnost
yield
ctpa
waikato
hospit
consist
intern
standard
adequ
use
rule
test
adher
diagnost
protocol
could
potenti
improv
posit
yield
grant
support
fund
financi
support
receiv
organ
abstract
withdrawn
